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ABSTRACT 
Sleep problems are one of the most common complaints in patients with diabetes. Sleep 
problems can impact on quality of life and contribute even further to the burden of living with 
diabetes. The aim of this thesis was to establish if there were any differences in objective 
sleep between patients with painful peripheral neuropathy and a historically created healthy 
control group. A further aim was to investigate the impact of pain, glucose and clinical sleep 
disorders such as sleep apnoea and periodic limb movements on sleep in patients with painful 
diabetic peripheral neuropathy. In addition the study investigated three of the most common 
treatments for neuropathic pain in this patient group: pregabalin, duloxetine and 
amitriptyline, to see if there were improvements in pain and sleep. 
Polysomnography was used to asses sleep in both the diabetes group and healthy control 
group. Diabetic patients had significantly less total sleep time, lower sleep efficiency, more 
wake time, increased latency to sleep and felt they were significantly sleepier during the day 
compared with healthy volunteers. The poor sleep in the diabetic study group was not 
associated with pain or nocturnal glucose levels (hyperglycaemic/hypoglycaemic events). 
Prevalence of periodic limb movement was high in this patient group but the number of 
events was considered mild and not associated with any arousals or awakenings. Sleep 
apnoea did however correlate with the number of awakenings and there was a correlation 
between an increase in lighter stage 1 sleep and an increase in apnoea/hypopnoea index. 
All three treatments were effective at reducing pain, and no treatment was superior with 
regards to analgesic efficacy. Clear separation of the treatments was found when looking at 
objective sleep with pregabalin significantly improving and duloxetine worsening sleep while 
amitriptyline showed little change when compared with placebo. Clinical sleep variables 
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however suggested that pregabalin might increase the incidence of apnoeas highlighting that 
all factors need to be considered when deciding on the best treatment regime. 
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CHAPTER 1 GENERAL INTRODUCTION 
1.1 Diabetes mellitus 
The prevalence of diabetes mellitus (DM) worldwide in 2000 was estimated to be 171 million 
according to the World Health Organisation, making it one of the most common chronic 
medical disorders seen in clinical practice (Galer et al. , 2000; WHO, 1999). The number of 
people with diabetes is increasing rapidly and the estimated prevalence for 2010 is 221 
million according to the International Diabetes federation (IDF). This increase is due to the 
increased prevalence of obesity and physical inactivity amongst people but also due to the 
growth of the world ' s population. It is thought the numbers will continue to rise and have 
been anticipated to have reached 334 million by 2025 and 366 million by 2030 according to 
IDF and WHO, respectively (Wild et al. , 2004). 
The two most common forms of diabetes are type I DM and type II DM, with the latter being 
the far most common of the two and accounting for around 90 % of all cases worldwide 
(Alberti and Zimmet, 1998; Graves and Eisenbarth, 1999; Kasuga, 2006; Lewis, 1999; Luna, 
2005; Vinik and Flemmer, 2002). 
1.1.1 Type I DM 
Type I DM is an autoimmune disorder known to have strong genetic links, but environmental 
factors such as viruses may also playa role in the development of type I DM (Bresson and 
Herrath von, 2004). The onset may occur at any age but it most commonly occurs in 
childhood and adolescence. The progression of the disease may vary from slow to rapid, and 
rapid progression is most common in children (Bresson and Herrath von, 2004; Pozzilli and 
DiMario, 2001; WHO, 1999). 
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1.1.2 Type II DM 
The onset of type II DM is more common later on in life and the risk of developing type II 
DM increase with age. However, its occurrence in children and adolescence is nowadays 
much more common and is thought to be due to the increased prevalence of obesity (Pinhas-
Hamiel et al., 1999). A study by Haines et al showed that 95 % of children diagnosed with 
type 2 DM were overweight and 83% were obese (Haines et al, 2007). Factors such as 
centripetal obesity and lack of exercise increase the risk of developing type II DM (WHO, 
1999). In fact, a body mass index (BMI) of> 25 increases the risk of developing type II DM 
by 3-fold and between 60% and 90% of diabetic patients are clinically overweight (Kasuga, 
2006; Petersen Falk and Shulman, 2006). However, type II DM is also known to have a 
strong genetic component. This has been shown in a study of identical twins, where a 100% 
concordance rate for type II DM was found (Barnett et al., 1981). Another study by Barnett et 
al. (1981) found that 48 out of 53 non-insulin-dependent diabetic identical twin pairs were 
concordant for diabetes. In the 5 pairs which were not concordant the diabetic twin had just 
recently been diagnosed. Tests on the 5 non affected twins in these pairs showed that they 
had higher fasting glucose levels and higher HbAlc compared to controls, indicating that 
they are also prone to develop type 2 DM (Barnett et al., 1981). These were very early studies 
and were just an indication of a possible genetic link. The genetics of type II DM are still 
unclear and thought to be extremely complex, but more recent studies have indicated stronger 
genetic links with frequent polymorphisms of many genes such as insulin, calpain 10 
involved in pathways of insulin secretion and glucose metabolism, and peroxisome 
proliferator-activated receptor (pP AR) gamma involved in regulation of metabolism of 
carbohydrate, lipids and protein. There is also evidence that differences in the insulin receptor 
substrate-l (IRS-I) gene may be associated with type 2 DM. IRS-l plays a important role in 
the insulin signalling pathway which will be discussed later (Hansen and Pedersen, 2005; 
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Kovacs et aI., 2003; Leahy, 2005; Malecki, 2005). Leahy (2005) has also suggested a 
decrease in p-cell mass through genetic factors as a possible predisposing factor for glucose 
intolerance and development of type 2 DM (Leahy, 2005). Further supportive evidence for a 
genetic aetiology is the high prevalence of type II DM in some ethnic populations. A study by 
Haines et al showed that the incidence rate of type 2 DM in children was far higher in south 
Asians and blacks, in fact 3.5 and 11 times higher, respectively, compared to Caucasians 
(Haines et al., 2007). Similar findings have been seen in the US with increased prevalence of 
type 2 DM seen in Pima Indians, Hispanics, Asians and Afro-Caribbeans compared to US 
Caucasians (American Diabetes Association, 2000; Zhang et al, 2009). However, this 
difference may be a combination of genetics as well as environmental factors and the fact that 
some ethnic groups appear to have higher prevalence of obesity which is known to be a risk 
factor in developing type 2 DM (American Diabetes Association, 2000; Wardle et al, 2006). 
Type II DM was historically considered a condition of wealthy Western nations but its 
prevalence is now rapidly increasing world-wide. Africa has shown a projected increase of as 
much as 111 %, and the projected increase in South East Asia is estimated to be another 40 
million cases by 2025. This increase may be due to change in life style (IDF, 2003). Type II 
DM is a global cause of increased morbidity and it is therefore important to try to understand 
its genetic and metabolic aetiologies (Petersen Falk and Shulman, 2006). 
1.2 Diabetes and glycaemic control 
Diabetes is a serious chronic metabolic disorder characterized by persistent high blood sugar 
levels (hyperglycaemia) which is caused by impaired glucose homeostasis (Graves and 
Eisenbarth, 1999; Luna, 2005; WHO, 1999). This impairment is due to defective insulin 
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action, insulin secretion or both. This will be discussed in more detail later on but first one 
needs to understand the complexity of normal glucose homeostasis. 
1.2.1 Normal glucose homeostasis 
Glucose is an important source of energy for the human body. Under normal circumstances 
there is a balance between the glucose in the systemic circulation and tissue glucose uptake 
and utilization - this is known as glucose homeostasis. This homeostasis is balanced by the 
organised interaction between insulin secretion, tissue glucose uptake and glucose production 
in the liver (hepatic glucose production), and is tightly regulated as it is important to keep the 
plasma glucose concentrations within a narrow window (Zierath and Kawano, 2003). Normal 
fasting plasma glucose levels should be below 6.1 mmolll and at 2 hour post glucose dose the 
levels should be below 7.8 mmoVI (Messier, 2005). 
1.2.1.1 Role of Insulin 
Insulin is a peptide hormone which is synthesized and secreted by the p-cells of the islets of 
Langerhans of the pancreas in response to increased circulating levels of glucose and amino 
acids. It plays an important role in metabolic processes such as carbohydrate (table 1.1), lipid 
and protein metabolism and is essential for maintenance of glucose homeostasis. 
Furthermore, insulin is important in cell proliferation and gene transcription. 
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Hepatocytes Muscle ceUs Adipocytes 
i Glycogenesis i Glycogenesis i Glycogenesis 
i Glycolysis i Glycolysis i Glycolysis 
i Glucose uptake i Glucose uptake 
i LGluconeogenesis 
L Glycogenolysis 
Table J.l: Role of insulin in carbohydrate metabolism. Insulin increases glycolysis (use of glucose for 
energy) in adipocytes, muscle cells and hepatocytes. It also increases glucose uptake to muscle cells and 
adipocytes by facilitating mechanisms that translocate GLUT4 glucose transporters to plasma membrane. 
Furthermore, insulin also stimulates glycogenesis (synthesis of glycogen from glucose) in adipocytes, muscle 
cells and hepatocytes. It also inhibits hepatic glycogenolysis (breakdown of stored glycogen into glucose) and 
can regulate gluconeogenesis (synthesis of glucose from non-carbohydrate sources). 
The different metabolic processes are mediated by insulin binding to its receptors on the 
plasma membrane of, for example, hepatocytes, adipocytes and skeletal muscle cells 
(Greenfield and Campbell, 2004; Lebovitz, 2005). The binding of insulin causes a rapid 
autophosphorylation of the insulin receptor activating the receptor and triggering a cascade of 
intracellular events (figure 1.1). The main pathway being activated is the insulin receptor 
substrate (IRS)/phosphatidylinositol 3 kinase (PI) pathway. This IRSIPI 3 kinase pathway is 
also called phosphoinositide dependent kinase(PDK)/ protein kinase B (PKB) pathway as it 
causes activation of these two kinases (Luna, 2005). The active insulin receptor can 
phosphorylate IRS which becomes active. Active IRS can activate PI-3 kinase via p85 
binding, which is the regulatory subunit of PI-3 kinase and acts as its adaptor. Active PI-3 
kinase can then phosphorylate PI 4,5-bisphosphate to form PI 3,4,5-trisphosphate. The latter 
can recruit PKB to the plasma membrane of the cell and PDK-l can then phosphorylate PKB 
which becomes active. This activation stimulates glycogen synthesis as active PKB 
phosphorylates and therefore inactivates GSK-3 (glycogen synthase kinase 3). Inactive GSK-
3 can no longer inhibit glycogen synthase and glycogen synthesis can therefore take place. 
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Active PKB is also thought to phosphorylate several other proteins involved in the 
translocation of GLUT 4 transporters to the plasma membrane in cells like adipocytes and 
skeletal muscle cells, therefore increasing the glucose uptake into these cells (Greenfield and 
Campbell,2004). 
The binding of insulin to its insulin receptor will also activate the Ras/mitogen-activated 
protein kinase pathway (RasIMAP kinase pathway) which is involved in the regulation of cell 
growth and proliferation (Luna, 2005). The adaptor protein, growth factor receptor bound 
protein 2 (GRB2) binds to the active insulin receptor and son of sevenless protein (SOS) can 
then interact and bind to the SRC homology 3 (SH3) domain on GRB2. Activated SOS is 
involved in the formation of active Ras as it promotes the exchange of guanosine diphosphate 
(GDP) for guanosine triphosphate (GTP). Active Ras-GTP triggers the phosphorylation 
cascade involving MAP kinases and these can finally phosphorylate target proteins such as 
transcription factors in the nucleus. 
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Figure 1.1: Insulin signa lling pathways in adipocytes and muscle cells. 1. IRSIPI-3 kinase pathway. 
Binding of insulin activates insulin receptor and triggers IRS/PI-3 kinase pathway. This results in glycogenesis 
and possible translocation of GLUT 4 transporters. 2. Ras/MAP kinase pathway. Binding of insulin and 
activation of insulin receptor can also triggers Ras/MAP kinase pathway involved in cell growth and gene 
expression. IRS-insulin receptor substrate, P-Phosphate group, Pl-phosphatidylinositol, PDK-phospoinositide 
dependent kinase, PKB-protein kinase b, SOS-Son of sevenless protein, Ras-small GTP binding protein, GRB2-
adapter protein, GLUT 4-g\ucose transporter, MAP kinase-mitogen activated protein kinase. 
1.2.1.2 Glucose transport and metabolism 
1.2.1.2.1 Fasting state 
In the fasting state, blood glucose levels are maintained predominantly by hepatic 
glycogenolysis (breakdown of stored glycogen into glucose) and gluconeogenesis (glucose 
formation from a non carbohydrate source). When glucose levels decrease, the body responds 
by secreting glucagon from the pancreatic a-cells. Glucagon stimulates glycogenolysis and 
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therefore more glucose is released into the blood for transport to different tissues (figure 1.2) 
(Heller, 1999; Lewis, 1999). The rate of hepatic glucose production during fasting correlates 
with the rate of tissue glucose uptake in vital tissues and organs that require glucose as their 
energy source such as the central nervous system (eNS). This matching regulation of hepatic 
glucose production and tissue glucose uptake will maintain the fasting blood glucose levels at 
a constant concentration. 
1.2.1.2.2 Fed state 
After a meal (fed state) the blood glucose levels rises in the body and this will increase the 
production and secretion of insulin from the pancreatic ~ cells. As mentioned earlier the 
insulin molecules will bind to receptors located on the plasma membrane of the cells, 
resulting in autophosphorylation of the receptors and receptor activation. This activation 
stimulates the synthesis and translocation of GLUT 4 glucose transporters and increases the 
peripheral glucose uptake. GLUT 4 is only found in insulin sensitive cells such as the skeletal 
muscle cells, adipocytes and cardiac muscle cells and is the major transporter responsible for 
the insulin dependent glucose uptake. Skeletal muscle cells account for 75% of the glucose 
uptake, making it the major site of glucose disposal following ingestion or infusion of 
glucose while the adipocytes and cardiac muscle cells metabolize a smaller percentage 
(Zierath and Kawano, 2003). 
Activation of insulin receptors promotes the metabolic pathway which converts the excess 
glucose into glycogen (glycogenesis). This process occurs mainly in hepatocytes (liver cells) 
but also in muscle cells, and the produced glycogen is stored and used as an energy reserve. 
Furthermore, the increase in plasma insulin concentration suppresses hepatic glucose 
production by decreasing glycogenolysis. All these responses minimize hyperglycaemia (high 
blood glucose levels) and return glycemic levels to lower pre-meal values. 
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Figure 1.2: Simplified d iagram of glucose homoeostasis. Fed state: 1. Levels of blood glucose increase after a 
meal (blue triangles), and trigger the secretion of insulin from the pancreas. 2. This results in increased insulin 
concentrations (red circles). 3. Increased insulin concentration aids the insulin dependent uptake of glucose into 
skeletal muscle cells, adipocytes and hepatocytes (green arrows). Note that glucose uptake in the brain and liver 
is insulin independent. In addition, increase in insulin levels inhibits hepatic glycogenolysis (glucose synthesis 
from stored glycogen) and no further glucose is released into the blood stream (red arrow). These mechanisms 
regulate blood glucose levels which return to normal levels. Fasted state: 1. Low glucose levels trigger the 
secretion of glucagon (green circles) from the pancreas. 2. This results in high levels of glucagon. 3. Glucagon 
stimulates glycogenolysis in the hepatocytes so that glucose is synthesised and released into the blood stream 
and transported to vital tissues and organs such as the brain. 
However, in diabetes this regulation malfunctions and blood glucose levels remaIn high 
(hyperglycaernia) and this is the main hallmark of diabetes (Graves and Eisenbarth 1999; 
Herman and Kahn, 2006; Lebovitz, 2005; WHO, 1999). 
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1.2.2 Defects of glucose homoeostasis in diabetes 
The malfunction of glucose homeostasis in DM is caused by either an autoimmune 
destruction of the insulin secreting ~ cells as seen in type I DM or by insulin resistance and ~ 
cells dysfunction seen in type II DM (Herman and Kahn, 2006; Porte, 2001). Such defects 
result in elevated glucose levels and diabetes is defined as fasting plasma glucose levels 
above 7.0 mmolll or above 11.1 mmolll at 2 hours post glucose dose (Messier, 2005). 
1.2.2.1 P cell destruction (autoimmune) in type I DM 
The destruction of ~ cells of the pancreatic islet of Langerhans is a result of an abnormal 
immune response to self antigens and only occurs in type I DM. Autoimmune ~ cell 
destruction will result in no or too little insulin being released (insulin deficiency). The 
deficiency of insulin results in no translocation of GLUT 4 transporters to the plasma 
membrane of adipocytes and muscle cells, and the insulin dependent glucose uptake into 
these cells is therefore inhibited. The result is that more glucose remains in the blood stream, 
leading to impaired glucose homoeostasis (Bresson and Herrath von, 2004; Graves and 
Eisenbarth, 1999; Narendran et al., 2003; Pozzilli and DiMario, 2001). Another effect of 
insulin deficiency is the increase of glycogenolysis in hepatocytes. Normally, insulin binds to 
its receptors on hepatocytes, triggering an intracellular cascade leading to the activation of 
glucogenesis. In the absence of insulin this process is inhibited and glycogeneolysis occurs 
instead. The produced glucose can then be transported into the blood stream via the insulin 
independent GLUT 2 transporters and contributing even further to the hyperglycaemic state 
(see figure 1.3). 
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Figure 1.3: Sim plified diagram of the defects of glucose bomoeostasis in type I DM. In type I DM there is 
autoimmune destruction of pancreatic ~-cells leading to insulin deficiency. Insulin deficiency results in no 
translocation of GLUT 4 transporters to the plasma membrane of adipocytes and muscle cells, and the insulin 
dependent glucose uptake into these cells is therefore inhibited. The result is that more glucose remains in the 
blood stream. Another effect of insulin deficiency is the increase of glycogenolysis in hepatocytes. The 
produced glucose is transported into the blood stream via the insulin independent GLUT 2 transporters, 
increasing the glucose concentration even more. 
1.2.2.2 Insulin resistance in type II DM 
Insulin resistance means that insulin is still synthesised and secreted in response to increased 
blood glucose and will still bind to the insulin receptor (see figure 1.4). There are however 
defects in the intracellular signalling pathway, making the signal weaker (Lebovitz, 2005). 
This resistance to insulin is also thought to be due to abnormal insulin receptors and/or a 
deficiency of insulin receptors on the liver, muscle and fat cells (Lewis, 1999). Insulin 
resistance may be present for several years before overt hyperglycaemia occurs, as initially 
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the ~-cells can cope with glucose loads by over production of insulin. Thereafter this 
mechanism begins to fail and gradual ~-cell dysfunction will lead to hyperglycaemia (Kahn, 
2000; Kahn et aI., 1999; Kasuga, 2006; Porte, 2001; Prentki and Nolan, 2006). 
1.2.2.3 p- cell dysfunction in type II DM 
The most characteristic dysfunction of the ~ cells in type II DM is impaired insulin secretion. 
If an individual has reduced insulin sensitivity the ~ cells will as mentioned earlier respond 
by increasing the insulin secretion. However, this protective mechanism will eventually fail 
as the ~ cells cannot cope with keeping up this increase, resulting in an underproduction of 
insulin and recent studies suggest that type II DM only develops in insulin resistant people 
once ~ cell dysfunction occurs, resulting in a decline in insulin secretion (hyposecretion). 
This leads to failure in sustaining an adequate ~ cell compensatory response in the wake of 
insulin resistance (Kahn, 2000; Luna, 2005; Prentki and Nolan, 2006). 
In type II DM there is also a change in insulin to proinsulin ratios. Proinsulin is an inactive 
precursor of insulin and only after enzymatic processing is it converted to active insulin, 
which is then secreted from the ~ cells. In healthy individuals a small amount of proinsulin 
escapes this processing and is released together with the insulin. However, in type II DM 
patients this proinsulin processing is reduced, leading to an increased secretion of 
biologically inactive proinsulin. The change in insulin to proinsulin ratio is also related to p-
cell dysfunction and levels of hyperglycaemia (Kahn, 2000; Kahn et al., 1999; Kasuga, 2006; 
Porte, 2001; Prentki and Nolan, 2006; Roder et al., 1998). 
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Figure 1.4: Simplified diagram of the defects of glucose homoeostasis in type II DM. Insulin resistance is 
due to several different factors . It can be due to abnormal insulin receptors or due to deficiency of insulin 
receptors , This means that even if insulin is secreted it can' t bind to insulin receptors and therefore its signalling 
actions are inhibited. Another factor can be a defect in the intracellular pathway, insulin can still bind to its 
receptor but defects in the pathway result in no signalling. When insulin resistance occurs the ~-cells 
compensate by over production of insulin. However, this mechanism begins to fail when the ~-cells cannot cope 
any longer and gradual B-cell dysfunction occurs. This results in inhibition of insulin dependent glucose uptake 
into adipocytes and muscle cells and glucose remains in the blood stream. Glycogenesis in hepatocytes is 
decreased in the absence of insulin action and glycogenolysis (breakdown of glycogen to produce glucose) 
occurs instead. The produced glucose can be transported into the blood stream via GLUT 2 transporters 
contributing even fu rther to the hyperglycaemic state, 
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1.2.3 Hyperglycaemia 
Hyperglycaemia is as mentioned earlier caused by several defects in glucose homoeostasis 
(Herman and Kahn, 2006; Porte, 2001). Asymptomatic hyperglycaemia and insulin resistance 
can be present for a long period of time before overt diabetes occurs (Laakso, 1999). In this 
state fasting plasma glucose can still be within the normal range, but increases abnormally in 
the fed state. This can later lead to overt hyperglycaemia which is when a subject has 
consistent blood glucose levels > 7.0 mmollL, but symptoms may not occur until higher 
levels of above 15 mmollL are reached. Hyperglycaemia is a risk factor for the development 
of diabetic complications as chronic levels of > 7.0 mmollL can cause damage to blood 
vessels and organs. Such complications will be discussed in more detail later. The definition 
of acute hyperglycaemia varies between studies with values from 7.8 mmollL to above 15 
mmollL. 
Symptoms of chronic and acute hyperglycaemia include excessive thirst and excessive 
urination, blurred vision, fatigue, dry mouth and can lead to coma. In addition, acute 
hyperglycaemia > 16.5 mmollL has been shown to result in impaired cognitive function and 
reduced mood (Sommerfield et al., 2004). 
1.2.4 Hypoglycaemia 
Hypoglycaemia is defined as low blood glucose levels. Low blood glucose in diabetic 
patients is described as < 3.3 mmolll or in some cases < 3.9 mmolll. However, symptoms 
rarely occur until levels fall below 3.3 mmoill. Hypoglycaemia occur if there is an 
inappropriate excess of insulin relative to glucose. This scenario may for example occur if a 
diabetic patient receives too much insulin in relation to an inadequate carbohydrate meal. One 
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rare example is the patient with an insulinoma (insulin secreting tumour) in whom excessive 
and inappropriate insulin secretion leads to spontaneous hypo glycaemia. 
When plasma glucose concentration falls, there is a physiological response by the release of 
some hormones such as glucagon which stimulates glucose synthesis, and adrenaline which 
inhibits glycogen synthesis. Glucagon is secreted by the pancreatic a. cells and acts by 
binding to membrane receptors on target cells and activating the adenyl ate cyclase second 
messenger system. This results in increased hepatic gluconeogenesis and glycogenolysis 
leading to an increase in plasma glucose. The action of glucagon is therefore essential in 
regulating glucose levels and high insulin levels inhibit glucogon release and action (Heller, 
1999; Lewis, 1999). In patients with diabetes, the glucagon and adrenaline response to 
hypo glycaemia begins to fail after about 2 years. These defects are progressive and most 
patients with type I DM have a reduced glucagon response after 5 years and - 40% have 
defects in adrenaline response after 15 years (Heller, 1999). The symptoms of hypoglycaemia 
are sweating, trembling, clamminess and anxiety and hypoglycaemia is a dangerous condition 
which may have serious effects on cerebral function. The brain is highly dependent on 
glucose and needs a continuous and adequate energy supply to maintain normal function. 
When this fails a second set of symptoms can be seen, such as headache, difficulty in 
thinking and confusion. Hypoglycaemia can even lead to unconsciousness, coma and even 
death unless glucose is rapidly administered and it is the most common cause for A&E 
attendance in diabetic patients (Lewis, 1999). 
1.2.5 Managing of glucose homoeostasis in diabetes patients 
Good glycaemic control is the primary objective for diabetic patients, as this will reduce the 
risk of hyper/hypoglycaemia as well as the risk of diabetic microvascular and cardiovascular 
complications (see section 3, diabetic complications). 
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Patients with diabetes must therefore learn how to monitor and control their glucose levels to 
minimize the risk of such complications. The most common way to do so is by self 
monitoring of blood glucose (SMBG). 
1.2.5.1 Self monitoring of blood glucose (SMBG) 
An instrument for the 5MBG (finger stick blood glucose readings) has been developed to 
help control glucose levels. This is widely used by patients with type I DM, but is also used 
in some patients with type II DM, especially those treated with insulin. However, it has also 
been shown that 5MBG may be a useful tool in some type II DM patients who are on diet 
treatment alone and/or oral hypoglycaemic agents (Harris, 2001; Ozmen and Boyvada, 2003; 
Wels~hen et ai., 2005). To achieve optimal use of 5MBG, patients should go through proper 
glucose monitoring education, focusing on specific glycaemic targets and on how to respond 
to different glucose readings. 5MBG provides real-time information about blood glucose 
levels, and helps the patient understand the impact of diet, medications and physical exercise 
on glucose levels on a daily basis (Harris, 2001). The frequency and timing of glucose 
monitoring varies widely amongst patients and often depends on different treatment regimes. 
1.2.5.2 Continuous glucose monitoring system (CGMS) 
The continuous glucose monitoring system (CGMS) is another instrument used to determine 
glucose levels. It should be used occasionally and be a supplement to 5MBG rather than be 
used on a daily basis. There are various manufacturers on the market, but the principle of how 
they work is similar. A CGMS will measure the glucose continuously with an interval of for 
example 10 seconds and then give an average of these measurements every 5 minutes. Over a 
24 h period it will provide 288 glucose readings which can then be downloaded to a computer 
for analysis. The CGMS can be worn for a period of up to 72 hours (Caplin et aI., 2003; 
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Salardi et aI., 2002). As the CGMS reads glucose levels continuously, it not only identifies 
glucose trends, but can also identify nocturnal hypo glycaemia, when glucose checks by 
means of 5MBG are difficult and impractical (Jeha et aI., 2004; Melki et al., 2006). 
Hypoglycaemic episodes at night are common in patients with type I DM and being able to 
detect them by means of the CGMS is a great advantage (Jeha et al., 2004). In addition, the 
CGMS can be a excellent tool to improve metabolic control and this can lead to lower 
glycosylated haemoglobin (HbA1c) levels (see section 1.2.5.3 below). In order to validate the 
CGMS system it is important that the CGMS is calibrated with a 5MBG test (finger stick 
reading) at least four times a day. 
1.2.5.3 G/ycosy/ated haemoglobin (HbA1J measurements 
HbAlc measurements are used to assess long term glycemic control (6zmen and Boyvada, 
2003). The glycosylation take place on haemoglobin 1 on the erythrocytes (red blood cells) 
and is an irreversible process. The HbAlc levels indicate the amount of glycosylated 
haemoglobin present and the higher the blood glucose the higher levels of glycosylated 
haemoglobin. Erythrocytes have a life cycle of around 3 months and HbAlc levels are 
therefore a good indicator of how a patient's glucose control is managed over a 2-3 months 
period. HbAlc measurements can be used in combination with for example 5MBG and 
CGMS (Messier, 2005; 6zmen and Boyvada, 2003; Salardi et aI., 2002; Saudek et aI., 2006; 
Saudek et aI., 2005). The use of 5MBG and/or CGMS gives valuable data for both patients 
and physicians and can be used to improve metabolic control and therefore reduce the HbAlc 
levels (Ludvigsson and Hanas, 2003). 
The nonnal value of HbAlc in healthy people is between 4% and 5.9% while people with 
diabetes will often have higher values. The International Diabetes Federation (IDF) 
recommends HbAlc values below 6.5% for diabetic patients, while the American Diabetes 
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Association (ADA) recommends a value below 7%. A very high HbAlc such as between 10.9 
and 15.5 % represents very poor glucose control (Messier, 2005) and is strongly associated 
with complications of diabetes especially microvascular complications. If patients achieve a 
value of below 7% they dramatically decrease their risk of such complications (American 
Diabetes Association; Saudek et aI., 2006; Saudek et aI., 2005). 
1.3. Diabetic complications 
Unfortunately, many diabetic patients fail to achieve adequate glycaemic control, and as 
mentioned earlier, this may lead to diabetic complications. Possible complications of diabetes 
are many and may vary in severity. Complications may include microvascular problems such 
as retinopathy, nephropathy and neuropathy but diabetes also increases the risk of conditions 
such as cardiovascular disease and stroke. Cardiovascular disease is the most common cause 
of mortality in patients with diabetes and is estimated to be the cause of death in - 65% of 
diabetes patients (Laakso, 1999; Lewis, 1999; Ozmen and Boyvada, 2003; Vinik and 
Flemmer, 2002). Several studies carried out in the Scandinavian countries as well as in the 
UK, US and Germany have shown that hyperglycaemia and poor glycemic control increase 
the risk of cardiovascular complications. It has also been shown that the risk of developing 
cardiovascular disease is reduced if a patient has good glycaemic control, together with low 
LDL (low density lipoprotein) and normal blood pressure «130/80 mmHg) (Haffner and 
Cassells, 2003; Idris et al., 2006; Laakso, 1999; Vinik and Flemmer, 2002). 
Diabetic nephropathy is a progressive kidney disease and is another serious complication of 
diabetes. Patients are at higher risk of developing the syndrome if they have poor glucose 
control with the presence of hyperglycaemia. Diabetic nephropathy is a common cause of 
chronic kidney failure and end-stage kidney disease (Head, 2003; Rippin et aI., 2001). 
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Diabetic retinopathy on the other hand affects the eyes and is the most common cause of 
blindness in the younger population of the Western countries (Head, 2003). Another 
important microvascular complication is diabetic neuropathy, which affects the nervous 
system. All these microvascular complications are specific to diabetes and are a significant 
source of mortality and morbidity in diabetic patients (Vinik and Mehrabyan, 2004). 
1.3.1 Diabetic neuropathy 
Up to approximately 60 % of all diabetes patients develop diabetic neuropathy during the 
course of their disease, however the true prevalence is not known (Atli and Dogra, 2005; 
Boulton, 2003; Galer et al., 2000; Gore et al., 2005; Spruce et al., 2003; Tesfaye and 
Kempler, 2005; Tt>lle et al., 2006; Vinik and Mehrabyan, 2004). Diabetic neuropathies are a 
family of nerve disorders caused by diabetes mellitus and can be classified into different 
groups (peripheral, autonomic, proximal or focal) as they affect different parts of the body in 
different ways. The most common form of diabetic neuropathy is peripheral neuropathy, also 
known as distal symmetric sensorimotor polyneuropathy (Galer et al., 2000; Gore et al., 
2005; Greene et al., 1999; Nicholson, 2006; Nokleby and Berg, 2005; Tesfaye and Kempler, 
2005; Vinik and Mehrabyan, 2004). 
1.3.1.1 Diabetic peripheral neuropathy (DPN) 
The risk of developing diabetic peripheral neuropathy (DPN) is increased by the duration of 
diabetes and by poor glycaemic control. Other independent risk factors are smoking, drinking 
alcohol, hypertension and hyperlipidaemia, (Gore et al., 2005; Tesfaye and Kempler, 2005). 
The onset of peripheral neuropathy first occurs in the most distal extremities such as the toes. 
This process then extends to the feet and the legs. There is also the possibility of upper 
extremity involvement. This will start in the fingertips and can progress to the hands and 
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arms. This distinct spread of the condition is also known as "stocking-glove distribution" 
(Greene et aI., 1990; Greene et aI., 1999; Vinik and Mehrabyan, 2004). Foot ulceration and 
neuropathic pain are two main complications of DPN (Coppini et aI., 2000; Tesfaye and 
Kempler, 2005; Vinik and Mehrabyan, 2004). 
1.3.1.1.1 Painful DPN and Mechanism of Neuropathic Pain 
It is as mentioned earlier acknowledged that diabetic patients are at risk of developing painful 
DPN although it is difficult to estimate the true prevalence of neuropathic pain as different 
criteria are used for its definition. Some reports estimates that 10-20% of patients with 
diabetes have neuropathic pain, while others suggest it is as high as 50% in patients with a 
long diabetes duration (Gore et al., 2005; Tesfaye and Kempler, 2005; T611e et aI., 2006; 
Vinik and Mehrabyan, 2004). A recent study by Davies et al (2006) shows a prevalence of 
painful DPN of 26%. This study was done in patients over 18 years old and the mean age for 
the study population was 66 years. It was found that 60% of the study population of 269 type 
2 DM patients had some degree of DPN and 26 % of whole study population had painful 
DPN or mixed pain (painful DPN as well as non neuropathic pain).This was determined by 
clinical examination as well as subjective pain questionnaires (Davies et aI., 2006). 
Pain can be divided into nociceptive pain (figure 1.5) or neuropathic pain (figure 1.6). 
Nociceptive pain is normal pain caused by external stimulation leading to receptor 
stimulation and activation of normal pain pathways, while neW'Opathic pain does not require 
any receptor stimulation and is caused by dysfunction of the nervous system. Under normal 
conditions, a noxious stimulus will activate nociceptors which are nerve endings of thinly 
myelinated A-8 fibres and unmyelinated C-fibres, both of which transmit painful stimuli and 
temperature sensation. These peripheral nerve fibres will transmit the pain signal into the 
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dorsal hom of the spinal cord where they synapse with second-order sensory neurons. The 
synapse occurs in lamina I (marginal zone) and in lamina II (substantia gelatinosa). 
The synapse results in the release of specific excitatory neurotransmitters from the afferent 
neurons (de Leon-Casasola, 2007). The main excitatory neurotransmitters thought to be 
involved in the pain pathway are glutamate and substance P. The post synaptic response of 
glutamate release is mainly mediated via N-methyl-D-aspartate (NMDA), kainite (KA) and 
a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMP A} receptors while substance 
P interacts with tachykinin receptors (NK1). Glutamate and Substance P binds to AMPA and 
NK-1 receptors respectively and if the stimulus is strong enough AMP A receptors will 
depolarise the membrane and remove Mg2+ blockage of NMDA receptors. Glutamate can 
bind to the unblocked NMDA receptors on second order sensory neurons of dorsal hom and 
Na+ and Ca2+ can be transported in. In addition, substance P binding increases sensitivity of 
these second order sensory neurons and up-regulates voltage gated Na + channels and 
facilitates NMDA mediated transmission (de Leon-Casasola, 2007; Zhuo, 2007) and pain 
signals can then be transmitted via the spinothalamic tract to the thalamus in the brain where 
the signal is perceived as pain (figure 1.5). As important as the ascending pain pathway just 
described, is the descending system which includes the serotonergic and noradrenergic 
pathways and originates from the cortex, thalamus and brainstem (Brodal, 2005). The 
activated descending pain modulatory neurons can project to the dorsal hom of the spinal 
cord and release neurotransmitters such as noradrenaline (NA) and serotonin (5H1). These 
neurotransmitters suppress pain by inhibiting the transmission of incoming painful stimuli 
from the afferent nociceptor neurons as well as inhibition of second order sensory neurons 
(de Leon-Casasola, 2007). 
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Figure 1.5: Simplified overview of the mechanism of normal nociceptive pain ascending pathway. A. A 
noxious stimulus will activate the nociceptors of the peripheral nerve fibres . The pain signal is then transmitted 
by the A-O fibres and unmyelinated C-fibres to the dorsal hom in the spinal cord. Here the afferent neurons will 
synapse with second order sensory neurons. The pain signal is then transmitted by these neurons to the thalamus 
in the brain via the spinothalamic tract. In the brain the perception and interpretation of the pain signal take 
place and the descending pathway can be activated which can have an inhibitory action on sensory neurons. B. 
The synapse between afferent neurons and second order sensory neurons takes place in the dorsal root. The 
afferent neurons will release excitatory neurotransmitters such as glutamate and substance P. Glutamate can then 
bind to AMPA and NMDA receptors on the sensory neurons, while substance P binds to NKl. These 
interactions will result in activation of receptors and stimulation of the sensory neurons membrane and the pain 
impulse can be further transmitted. 
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In painful DPN it is the damage of the peripheral nerves that initiates the neuropathic pain. It 
mainly involves the damage of the small thinly myelinated A-o fibres and unmyelinated C-
fibres which as mentioned earlier transmit painful stimuli. However, larger fibres such as 
myelinated A-P fibres which transmit touch, vibration and position perception may also be 
involved. Furthermore, motor involvement with large myelinated A-a. fibres can also be 
involved in peripheral neuropathy (Quattrini and Tesfaye, 2003; Tesfaye and Kempler, 2005; 
Vinik and Mehrabyan, 2004). 
The signs and symptoms ofDPN vary depending on which fibres are involved but commonly 
there is involvement of both large and small fibres. This damage of fibres may be due to the 
effect of hyperglycaemia and the degree of damage correlates with the degree and duration of 
hyperglycaemia. However, the full mechanism of neuropathic pain in DPN is not fully 
understood (Benbow and Macfarlane, 1999; Boulton, 2003; Kapur, 2003; Quattrini and 
Tesfaye, 2003; Tesfaye and Kempler, 2005; Tolle et al., 2006). It is thought that damage will 
result in hyperactive nociceptors which continuously fire without noxious stimuli present. 
This constant stimulation may result in peripheral sensitization, meaning that there is a 
decrease in the threshold at which the nociceptor responds. The pain signal is then 
transmitted via afferent neurons to the dorsal hom where they synapse with sensory neurons 
as explained previously (see figure 1.6). Sprouting is a phenomenon that may also occur. This 
is a re-structure of afferent neurons which sprout and form new connections with the neurons 
in the dorsal hom. It is for example thought that A-P fibres can sprout to a region in the 
dorsal hom (lamina II) where nociceptive C-fibres are located (International Association for 
the Study of Pain, 2000). This will result in a normal non-painful sensory input carried in A-P 
fibres being transmitted as a pain signal (allodynia). Sprouting may also enhance the release 
of neurotransmitters which increase pain signal transmission. Glutamate and Substance P can 
as described earlier bind to AMPA and NK-l receptors respectively and NMDA receptors are 
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as a result unblocked. Glutamate can bind to NMDA receptors on second order sensory 
neurons and transmit the pain signal. These neurons can also become sensitized which means 
that they can respond at a lower threshold and to a wider peripheral area and this is called 
central sensitization (figure 1.6). The peripheral sensitization of nociceptors and central 
sensitization of second order sensory neurons is believed to play a large role in the 
mechanism of neuropathic pain. 
The descending inhibitory pathway may also be affected by nerve injuries. Under normal 
circumstances serotonergic and noradrenergic systems release serotonin and noradrenaline 
which can inhibit both the sensory neurons in the dorsal hom as well as the release of 
neurotransmitters from afferent nociceptive neurons (de Leon-Casasola, 2007). Dorsal hom 
GABA can also assist in the inhibitory action by blocking the excitatory activity of 
glutamate. In the case of nerve injuries these inhibitory actions can be reduced resulting in 
excessive release of glutamate and substance P and second order sensory neurons can 
continue to transmit pain signals. 
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Figure 1.6: Mechanisms of pain ascending pathway and the damage seen in painful DPN. 
A. In painful DPN there is damage of unmyelinated C-fibers, myelinated A-alP and A-o fibers which transmit 
noxious information and this damage leads to hyperactive nociceptors and constant firing without noxious 
stimulus. B. The constant firing will stimulate the release of excitatory neurotransmitters such as glutamate from 
afferent neurons. Possible sprouting due to injury can result in enhanced neurotransmitter release, therefore 
enhancing transmission of the pain signal via second order sensory neurons. In addition, A-P which normally 
transmits sensation of touch can sprout into lamina II where nociceptive C-fibres are located. This sprouting 
may result in that a normally non painful stimulus is transmitted as painful signal and this give rise to allodynia. 
Furthermore, there may be a defect in the inhibitory input of the descending pathway, resulting in an increased 
pain response. The constant stimulation of second order sensory neurons in the substantia gelatinosa of the 
dorsal hom can result in sensitization, which means that these neurons can respond at a lower threshold and to a 
wider peripheral area, leading to central sensitization. 
One should be aware of that this is just a broad overview of the pain pathway and there are 
more mechanisms involved. 
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Patients with painful DPN can experience different types of neuropathic pain and symptoms 
may vary from patient to patient. Most commonly, the pain is characterized as burning, 
shooting and tingling (Benbow and Macfarlane, 1999; Gore et a1., 2005; Greene et a1., 1999; 
Quattrini and Tesfaye, 2003; Vinik and Mehrabyan, 2004; Woolf and Mannion, 1999). This 
type of pain can in many cases be associated with hyperalgesia (increased pain response) and 
allodynia which means the pain is due to a stimulus which does not normally provoke pain 
(Woolf and Mannion, 1999; Zhuo, 2007). This stimulation can be gentle pressure, cold, 
warmth or touch. Patients may for example experience pain due to the sensation of clothing 
touching their feet or from the sensation of sheets against the affected area (Greene et al., 
1999; Vinik and Mehrabyan, 2004). It is thought that the central sensitization seen in painful 
DPN contributes to the occurrence of hyperalgesia and sprouting of A-~ fibres can result in 
allodynia (de Leon-Casasola, 2007). Another condition which can be seen in peripheral 
neuropathy is hypoalgesia (Vinik and Mehrabyan, 2004). This condition is defined as 
diminished pain or sensation in response to normal painful stimulus and is caused by loss of 
small fibres. The perception of pain and sensation is impaired and patients might therefore 
not feel injuries such as cuts from sharp objects or burns from e.g. hot water. 
Painful DPN can be either acute or chronic. Acute painful DPN usually resolves after 6 
months and is relatively uncommon. It occurs in type I and type II DM patients with poor 
glycaemic control (Greene et al., 1999; Quattrini and Tesfaye, 2003). Chronic painful DPN 
often occurs in patients who have a long history of diabetes, and the neuropathic pain often 
persists for longer than 6 months (Nicholson, 2006; Vinik and Mehrabyan, 2004). Patients 
may experience extreme pain in the feet which is often worse at night (Quattrini and Tesfaye, 
2003). Other symptoms may be insomnia, anxiety and a worsening of quality of life. Chronic 
painful DPN is very difficult to treat, although various treatments are available. The side-
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effects and drug tolerance of currently available medications may however be problematic 
(Quattrini and Tesfaye, 2003; Vinik and Mehrabyan, 2004). 
1.3.1.1.2 Foot ulceration 
The loss of pain and temperature sensation caused by small fibre damage may increase the 
risk of injury and also increase the risk of possible foot ulceration and subsequent infections 
as well as gangrene (Greene et al., 1999). Foot ulceration is a serious condition which may 
lead to amputation of the toes and in severe cases the whole foot. In fact, neuropathy 
increases the risk of amputation 1.7-fold. If there is deformity the risk increases 12-fold and if 
there have been previous ulcerations the risk of amputation increases 36-fold (Vinik and 
Mehrabyan, 2004). Foot ulceration is commonly associated with discomfort and in a study by 
Ribu et al. 75 % of patients had pain due to diabetic foot ulceration (DFU). Furthermore, 57% 
of these patients also reported pain in association with activity (walking/standing) and at 
night (Ribu et al., 2006). It is therefore important that diabetic patients receive a good 
education on daily foot care and check their feet regularly. Furthermore, the patients should 
try and achieve good glycaemic control, as this decreases the risk of nerve damage and 
subsequent foot ulceration. 
1.4 Diabetes and the Central Nervous System 
Diabetes is a complex disease with many possible complications as described previously. 
Diabetes has been linked with impairment of sleep, cognitive function and, as a result, a 
reduced quality of life (QOL). Painful DPN is one complication which can have a severe 
impact on all the above parameters. In a study by Gore and colleagues, patients with painful 
DPN are reported to have a significant disturbance in sleep and QOL when compared to both 
diabetic and non-diabetic controls (Gore et al. 2005). 
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1.4.1 Diabetes and Sleep 
Sleep is an important biological function and an essential factor for human well being and to 
be able to function properly. Sleep deprivation can affect a person's mood and also impair 
psychomotor performance and cognitive function the next day, and extreme sleep deprivation 
can cause hallucinations and paranoia. 
It is important to understand the physiology of normal sleep and the mechanisms involved in 
sleep-wake states in order to investigate the negative effects that diabetes and complications 
such as neuropathic pain and hyper/hypoglycaemia may have on sleep quality. 
1.4.1.1 Physiology of normal Sleep 
1. 4.1.1.1 Sleep and wake mechanisms and neurotransmitters involved 
The sleep-wake cycle is very complex and all of the mechanisms involved are not fully 
understood. It is known that the sleep-wake cycle is regulated by both a circadian process 
(process e) and homeostatic process (process S). The homeostatic process involves a 
person's sleep drive and is dependent on the duration of prior wakefulness and also the 
duration and quality of prior sleep episodes. The longer a person remains awake the stronger 
the urge and need to sleep become. The circadian process is an approximately 24 hour cycle 
which is controlled mainly by the suprachiasmatic nucleus (SeN), the master clock in the 
brain. The SeN receives light input from the retina via the optic nerve and is therefore under 
the influence of the environmental 24 hour light/dark cycle. The SeN itself can then regulate 
many functions such as body temperature, hormone release, and neuronal projections which 
activate either sleep or wake promoting neurons. One important honnone which is driven by 
the SCN clock is melatonin (Saper et al., 2005). Melatonin has sleep-inducing properties and 
is secreted during darkness; the levels rises when the sun goes down and starts to decrease 
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again in the latter part of the night. There are several other hormones and neurotransmitters 
involved in the sleep-wake mechanism and there is a fine balance between the sleep-
promoting neuronal group and wake- promoting neuronal group with the activity of one 
group inhibiting the activity of the other group. This has been described as a "flip-flop 
model" (see figure 1.7A and B) as the change from a stable wake state to sleep occurs very 
quickly (Saper et aI., 2001; Saper et al., 2005). In wake, the major excitatory 
neurotransmitter glutamate is released and can directly stimulate the cerebral cortex, leading 
to cortical activation and wakefulness. In addition, glutamate will activate orexin-containing 
neurons and other wake-promoting neuronal groups located mainly in the brainstem and 
hypothalamus. Orexin can increase the activity of the wake-promoting neurons which will 
release neurotransmitters such as acetylcholine, noradrenaline, serotonin, histamine, and 
dopamine, which all have several actions (Saper et al., 2005). These neurotransmitters can 
inhibit sleep-promoting neurons in the ventrolateral preoptic nucleus (VLPO), switching this 
system off and they can all produce alertness and wakefulness as they promote cortical 
activation (Gallopin et al., 2000). In addition, hormones such as cortisol and adrenaline are 
also involved in stimulating wakefulness and a person is now in a stable wake state (see 
figure 1.7 A). When the desire and need to sleep is strong enough (homeostatic control) and 
the main inhibitory neurotransmitter GABA is released, the switch to sleep will take place. 
GABA is released by GABA neurons which project to the VLPO. These neurons are active 
during sleep and release not only GABA but also galanin (Saper et al., 2001). Activation of 
these neurons will inhibit wake promoting neurons and therefore assist in the switch to sleep 
taking place. Another neurotransmitter which is believed to be involved in promoting sleep is 
adenosine (Saper et al., 2005). Adenosine levels build up over time and it is thought that 
when high levels are reached this will also induce sleep by inhibiting the release of wake 
promoting neurotransmitters. In addition, several hormones are associated with sleep. These 
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include melatonin, prolactin, insulin and growth hormones (GH). The levels of these 
hormones increase and are thought to help facilitate sleep (see figure 1.7B). 
A. Under the influence of Circadian process and Homeostatic process 
- Circadian arousal signal and homeostatic wake drive stimulate wakefulness 
• 
I Cerebral cortex I 
/ t 
Acetylcholine Serotonin 
• Wake/arousal promoting neurons 
will be active and the release of 
neurotransmitters will inhibit the 
action of sleep promoting neurons in 
the VPLO 
• Secretion of cortisol is 
increased during early morning 
hours just before awakening, 
while melatonin production 
decreases 
• Adrenaline levels are 
increased during wakefulness 
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Figure 1.7A: Wake/Sleep Switch Model-Wake state. There is a fine balance between sleep pronwting 
neuronal groups and arousal/wake promoting neuronal groups and there is a mutually inhibitory effect from both 
these groups. The switch between stable wake and sleep is quick and the full mechanism of the switch between 
these states is not known, however both the circadian process and homeostatic process plays a regulatory role in 
the whole wake-sleep cycle. Wakefulness is generated by signals from these 2 processes and triggers a series of 
responses. Glutamate which is the major excitatory neurotransmitter in the brain can directly stimulate cerebral 
cortex, leading to cortical activation and wakefulness. In addition, glutamate will activate orexin containing 
neurons. These neurons can then activate the whole arousal system which contains wake promoting neurons. 
These can in turn release neurotransmitters such as serotonin, noradrenaline, dopamine and also histamine, 
which all have several actions. They can inhibit sleep promoting neurons in the VPLO, switching this system off 
and they can also cause cortical activation and wakefulness by stimulating the cerebral cortex. Increased levels 
of honnones such as cortisol and adrenaline can also contribute to a stable wake state. VPLO= ventrolateral 
preoptic nucleus 
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B. Under the influence of Circadian process and Homeostatic process 
- Circadian hypnotic signal via SeN and homeostatic sleep drive will promote sleep 
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Figure 1.7B: Wake/Sleep Switch Model-Sleep state. During wake adenosine levels build up and it is thought 
that when high levels are reached this will induce sleep by inhibiting the release of wake promoting 
neurotransmitters. The levels of hormones such as insulin, prolactin, growth hormone and melatonin are 
increased and will further induce sleep. When the desire and need to sleep is strong enough the switch will take 
place and neuronal projections of GABAergic neurones will activate sleep promoting neurones in the VPLO, 
which in turn will release neurotransmitters such as GABA and galanin. GABA is also a major inhibitory 
neurotransmitter and can therefore inhibit the activity of wake promoting neurons and this inhibition will result 
in no action of arousal promoting neurotransmitters and therefore no cortical activation. SCN=suprachiasmatic 
nucleus, VPLO= ventrolateral preoptic nucleus, GABA= y - aminobutyric acid 
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1.4.1.1.2 Sleep cycle 
Once sleep is initiated there will be defined periods of rapid eye movement (REM) sleep and 
non rapid eye movement (NREM) sleep throughout the sleep period. Each REMINREM 
cycle last approximately 90-110 minutes with approximately 4-5 cycles per night (Nicolau et 
a1.,2000). 
NREM sleep consists of light sleep (stage 1 and 2) and deep sleep (stages 3 and 4). Stage 1 
sleep is the interim between wake and sleep and usually accounts for 4-5 % of total sleep 
time. Stage 2 sleep is the most common stage of sleep, making up 45-55 % of total sleep 
time. Stage 3 is when deep sleep begins and body temperature and blood pressure decrease. 
When a person enters stage 4 sleep body temperature and blood pressure decreases even 
further and muscle activity is very limited (figure 1.8). A combination of stage 3 and 4 
together is also known as slow wave sleep (SWS) or delta sleep and is thought to be the 
restorative phase of sleep (Tasali et al., 2007). SWS is most common during the first part of 
the night and decreases as the night progresses. REM sleep is on the other hand most 
common during the second half of the night and is the phase when the brain is more active 
and dreaming occurs. The first REM period normally occurs around 70 to 90 minutes after 
sleep onset and is relatively short. The REM periods will then increase in length as the night 
progresses and the last REM period can last up to 1 hour. REM sleep makes up 20-25% of 
total sleep time and is thought to be involved in memory consolidation (Kamel and 
Gammack, 2006; Najib, 2006; V gontzas and Kales, 1999). 
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Figure 1.8: Sleep cycle. Nonnal sleep is defined by cyclic appearance of non rapid eye movement sleep 
(NREM) and rapid eye movement sleep (REM) with each cycle being approximately 90-110 minutes in 
humans. Stage 1 is the first stage of sleep and takes up around 4-5 % of total sleep time. Stage 2 is characterised 
by appearance of K-complex and spindles (explained in more details in section 2.4 of general material and 
methods) and is the most common stage of sleep with 45-55 % of total sleep time. Stages 3 and 4 are called deep 
sleep or slow wave sleep due to the occurrence of slow delta waves. In young healthy adults stages 3 and 4 
occupy 4-6 % and 12-15% of total sleep time, respectively. Stage 3 is when 20-50% of a 30 second epoch 
consists of slow delta waves and stage 4 is defined as above 50% delta waves in a 30 second epoch. In REM 
sleep the brain waves wiJl speed up and rapid eye movement occurs and this phase is also called stage 5 and 
occupies around 20-25 % of total sleep time. For more detailed descriptions about sleep stages and staging 
please see section 2.4 in general method and materials. BP= Blood pressure. 
Several studies have looked at the homeostatic regulation of sleep and the effects it as on 
sleep stages and on the intensity of slow wave sleep. A study in healthy young subjects by 
Brunner and colleagues (1993) showed that after sleep deprivation (4 hours sleep for 4 
nights), there was an increase in both total sleep time and REM sleep as well as a decrease in 
sleep onset latency in the first two recovery nights. SWS was also increased but only in the 
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first recovery night and slow wave activity (spectral power density in the 0.75-4.5 Hz range) 
in NREM sleep increased by around 20% in the first recovery night. Similar results were seen 
in another study by Dijk and colleagues (1991). Subjects were kept awake for 24 hours before 
recovery sleep started in the morning. Even though the recovery sleep was initiated at a 
circadian phase where NREM sleep propensity was not high one could see an increase in 
slow wave activity in NREM sleep during daytime recovery sleep compared with baseline 
nocturnal sleep. Furthermore, other studies have looked at the effect of specific SWS 
deprivation rather than full sleep deprivation. It has been shown that slow wave activity does 
not only increase after full sleep deprivation but also after specific SWS deprivation. This 
increase in slow wave activity could be seen in the first hour after SWS deprivation both 
during nocturnal sleep but also in daytime recovery sleep (Dijk and Beersma, 1989). Other 
studies have looked at slow wave activity and circadian rhythm and an example of this was a 
study by Dijk and colleagues. Subjects were scheduled to 28 hours day/night cycle so that the 
sleep episodes eventually occurred at different parts of the circadian 24 hour cycle. The 
results showed that slow wave activity during NREM sleep had a low circadian modulation 
and did not follow the circadian rhythm of sleep propensity (Dijk and Czeisler, 1995). This 
suggests that slow wave activity is a good marker of the homeostatic regulation of sleep. 
1.4.1.1.3 Gender and age difference of normal sleep cycle 
There are differences in human sleep patterns due to both age and gender. It is for example 
well known that total sleep time decreases with age. Hume et aI (1998) showed that this 
decrease in total sleep time was partly due to increased wake periods within sleep, therefore 
more fragmented sleep. Older adults aIso have a tendency to have more arousals than 
younger adults (Boselli et aI., 1998; Neubauer, 1999). Furthermore, the amount of SWS 
decreases with age, while the amount of REM is only slightly reduced (Carrier et aI., 2001; 
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Ehlers and Kupfer, 1997; Neubauer, 1999). In addition, the prevalence of many sleep 
disorders increases with age and may cause a disturbance of sleep with increase awakenings, 
more fragmented sleep, arousals and delayed sleep onset (Hornyak and Trenkwalder, 2004; 
Wolkove et al., 2007). 
There is also a gender difference in sleep and Dijk and colleagues were amongst the first to 
look at such differences in EEG spectral power. They found that young women had 
significantly higher power densities over a wide frequency range including delta, theta and 
low alpha compared with young men (Dijk et al., 1989). A later study by Carrier and 
colleagues (2001) showed a gender difference across the age when looking at sleep in 
subjects aged 20 to 60 years with women having higher power density in for example the 
delta frequency range compared with men. Another study carried out in depressed patients 
showed no gender differences in general spectral power but a significant reduction in delta 
activity in the depressed men compared with the women (Nissen et al., 2002). A study by 
Ehlers and Kupfer (1997) showed that men and women had similar amount of SWS (by 
visual scoring) and similar mean slow wave activity (by spectral analysis) when in their 
twenties (20-29yrs). However, a significant reduction in both SWS and slow wave activity 
occurred in men in their thirties (30-40 yrs) while this decrease was not seen in women of 
same age, suggesting that the gender difference seen in regards to SWS may not become 
apparent until the age of 30-40 yrs (Ehlers and Kupfer, 1997). 
1.4.1.1.3 Normal physiological processes within a sleep episode 
As mentioned previously the sleep-wake cycle involves the central nervous system and 
reflects changes in cerebral cortex activation. However, there are several other changes 
occurring between wake state and sleep state as well as during the sleep episode. Both body 
temperature and blood pressure decrease during NREM and then increase again during REM 
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(see figure 1.8). Respiratory function also changes during sleep. At sleep onset and in NREM 
sleep stage 1 and possible stage 2 there may be evidence of periodic breathing. This means 
that there are oscillations in breathing amplitude. There may be clusters of breaths separated 
by apnoea or near apnoea events. When one enters a more steady state of NREM sleep, 
including stages 2, 3 and 4, these oscillations disappear and breathing occur in a more steady 
and regular pattern. In REM the breathing changes again and can become erratic and shallow 
with an increase in hypo ventilation. This may result in lower levels of blood oxygen 
saturation and therefore greater hypoxemia than during NREM sleep (Kryger et aI., 2005). 
Furthermore, sleep will have an effect on endocrine and metabolic function. Hormone levels 
of prolactin and growth hormone are, as previously mentioned, increased during sleep while 
cortisol levels are decreased as its release is inhibited. In addition, glucose regulation is 
changed during sleep and nocturnal glucose levels increase. The increase in nocturnal glucose 
concentration is due to a decrease in glucose utilisation, mainly by the brain but also by a 
decrease in peripheral glucose use due to lower muscle tone during sleep. Blood glucose 
concentration rises during the first part of the night and there is a peak in the middle of the 
sleep episode. Levels will then drop during the latter part of the night (Boyle et al., 1994). 
The rise may be due to the fact that the reduction in cerebral glucose metabolism mainly 
occurs during slow wave sleep which is most predominant at the beginning of the night. 
Another factor which is influenced by sleep is appetite. Ghrelin and leptin are two important 
hormones involved in regulating appetite. They have been associated with changes in hunger, 
ghrelin which stimulates appetite and leptin which suppresses appetite and food intake. 
Several studies have shown that if there is a reduction in sleep duration, e.g. during sleep 
restriction or sleep deprivation, levels of gherlin increase while levels of leptin decrease, 
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suggesting that sleep loss will lead to increase in appetite and therefore possible weight gain 
(Spiegel et al., 2004; Taheri et al., 2004, van Cauter et al., 2005). 
One should be aware that there are many more physiological changes that are regulated by 
sleep and the onset of sleep, and above is just a brief overview of normal sleep physiology 
and the mechanisms involved in the sleep-wake cycle. 
1.4.1.2 Possible physiological changes of sleep in diabetic patients 
There are many disorders that can affect people's sleep, such as insomnia, restless leg 
syndrome, periodic limb movements and sleep disordered breathing (including apnoeas and 
hypopnoeas), and they all appear to have a high prevalence in diabetic patients (Chansens, 
2007). Sleep apnoea is very common in diabetics and can cause arousals and awakenings all 
through the night (West et al., 2006). Frequent awakenings will result in more fragmented 
sleep, with a reduction in total sleep time and possibly a reduction in SWS. In addition, 
diabetic patients with painful DPN may report that their pain interferes with their sleep 
leading to difficulties falling asleep and increase in wake periods (Benbow et al., 1998; Galer 
et al., 2000). Another factor which may affect the sleep of diabetic patients is nocturnal 
glucose levels (Bendtson et al., 1992). 
1.4.1.2.1 Sleep Apnoea and Hypopnoea 
Sleep apnoea is a disorder with complete cessation of breathing (apnoea) and/or shallow 
breathing (hypopnoea) during sleep. It is thought to be more common in men than women 
and other factors can increase the risk of sleep apnoea including age and obesity. Sleep 
apnoeas 'can be either central (CSA) or obstructive (OSA) with the latter being the far most 
common, resulting from partial or full collapse of the upper airway. OSA is commonly 
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associated with metabolic syndrome and diabetes and may be explained by the high 
prevalence of obesity seen in type II DM patients (Resnick et al., 2003). A study by West and 
colleagues showed that the prevalence of OSA was significantly higher in diabetic male 
population compared with healthy population and could partly be explained by body mass 
index (West et al., 2006). OSA seen in particularly type II diabetics has been thought to be a 
complication of the disease or a result of obesity but recent studies suggest that such 
dysfunction in breathing occurs at an early stage in subjects with pre-diabetes. A study by 
Punjabi et al. (2002) with overweight middle aged men with OSA showed that 12 % of 
subjects had undiagnosed diabetes and as much as 40% had impaired fasting glucose (Punjabi 
et al., 2002). Another study has suggested that SDB causes metabolic disturbance and is 
associated with insulin resistance and glucose intolerance, independently of risk factors such 
as age, gender and obesity (Punjabi et al., 2004). SDB can be a major cause of sleep 
disturbance, with increased arousals and awakenings resulting in excessive daytime 
sleepiness. 
1.4.1.2.2 Periodic Limb Movements of Sleep 
Restless leg syndrome (RLS) is another disorder commonly seen in type II DM patients 
(Lopes et al., 2005). It has been suggested that this is triggered by an abnormal sensory input 
from small fibers and is therefore thought to be a feature of DPN (Gemignani et al., 2007). 
RLS is characterized by unpleasant limb sensations such as burning and creeping. 
Furthermore, patients have an uncontrollable urge to move limbs when at rest and this 
irresistible urge to move is an effort to relieve the uncomfortable/irritating feeling 
(Clavadetscher et aI., 2004). RLS may therefore interfere with sleep onset latency, increasing 
the time to fall asleep. Commonly associated with RLS are periodic limb movements of sleep 
(PLMS) and as many as 80 to 90% of patients with RLS also have PLMS (Alsaeedi and 
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Alshammari, 2005; Paulson, 2000; Rijsman et al., 2004). PLMS can occur independently 
without concurrent of RLS. Prevalence of PLMS increases with age and over one third of 
population above 65 years have some degree of periodic limb movements. PLMS do not 
necessarily cause interference of sleep, however if the rate of movements is high they can 
cause arousals and increase nocturnal awakenings, resulting in sleep fragmentation and 
therefore impairment of sleep (Alsaeedi and Alshammari, 2005; Neubauer, 1999; Paulson, 
2000). 
1.4.1.2.3 S/eepandpainful DPN 
Sleep disturbance is very common in patients with pain and between 50-70% of people 
seeking help for chronic pain have reported sleep impairment (Gore et al., 2005). In a study 
by Galer and associates it was shown that painful DPN had a high impact on sleep and more 
than half of the patients experienced worsening of the pain at night time (Galer et al., 2000). 
This was also supported in a study by Benbow et al. (1998) where the diabetic study group 
had problems with their sleep as their neuropathic pain got worse at night. In addition to 
worse sleep quality, patients with chronic pain report a higher rate of insomnia, twice as high 
as seen in subjects without pain (Moldofsky, 2001; Sutton et al., 2001). Pain is thought to 
interfere with sleep by increasing the number of arousals, awakenings and sleep stage shifts, 
resulting in sleep fragmentation and worse sleep efficiency. There is evidence that pain 
decreases the percentage of slow wave sleep and increases the percentage of the lighter stage 
1 sleep. 
1.4.1.2.4 Sleep and nocturnal glucose levels 
It is known that hyperglycaemia can increase the risk of cardiovascular complications as well 
as worsening painful DPN (Gore et al., 2005; Haffner and Cassells, 2003; Idris et aI., 2006; 
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Laakso, 1999; Tesfaye and Kempler, 2005; Vinik and Flemmer, 2002). However, the effect 
on sleep is not fully known. It is thought that nocturnal hyperglycaemia is associated with 
sleep apnoea/hypopnea and severe oxygen de saturation, and a study by Pallayova et al. 
(2006) showed a strong correlation between the two. Several other studies have shown a link 
between obstructive sleep apnoea, sleep loss and insulin resistance (Punjabi et aI., 2002 
Punjabi et al., 2004, Spiegel et al., 2005). 
Another concern is nocturnal hypo glycaemia. This is commonly seen in diabetic patients, 
especially in type 1 DM where it occurs in 29-56% of all patients (Bendtson et al., 1992). 
Almost 50 % of all severe hypoglycaemic events occur during sleep at night and the duration 
of nocturnal hypo glycaemia varies between 1 and 8 hours. These severe episodes can cause 
coma and may also lead to cardiac arrhythmias and death (Allen and Frier, 2003). Nocturnal 
hypo glycaemia can also cause more common side effects, such as impaired cognitive 
function (Matyka et aI., 2000), and it may also disrupt patients' sleep architecture. In a study 
by Gais et al (2003) it was reported that hypo glycaemia had an awakening effect on healthy 
subjects when using a hypoglycaemic clamp. Bendtson et al (1992) found that 
hypo glycaemia reduced the duration of deep sleep and there was an increase in short 
arousals. However, other studies contradict these findings and suggest that sleep architecture 
is not disturbed by nocturnal hypoglycaemia. In a study in type II DM adolescents Porter et al 
(1996) found that there were no changes in sleep stages, fragmentation or arousals due to 
nocturnal hypoglycaemia. Matyka et al (2000) showed similar results in a study carried out in 
diabetic children. There were no significant differences in sleep architecture in children with 
a hypoglycaemic night compared with non hypoglycaemic night. Sleep was measured by 
polysomnography and glucose levels were measured by a glucose oxidase method involving 
overnight blood sampling. However, they did find found defects in sleep architecture in 
children with type I DM compared with controls. Type I DM children had more disrupted 
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sleep and awakenings of various length when compared with control. Such disturbances can 
have a significant impact on daytime functioning and these will be discussed later. But as 
stated above there appears to be no direct evidence to suggest that these abnormalities in 
sleep architecture are related to nocturnal hypo glycaemia (Matyka et aI., 2000). Another 
study by Pillar and associates (2003) found that the arousals from sleep may be due to rapid 
changes in blood glucose levels even if the absolute levels not necessarily are low (Pillar et 
aI., 2003). Rapid falls in glucose levels, as measured by continuous glucose monitoring 
system, were associated with awakenings from sleep while profound nocturnal 
hypoglycaemia was not. 
Apnoeas, PLMS, pain and possible nocturnal glucose levels can all interfere with a patient's 
sleep, with increased arousals and awakenings resulting in fatigue and excessive daytime 
sleepiness. This can lead to cognitive dysfunction and may also affect patient mood and alter 
quality of life. 
1.4.2 Diabetes and Cognitive function 
As mentioned previously a good night's sleep is important for people to be able to function 
properly and loss of sleep due to pain or sleep apnoea can result in severe impairment of next 
day performance such as concentration, attention, psychomotor skills and memory. Daytime 
performance may also be affected by medications and neuropathic pain itself, as it can make 
it more difficult to carry out attention based tasks. To be able to assess a person's 
neuropsychological function a broad battery of cognitive function tests can be used. Test 
batteries have generally involved assessment of psychomotor skills, attention skills and long-
tenn, short-tenn and working memory (Draelos et al., 1995; Sommerfield et al., 2003). 
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Patients' glucose control can also affect daytime performance as episodes of both 
hyperglycaemia and hypoglycaemia can result in cognitive dysfunction (Cox et al., 2005; 
McAulay et aI., 2001; Sommerfield et aI., 2004; Sommerfield et aI., 2003). It is thought that 
optimal cognitive function is achieved when the glycaemic range is between 4 and 15 mmoVl 
and that dysfunction occurs if values are outside this range. It is therefore important for 
diabetic patients to have a good glycaemic control to minimise the risk of impaired cognitive 
function (Cox et aI., 2005). 
1.4.2.1 Effect of hyperg/ycaemia episodes on cognitive function 
Evidence for the effects of acute hyperglycaemia on cognitive function is contradictory. 
Several studies have reported that acute hyperglycaemia is associated with mild cognitive 
impairment (Cox et al., 2005; Sommerfield et al., 2004) while others have reported no 
changes in cognition related to the hyperglycaemic state (Draelos et al., 1995). Most studies 
reporting cognitive impairment have been carried out in patients with type I diabetes, but 
more evidence is now accumulating with respect to type II diabetic patients. In a study done 
by Sommerfield and associates (2004) it was reported that acute hyperglycaemia significantly 
impaired working memory, attention and decreased speed of information processing in 
patients with type II diabetes. Furthermore, acute hyperglycaemia also had a detrimental 
effect on patient mood (Sommerfield et al., 2004). Another study carried out by Cox and 
associates (2005) assessing both type I and II diabetic patients showed impairment in 
cognitive function at a glucose threshold of around 15mmoVl and this impairment was seen in 
55% of all subjects (Cox et aI., 2005). However, such decline in cognitive function due to 
hyperglycaemia was not seen in a study done by Draelos et al (1995). This study involved 
patients with type I diabetes and no changes in cognitive function were seen at glucose levels 
as high as 14.4 mmol/l or even as high as 21.1 mmol/l (Draelos et aI., 1995). 
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1.4.2.2 Effect of hypog/ycaemia episodes on cognitive function 
Hypoglycaemic episodes can have serious effects on the human brain. One consequence of 
hypo glycaemia is acute neuroglycopenia which causes deterioration of cognitive function. 
Neuroglycopenia refers to a lack of glucose (glycopenia) in the brain and as this affects 
function of neurons, it can lead to change in behaviour and altered brain function (McAulay 
et al., 2001; Sommerfield et al., 2003). This deterioration in cognitive function occurs when 
glucose levels fall to < 3.0 mmol/l (McAulay et aI., 2001; McCall, 2004; Sommerfield et al., 
2004; Warren and Frier, 2005). Furthermore, the onset is immediate and progressive, but 
reversible, as it has been observed that cognitive function returns to normal within 90 min 
after glucose levels return to normal (Sommerfield et al., 2004). However, severe and drawn-
out hypo glycaemia can cause permanent brain damage or even lead to death. It is not clear 
which part/parts of the brain are affected by neuroglycopenia. However, areas of injury have 
been seen in neuroimaging studies in the hippocampus and in the frontal lobes of patients 
who suffered severe but non-fatal hypoglycaemia (Warren and Frier, 2005). 
1.4.3 Diabetes and quality of life (QOL) 
The complications of diabetes which have been discussed can all affect a patient's QOL. As 
mentioned previously, hyperglycaemia and hypoglycaemic can both impair cognitive 
function enough to interfere with a patient's daily life. Hypoglycaemia can also affect a 
patient's well-being and productivity (Davis et al., 2005). Furthermore, nocturnal 
hypoglycaemia still remains a common problem as it not only affects the well being of the 
patient but also causes concern for their carers and family members. 
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Painful DPN can have a substantial effect on patient's QOL (Benbow et aI., 1998; Davies et 
aI., 2006; Galer et al., 2000). As mentioned earlier, it is common for patients to have impaired 
sleep as a result of worsening of the pain at night time, and painful DPN can also have a 
significant impact on enjoyment of life (Galer et al., 2000). Furthermore, in the same study 
carried out by Galer and associates it was shown that painful DPN had a moderate impact on 
parameters such as recreational activities, normal work, social activities, mood and mobility. 
The conclusion from this study is that painful DPN has a negative impact on patient's quality 
of life (Galer et aI., 2000). Neuropathic pain also impacts on employment and a study by 
Meyer-Rosberg on patients with various neuropathic conditions reported that 52% had to 
reduce their working hours as a direct result of pain (Meyer-Rosberg et al., 2001). A similar 
pattern was seen in a study carried out by Tolle et al. (2006). They observed that almost one 
working day per week was lost due to neuropathic pain and that pain severity was associated 
with reduced productivity. 
1.5 Hypothesis and Aims 
The aim of this research project was to characterise sleep in patients with painful DPN and 
investigate the effect pain, obesity and glucose control may have on sleep variables. Increase 
in pain may be associated with decrease in sleep quality and reduced total sleep time. One 
may also find an increase in sleep onset. Obesity is commonly associated with diabetes (type 
2 DM in particularly) and with OSA. One may therefore expect to see a high prevalence of 
OSA in this study group. Furthermore, DPN are thought to increase the occurrence of PLMS. 
And both these conditions may have a negative effect on sleep. 
Another aim was to investigate pregabalin, duloxetine and amitriptyline, all three used in the 
treatment of painful DPN and the effect they may have on pain, glucose levels and sleep 
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parameters including objective and subjective measures. Pregabalin and amitriptyline are 
thought to improve sleep, however, the latter may cause hangover effects in the morning. 
While duloxetine can possibly reduce sleep quality and efficiency due to an alerting effect of 
the drug. Furthermore, both duloxetine and amitriptyline are thought to cause REM 
suppression. Please see Aim and Hypothesis section in each result chapter for more detailed 
description. 
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CHAPTER 2 GENERAL METHODS AND MATERIALS 
2.1 Subjects 
83 diabetic patients (male and females) with painful peripheral neuropathy were recruited for 
this study. Recruitment and screening took place at the Royal Bournemouth Hospital and 
Poole General Hospital. Patients aged 18 years and above, with diagnosis of diabetes mellitus 
for at least a year and neuropathic pain of diabetic origin with a score above 12 on the Leeds 
Assessment of Neuropathic ymptoms and Signs (LAN S) were eligible for enrolment. 
Patients were excluded if there was evidence of end stage disease of a major system evidence 
of recurrent and/or a severe hypoglycaemic event in last 3 years, or evidence of recent 
ischemic event. Pregnant or breast-feeding women and patients with a history of dependence 
on or abuse of alcohol/recreational drugs were also excluded. Furthermore, patients were not 
allowed to enter the study if they had been involved in another clinical trial within the last 3 
months prior to this study. 
The patients were sequentially randomized into three treatment arms (pregabalin, 
amitriptyline, and duloxetine). The groups were matched for age and gender where possible. 
2.2 Study design 
The study was a double-blind, randomised, parallel groups investigation into the effects of 
pregabalin, duloxetine and amitriptyline on aspects of pain, sleep and next day performance. 
The study design was over 36 days and consisted of 3 different treatment periods and was 
conducted according to ICH-GCP guidelines (Good Clinical Practise) at the urrey linical 
Research entre (Surrey RC), Faculty of Health and Medical Sciences, University of 
Surrey, UK and approved by the Essex I Research Ethics Committee. All patients had written 
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informed consent before screening. Period one included an 8-day single-blind placebo run-in 
with a polysomography (PSG) habituation night (time in bed 2300-0700) on (D6) to 
familiarize the subjects with the environment. Furthermore, subjects had a CGMS sensor 
inserted once arriving to the Surrey CRC (D6). This sensor was used to monitor subject's 
glucose levels continuously while they were in the unit (D6-8, D20-22, and D34-36). On day 
7 patients were trained on psychometric assessment and on night 7 a full PSG assessment was 
made to determine baseline (placebo) sleep characteristics (time in bed was again 2300-
0700). On day 8 baseline (placebo) psychometric measures were made and patients were 
discharged at 1700 hours. Patients took their first dose of medication at home on the evening 
of day 8. The second treatment period consisted of 14 days of lower dosing (D9-D22) of 
either pregabalin 150mg twice a day, duloxetine 60mg every morning, or amitriptyline 25mg 
twice a day. A re-habituation night took place (D20) followed by re-familiarisation of 
psychometric tests on day 21. A chronic "low dose" PSG night (D21) was carried out and 
psychometric testing was performed on day 22. Patients were discharged at 1700 hours on 
day 22. Dosing with the higher dose took place on evening of day 22 and the third treatment 
period consisted of another 14 days of higher dosing (D23-D36) of either pregabalin 300 mg 
twice a day, duloxetine 60mg twice a day, or amitriptyline 25mg every morning and 50 mg 
very evening. Patients arrived to eRC on day 34 of treatment period 3. A re-habituation night 
took place (D34) followed a chronic high dose PSG night (D35). Re-familiarisation of 
psychometric assessment was performed on day 35 and psychometric assessment of chronic 
high dose took place on day 36. Patients were then discharged at 1700hours. An overview of 
the study schedule can be seen in appendix 1 and an overview of the dosing schedule can be 
seen in figure 2.1. 
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Dosing Schedule 
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Visit 2 at the eRe: 
study day 20-22 
for low dose. First 
high dose on the 
evening of day 22 
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, 
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I 
I 
I 
Visit 3 at the eRe: 
Day 34-36, high 
dose. last high 
dose on the 
morning of day 36 
Figure 2.1: Dosing Schedule and study design. An overview of the 36 days study design, with dosing 
schedule indicated . Subjects received placebo for 8 days, fIrst visit to the Surrey eRe was scheduled for study 
days 6-8 . First low dose of medication was taken on the evening of day 8 following discharge from Surrey eRe. 
Low dose medication was then received for 14 days in total and the last days of this period were spent in the 
Surrey eRe looking at low dose assessment (study days 20-22). High dose medication was taken on the evening 
of day 22 following discharge and then continued for 14 days. The fmal residential visit occurred at the end of 
these 14 days (study days 34-36). The fInal visit (visit 3) assessed high dose medication with the last high dose 
taken in the moming of study day 36. 
The decision of dose ranges of the study medications was made after discussion with the 
study diabetologists and was determined by their recommendations as well as previous 
published literature. The dose range was chosen in regards to the medications analgesic 
effect. 
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2.3 Sleep recording 
On each residential night, PSG recordings were carried out from 2300 hours to 0700 hours 
using the Compumedics Siesta System® (Compumedics Ltd., Australia). The patients slept in 
individual sleep labs. Each sleep lab was soundproof and temperature controlled with a 
temperature of 18°C ± 1°C. 
2.3.1 Electroencephalography (EEG) 
Subjects sleep was assessed using a standard EEG montage. The head montage consisted of 4 
electrodes (C3, C4, 01 and 02) and their positions were determined using the internationally 
standardised 10-20 system which was developed by Jasper (1958). The system is termed "10-
20" due to the fact that electrodes are located either 10% or 20% of the total distance between 
a given pair of skull landmarks. There are four landmarks in this system, the nasion, the inion 
and the left and right preauricular points. The preauricular points are located just above the 
cartilage which covers the external ear opening. The inion is a knob that can be felt when you 
run the fingers from the neck and up to the skull while the nasion is located between the 
eyebrows at the start of the forehead. These four landmarks are then used when measuring up 
the electrodes placement (figure 2.2). Note that the letters F, T, P, 0 and C seen in figure 2.2 
were used to name electrode placement and stands for frontal, temporal, parietal, occipital 
lobe of the brain. C is only used for identification purposes of ''the central line". All odd 
numbers (1, 3, 5, and 7) refer to the left hemisphere and the even numbers (2, 4, 6, and 8) 
refer to right hemisphere. The z refers to the midline. 
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A 
20% Vertex 
Figure 2.2: The international 1 0-20 system of electrode placement. The system is termed " I 0-20" due to that 
the electrodes are located either 1 0% or 20% of the total distance between a given pair of skull landmarks. The 
four landmarks are nasion, inion, and left and right preauricalar points. Figure taken from Malmivuo and 
Plonsey (1995) with permission. 
2.3.1.1 Measuring of electrode placement using 10-20 system 
It is only necessary to record from one pair of electrodes (C3 and C4) in order to analyse 
sleep according to Rechtschaffen and Kales (1968). However, it is often easier to determine 
alpha activity from the occipital region and an occipital channel (01 and 02) was therefore 
included in this study. No further head electrodes were used in this patient group as it may 
cause increased pain and in'itation from electrode placement. The opposite ear (AI and A2) 
were used as referents and electro-oculogram (EOG) (EGO-left and EO G-right), and 
submental electromyogram (EMG) (EMG-Ieft and EMG-right) electrodes were also attached. 
The sub mental electromygram and electro-occulograms was used to measure chin activity 
and eye movement respectively, both especially important when looking at rapid eye 
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movement (REM) sleep which will be discussed later on. Furthennore, a ground electrode 
and a reference electrode were also used. The measure and placement of electrodes were 
carried out in different steps explained below. 
1. The distance in centimetres from the nasion to the inion was measured = nasion-inion 
distance. 10 % of this distance was calculated. Two 10% mark (of the nasion-inion 
distance) were made, one starting from nasion and measuring towards the top of the 
skull (FPZ site) and the other one starting from inion and measuring towards the top 
of the skull (OZ site), using a non-toxic marker pen. Half distance = 50% of the 
nasion-inion distance was also marked (CZ site) (see figure 2.2A). 
2. The distance in centimetres from left to right preauricular point .was then measured 
making sure the tape measure went through the CZ mark. 10% of this ear to ear 
distance was calculated and this 10% measure was marked out on each side of the 
skull starting from left preauricular point going up (T3) and from right preauricular 
point going up (T4). A further 20% from these two points was calculated (30% of the 
whole ear to ear measurement) to make up C3 mark on left side of the skull and C4 on 
the right side (see figure 2.2A and B). 
3. The next step was to measure the circumference of the subject's head (as when 
measuring for a hat). The tape measure passed through FPZ, T3 OZ and T4. 5% of the 
circumference or 10% of half of the circumference was calculated. This measurement 
was then used to mark two marks on each side of FPZ, Fp 1 and Fp2. OZ was then 
located and 01 were then marked on the left hand side from OZ and 02 on the right 
hand side (using distance calculated above), figure 2.2B. The distance between 01 
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and 02 should therefore be 10% of the whole circumference, and same between Fp 1 
and Fp2 on the forehead. 
4. Finally, the distance from Fpl to 01 was measured going through C3 and Fp2 to 02 
through C4, to be able to centre C3 and C4, respectively. Half this distance indicates 
the centre position of C3 and C4. 
For facial electrodes the Al electrode was placed behind the left ear and A2 electrode behind 
right ear (figure 2.2). A ground reference was also used and was attached on the forehead on 
Fpl, next to FPZ site. Furthennore, the two EMG electrodes were attached under the chin 
(submental electromyogram) and the EOG electrodes were placed on the outer comers of the 
eye. The right outer canthus (ROC) was placed on the outside of the right eye, approx 1 cm 
out and 1 cm up (raise). The left outer canthus (LaC) was placed on the outside of the left 
eye approx 1 cm out and 1 cm below (lower). Finally, a reference electrode was attached on 
the forehead next to the ground electrode on Fp2 site. 
2.3.1.2 Electrode attachment 
Once the electrode placement was measured and marked out the electrodes were attached to 
the subject's head. The area where the electrode is placed was cleaned using NuprepTM. This 
is a skin prepping gel which will help reduce the skin impedance and result in a better reading 
of the electrode trace. EC2 cream® was then put onto the electrode which was then placed 
onto the cleaned area. The EC2 paste was used to improve electrical contact. Gauze was used 
to fix the electrode to the skull and it took approximately 8-10 minutes for the paste to dry 
fully. All the facial electrodes were attached in the same way. However, Medipore™ tape or 
Micropore™ tape was used instead of gauze to fix the electrodes to the facial skin. 
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The aim was for impedances to be maintained below 5Kn to assure good quality recordings. 
This was checked by using a ohmmeter which is an instrument that measures electrical 
resistance. 
In addition to the head and face electrodes, leg EMG leads were used (one for each leg) and 
these were placed over the anterior tibialis muscles and attached using adhesive tape such as 
Micropore TM tape. 
Respiratory band, thermistor and pulse oximeter were also used. The respiratory band was 
placed across the thorax to measure chest effort. If patient was female the respiratory band 
was placed just beneath the breasts. Nasal airflow was measured by using Oro-Nasal Airflow 
Thermistor which was placed between the nose and the upper lip. The thermistor works by 
sensing changes in temperature during breathing as air is cold when inhaling and warm when 
exhaling. Finally, a pulse oximeter (Ohmeda Biox 3740f)) was placed over the patient's index 
finger on non-dominate hand to monitor oxygen saturation (Sp02) continuously throughout 
the night. This is a non invasive method of measuring oxyhemoglobin in real time. It consists 
of light emitting diodes (LEDs), one LED is red and the other is infrared with different 
wavelength and the absorption of these wavelength is different between deoxyhemoglobin 
and the oxygenated form. This difference in absorption will give the Sp02 reading. 
2.4 Sleep Staging 
For nights 7, 21, and 35, overnight sleep was manually scored directly from the computer 
screen and all records were scored according to the standard criteria by Rechtschaffen and 
Kales (R&K) (1968). 
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2.4.1 Staging of EEG 
The EEG signal obtained from the recording can be divided into different type of waves 
depending of its frequency and amplitude. The different brain waves produced are beta (~), 
alpha (a), theta (8) and delta (8) and an example of EEG tracing of these different brain 
waves can be seen in figure 2.3 . There are other existing brain waves but these will not be 
discussed as the most relevant ones for this thesis are alpha, theta and delta waves. 
aeta(P) ~ 
13-30 Hz 
Alpha (a) 
8 - 13 Hz 
Theta (0) 
4 -8 Hz 
Delta (6) 
0 .5 -4 Hz 
o 
Brain Waves: EEG Tracings 
1 2 3 
nme (Secs.) 
Figure 2.3: Brain waves - EEG tracings. The EEG signal can be divided into different brain waves depending 
on amplitude and frequency. Beta waves have a frequency of 13-30 Hz, alpha of 8-13 Hz, theta of 4-8 Hz and 
delta are the slowest waves with a frequency of 0.5-4 Hz. Figure taken from Malmivuo and Plonsey, (1995), 
with permission. 
Beta waves (13-30 Hz): The beta waves have a relatively high frequency. The waves are 
irregular and with a small amplitude (2-201-1 V). Beta waves are common in the awake and 
alert condition when a person is involved in mental or physical activity (Malmivuo and 
Plonsey, 1995). 
Alpha wave (8-13 Hz): The Alpha waves are rhythmic and have an amplitude of 20-60 1-1 V. 
Alpha waves are common in awake and relaxed condition when a person has hislhers eyes 
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closed. However, a small percentage of the population have difficulty in producing any 
alpha waves. Alpha waves can be measured from the occipital region (Malmivuo and 
Plonsey, 1995; Rechtschaffen and Kales, 1968). 
Theta waves (4-7 Hz): Low amplitude and mixed frequency waves which can be seen mainly 
in stage 1 and 2 sleep but also in REM sleep. 
Delta waves (0.5-4 Hz): The delta waves are very slow waves and have a high amplitude of~ 
75 ~V. These waves occur during deep sleep, also known as stages 3 and 4 (Malmivuo and 
Plonsey, 1995). 
These different brain waves can then be used when staging and divide sleep into different 
stages. The staging montage is set up on the computer screen and different derivations are 
used. C3/A2, 02/Al, LOC/A2, ROC/Al, EMGIIEMG2, C4/Al and OllA2 were used in this 
study. The criteria for scoring sleep stages should always be based on tracings obtained from 
C4/Al or C3/A2 and in this study C3/A2 trace were used (Rechtschaffen and Kales, 1968). In 
addition, LOC/A2, ROC/AI and EMGllEMG2 were used to determine the presence of REM 
sleep. Each record was staged epoch by epoch directly from the screen and one epoch is 
equal to 30 sec. The filter settings for the EEG channels were set to 0.3 Hz for the low 
frequency filter and 35 Hz for the high frequency filter as recommended by The American 
Academy of Sleep Medicine (AASM), 2007. 
The staging of sleep was as mentioned previously, carried out according to the standard 
criteria by Rechtschaffen and Kales (1968) and the different stages are Stage W, Stage 1,2,3 
and 4 and REM. 
Stage W: This corresponds to the waking state and is characterized by alpha activity when 
eyes are closed. This stage is also usually but not always associated with high tonic EMG 
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activity and eye blinks can be seen in the EOG tracing (figure 2.4). More than 50 % of one 
epoch has to consist of alpha activity to be scored as wake. 
C3·A2 
1"04uV 
02-A1 
1604 uV 
LOC-A2 
2r,0 uV 
ROC-A1 
.150 uV 
Figure 2.4: EEG trace of waking state. Characterized by alpha activity in C3 and 02 channels. High tonic 
submental EMG tracing in EMG I-EMG2 channel. Eye blinks can also be seen in EOG trace (LOC/ROC) and 
are circled in red above. 
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Stage 1: This is the transition from wakefulness to sleep and is also called light sleep (figure 
2.5). There will be a decreased amount of alpha activity and there will be a slowing of the 
EEG with decreased amplitude and frequency. There will be no rapid eye movements or 
blinks and tonic EMG are usually below those of wakefulness. An epoch can be scored as 
stage 1 if the slowing of the EEG is more than 50%, meaning that occurrence of alpha 
activity is less than 50% (Rechtschaffen and Kales, 1968) and therefore more than 50% theta 
activity. Vertex sharp waves can be present in the central channels C3 and C4 and slow 
rolling eye movements (SEM) may be seen in EOG trace. 
C3-.A2 
I 
02-Al 
I 
'MGl-ENG: 
Figure 2.5: EEG trace of tage 1 sleep. The EEG trace starts to slow down and alpha waves disappears in C3 
and 02 channels_ EMG trace is lower than in wake and slow rolling eye movements (SEM) are seen in EOG 
trace (LOC/ROC channel) and are circled in red above. 
75 
Stage 2: The definition of stage 2 is the occurrence of sleep spindles and/or K complexes and 
the absence of high amplitude and slow activity seen in delta waves (figure 2.6). An epoch 
can be scored as stage 2 if the first spindle or K complex occurs in the first part of the epoch. 
C3-A2 
1"0.4 uV 
02-A1 
150 .4 uV 
LOC-A2 
l~O uV 
ROC-A1 
11;OuV 
Figure 2.6: EEG trace of stage 2 sleep. Stage 2 sleep is characterized by the occurrence of K-complexes and! 
or spindles. Spindles are clearly defined at C3 channel above (marked with red circles). 
A spindle is defined as a set of distinctive waves with frequency of around 11-16 Hz with 
duration of at least 0.5 seconds and one should be able to see 6-7 waves within that 0.5 sec. A 
K complex is defined as a wave with a negative sharp wave followed by positive (see figure 
2.7) with a total duration of 2: 0.5 seconds (Rechtschaffen and Kales, 1968). 
K complex 
Figure 2.7: EEG trace with K complex and Spindle. K complex with a sharp negative wave, immediately 
followed by a positive component. Sleep spindle with 6 - 7 waves within 0.5 sec. 
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Stage 3: Stage 3 is defined as an epoch which has at least 20% of slow delta waves, but not 
more than 50% (figure 2.8). 
C3-A2 
150.4uV 
02-A1 
150 _-4uV 
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Figure 2.8: EEG trace of stage 3 sleep. Between 20 and 50 % of the epoch consist of slow delta waves and 
can be see above in the top C3 channel (marked yellow and circled red) and the epoch is scored as stage 3 sleep. 
Stage 4: The definition of stage 4 sleep is when more than 50% of an epoch consists of delta 
waves (figure 2.9). 
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)'-0 u 
Figure 2.9: EEG trace of stage 4 sleep. More than 50% of epoch consists of slow delta waves (marked yellow 
and circled red) and can be seen in top C3 channel above. The epoch is staged as stage 4 sleep. 
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REM: REM sleep is characterized by the occurrence of rapid eye movement seen in EOG 
trace in figure 2.10 (LOC-A2 and ROC-AI). The chin EMG tone is at its lowest levels. The 
EEG pattern is similar to that of stage 1 but without vertex sharp waves and may have some 
more alpha activity. Distinctive "saw-tooth" waves may appear, but there is normally an 
absence ofK complexes and spindles. 
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Figure 2.10: EEG trace of REM sleep. The rapid eye movements can be seen in EOG trace of LOC-A2 and 
ROC A-l (marked blue and circled in red above). In addition, low muscle tone can be seen in EMG trace and 
the epoch is staged as REM sleep. 
2.4.2 Staging of Clinical Sleep variables 
Other data to be analysed were clinical sleep variables such as arousals, limb movements and 
sleep apnoeas/hypopneas. The latter two was done by a full body PSG assessment, including 
leg EMG, respiratory belt, oximeter and thermistor. All staging of clinical sleep variables 
were carried out according to The AASM Manual of the Scoring of Sleep and Associated 
Events (2007). 
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2.4.2.1 Micro Arousals 
A micro arousal was scored if there was an abrupt shift of EEG frequency including alpha, 
theta and/or frequencies greater than 16 Hz (but no spindles) that lasted at least 3 seconds and 
up to 15 seconds (see figure 2.11). In order to score an arousal there had to be at least 10 
seconds of stable sleep preceding the event. In REM sleep there had to be an increase in 
EMGI-EMG2 trace lasting at least one second plus above criteria in order to score an 
arousal. Arousal scoring should incorporate information from both the central and occipital 
channels (The AASM Manual for the Scoring of Sleep and Associated Events, 2007). If the 
event was longer than 15 seconds and consisted of alpha activity the epoch was scored as 
wake instead. 
Figure 2.11: EEG trace of stage 4 leep with arou at. The epoch above is scored as sleep 4 as it consist of 
more than 50% of delta waves. A scored arousal can be seen at the end of the epoch (marked green). There is an 
abrupt change in EEG with alpha activity and this change is more than 3 seconds long but Ie s than 15 seconds 
and can therefore be scored as an arousal. In addition, there is an increase in chin EMG during the arousal which 
can be seen in the EMG trace (circled red). 
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2.4.2.2 Sleep Apnoea and Hypopnoea 
To be able to detect obstructive and/or central sleep apnoea as well as hypopnoea, IP belt, 
Thermistor and Pulse oximeter were used. A hypopnoea is an episode of shallow breathing or 
low respiratory rate compare to normal, while an apnoea is a complete cessation of breathing. 
To score an hypopnoea (see figure 2.12) all the following criteria needed to be met (The 
AASM Manual for the Scoring of Sleep and Associated Events, 2007): 
1. Nasal pressure signal/airflow trace (measured by thermistor) needs to drop by ~ 30% 
of baseline. One would normally see a drop in the thoracic trace too (measured by 
respiratory belt). 
2. The duration of this drop needed to be ~ 10 seconds. 
3. There was a ~ 4% decrease in oxygen desaturation (measured by pulse oximeter) 
compared to pre-event baseline. 
4. At least 90% of the event's duration had to have the reduction in amplitude mentioned 
above. 
Figure 2.12: EEG trace of tage 2 sleep and hypopnoea. cored hypopnoeas are marked in light blue on the 
airflow and thoracic channels. Each event was ~ 10 seconds. SA02 channel shows oxygen saturation (SA02) as 
a red line and hypopnoea associated 02 desaturations are marked in pink. 
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To be able to score an obstructive apnoea (see figure 2.13) the following criteria needed to be 
met (The AASM Manual for the Scoring of Sleep and Associated Events, 2007): 
1. There was a drop in the nasal pressure signal/airflow trace by 2: 90% of baseline with 
a continued or increased respiratory effort (measured by respiratory belt) throughout 
the entire period of absent airflow. 
2. The duration of the event needed to be 2: 10 seconds. 
3. At least 90% of the event' s duration had to meet the amplitude reduction criteria for 
apnoea. 
Of ! 
Figure 2.13: EEG trace of tage 1 sleep with ob tructive sleep apnoea. The obstructive apnoea event are 
marked in blue with associated oxygen desaturation marked in pink. There is a marked drop in altitude of 
airflow trace while there is a continued respiratory effort seen in thoracic trace. Each event was ~ 10 seconds. 
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To be able to score a central apnoea (see figure 2.14) the following criteria needed to be met 
(The AASM Manual for the Scoring of Sleep and Associated Events, 2007): 
1. There was a drop in the nasal pressure signal/airflow trace by 2: 90% of baseline 
together with an absent of respiratory effort throughout the entire period. 
2. The duration of the event needed to be 2: 10 seconds. 
3. At least 90% of the event's duration had to meet the amplitude reduction criteria for 
apnoea. 
Figure 2.14: EEG trace of tage 2 leep with central leep apnoea. The central apnoea events are marked in 
purple with associated oxygen desaturation marked in pink. There is an absence of both airflow and respiratory 
effort and therefore a marked decrease of airflow trace and thoracic trace, respectively. Each event was ~ lOs. 
To be able to score a mixed apnoea the same criteria as above needed to be followed e cept 
that the respiratory effort was absent in the initial period of the event, followed by resumption 
of the effort in the latter part of the event. All scored apnoeas and hypopnoea of a subject 
were added together and then divided by the total sleep time in order to get an 
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apnoea/hypopnoea index (AHI). This index defined the number of apnoeas and hypopnoeas 
per hour of sleep. An AHI of less than 5 episodes per hour was considered normal. An AHI 
of 5-15 per hour of sleep is generally defined as mild, 15-30 moderate and above 30 episodes 
per hour of sleep is considered severe (Ruehl and et aI. , 2009). 
2.4.2.3 Periodic Limb Movement of Sleep (PLMS) 
Periodic limb movements were scored from the trace of leg EMGs (figure 2.15). In order to 
score a limb movement (LM) the following criteria needed to be met: 
1. The minimum duration of a LM must have been 0.5 seconds with a maxImum 
duration of 10 seconds. 
2. There must have been a minimum increase in amplitude of8 IlV above resting EMG. 
One needs 4 consecutive LM with a minimum duration of 5 seconds and maximum duration 
of 90 seconds (defined as the time between onsets of consecutive LMs) in order to score a 
PLMS series. PLMS series can be scored from both left and right leg EMG. However, leg 
movements on two different legs which are separated by less than 5 seconds are scored as one 
single leg movement. 
.t------------------------------------------------------------------
!Wl2 , 
Figure 2.15: Trace of SA02, nasal airflow, thoracic chest effort, left leg and right leg EMG. Leg 
movements are marked in purple on the trace of the left leg, each movement was within the criteria of 0.5-10 
sec. The limb movement occurs in a periodic fashion with no less than 5 seconds between each movement and 
not more than 90 seconds which is the criteria for PLMS. 
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2.5 Subjective assessments 
Several subjective tests were used in this study. The Leeds sleep evaluation questionnaire 
(LSEQ) and sleep diaries were used for subjective assessment of sleep. The LSEQ was 
carried out at 0800h on day D8 for placebo, D22 for low dose and D36 for high dose, while 
the diaries were filled in by each patient on a daily basis throughout the study. Line analogue 
rating scales (LARS) were used to assess sedation and mood, while the Karolinska sleepiness 
scale (KSS) was used for assessment of daytime sleepiness. Both tests were performed at 
0800h, 1000h, 1300h and 1600h on above days. 
Subjective pain was assessed using the brief pain inventory (BPI) and visual analogue scale 
(V AS). The BPI was filled in by the patients on a daily basis throughout the study, while 
VAS was carried out at 0800h on D8, D22 and D36. 
2.5.1 Leeds Sleep Evaluation Questionnaire 
The LSEQ was used to assess subjective ratings of sleep quality and early morning behaviour 
(Hindmarch and Gudgeon, 1980; Parrot and Hindmarch, 1980; Zisapel and Laudon, 2003». 
The patients marked a series of 100 mm linear analogue scales. A score of 50 units indicated 
no change in subjective rating when compared with prior to treatment. Improvement was at 
one end of the scale «50) and worsening on the other end of the scale (>50). Four factors 
were assessed by LSEQ: the ease of getting to sleep, quality of sleep, ease of waking from 
sleep, and behaviour following awakening (Zisapel and Laudon, 2003). Appendix 2 
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2.5.2 Karolinska Sleepiness Scale 
Patients were shown a nine-point scale and asked to choose a number between 1 (very alert) 
and 9 (very sleepy and great effort to keep awake) to reflect the level of sleepiness they felt at 
that point (Gillberg et aI., 1994). Appendix 3. 
2.5.3 Brief Pain Inventory 
This was a short fonn of the brief pain inventory (BPI) and asked patients to describe and rate 
their pain from 0 being no pain to 10 being worse pain possible. The results gave a pain 
severity score. Patients were also asked if and how much their pain interfered with different 
aspects of their daily life such as pain interference on sleep, 0 being no interference and 10 
being pain completely interfering. The results gave a pain interference score. Appendix 4. 
2.5.4 Visual Analogue Scale 
The V AS was used for rating subjective pain and is a common tool to assess the analgesic 
properties of various drugs (Langley and Sheppeard, 1985). The V AS comprises of a vertical 
line, 100mm long. ''No pain" and ''very severe pain" is written at each end of the line and 
patients marked the line at the point they felt best represented their pain state at that particular 
moment in time. Score was determined by measuring from left end of the scale to the point 
where patients had marked the line. Improvement was «50) and worsening (>50). 
2.5.5 Line Analogue Rating Scale 
The LARS are rating scales which allow the subjective effects of a drug to be assessed 
(Hindmarch, 1980). The patients marked a series of 0-1 oOmm analogue scales where a score 
of sOmm indicated no change in subjective feelings. Factors being assessed were; sedation, 
mood and co-ordination. All positive effects such as less tired, more energetic and improved 
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mood were at one end of the scale «50) and all negative effects were on the other end of the 
scale (>50). Appendix 5. 
2.6 Continuous Glucose Monitoring 
The interstitial glucose levels were monitored over the period that the patients were in the 
Surrey CRC. This was carried out by using the CGMS@ System Gold™ Continuous Glucose 
Monitoring (Medtronic MiniMed, Inc., CA U.S.A). This system is designed to provide 
continuous measurements of interstitial glucose levels over the range 2.2-22.0 m.molll. The 
CGMS system consists of two major components, a glucose sensor and a small battery 
operated monitor. The sensor contains the enzyme glucose oxidase which catalyses a reaction 
in the presence of oxygen and glucose. This reaction transfers electrons and creates an 
electronic current which can be measured and converted into a glucose concentration. The 
sensor will measure glucose levels with an interval of 10 seconds and the monitor will then 
give an average of these measurements every 5 minutes. The disposable glucose sensor was 
inserted into the subcutaneous tissue in the abdominal area of the patient on the day of 
admission to the Surrey CRC (D6, D20, and D34). The sensor was then worn throughout the 
next day and night and removed in the afternoon of day 8, 22 and 36 (in total, approximately 
48 hours for each visit). This 48 hour period provided around 576 glucose readings which 
were downloaded onto a computer for analysis using The Medtronic Minimed CGMSIl 
Solutions™ Software Version 3.0. 
In order to validate the CGMS system it was important that the CGMS was calibrated with a 
5MBG test (finger stick reading) at least four times a day. This calibration was made 
approximately every 4 hours during wake periods. 
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CHAPTER3-RESULTS 
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CHAPTER 3 RESULTS 
3. A comparison of sleep architecture in diabetics and healthy volunteers 
3.1 Introduction 
Sleep disturbances are thought to be common in people with diabetes mellitus (DM) and 
diabetic patients have been reported to have a higher prevalence of sleep apnoeas and 
hypopnoeas compared with the healthy population and this may result in more fragmented 
sleep with arousals and awakenings (Foley et ai., 2004; Resnick et ai. , 2003, Vigg 2003). In 
addition, patients with painful diabetic peripheral neuropathy (DPN) often report that pain 
has a severe impact on sleep (Benbow et aI. , 1998; Galer et ai. , 2000; Gore et aI. , 2005). 
Other complications associated with DPN such as restless leg syndrome and periodic limb 
movements may contribute further to poor sleep (Foley et aI., 2004; Resnick et aI. , 2003 ; 
Vigg 2003). 
3.1.1 Study Aim 
Loss of sleep and poor sleep quality may impact on patients' overall well being and add to the 
burden of living with DM. Most data available in regards to sleep in diabetic patients are 
based on subjective questionnaires where patients rate their quality of sleep. Few studies have 
quantified sleep disturbances in these patients through polysomnography (PSG) which is 
considered to be the gold standard technique used in sleep research. The aim of this study 
was therefore to investigate the sleep architecture and sleep quality of diabetic patients with 
painful DPN using polysomnography in order to obtain a more objective profile of sleep 
problems in these patients. An additional aim was to see ifthere were any differences in sleep 
in patients with painful DPN compared with a healthy population, and if so whether this is 
due to the pain associated with DPN or due to a possibly higher rate of obesity seen in 
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diabetic patients. Obesity is known to be linked to heavy snoring and sleep apnoea which can, 
as mentioned earlier, disrupt sleep by leading to more nocturnal awakenings. 
3.2 Methods 
3.2.1 Subjects 
The subjects included in the analysis were a diabetic group and a group of healthy volunteers 
used for comparison. The diabetic subjects were randomly selected from the 83 subjects 
taking part in the main diabetic study conducted at the Surrey - CRC in 2008-2009 and 
approved by the Essex 1 Research Ethics Committee (study description in chapter 2 general 
methods and materials). The historical control group was created by using healthy volunteers 
from the Surrey Sleep Research Centre (SSRC) database. The healthy volunteers were 
selected from two large studies conducted at the Surrey-CRC, approved by Ravenscourt 
Ethics Committee and Quom Research Review Committee. The overnight study conditions 
for both the diabetic group and healthy control group were very similar (see 3.2.2) and the 
healthy volunteer data was therefore considered to be suitable to use as comparison with the 
diabetic group. All studies were conducted in accordance with the declaration of Helsinki and 
good clinical practice. All patients gave written informed consent prior to screening. 
3.2.1.1 Diabetic Group 
40 type 1 and 2 DM patients (males = 23, females = 17) with painful DPN were selected. 
Baseline night (equal to visit 1, night 7) was used for analysis. They had been diagnosed with 
OM for at least a year and had neuropathic pain of diabetic origin with a score above 12 on 
the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS). For more detailed 
exclusion/inclusion criteria please see chapter 2 section 2.1. 
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3.2.1.2 Healthy Control Group 
40 healthy subjects (23 male and 17 females) were selected for the analysis. They were 
gender and aged matched (± 2 years) with the diabetic patients. Subjects had been included in 
the SSRC studies if in the opinion of the principal investigator they were healthy on the basis 
of a physical examination, medical history, vital signs, electrocardiogram, and satisfactory 
laboratory test results. Subjects were excluded if they had a score of >5 points on the 
Pittsburgh Sleep Questionnaire Inventory (PSQI) scale, sleep apnoea (AHI of> 15/hour) or 
periodic limb movements (associated with arousal index> 15/hour) or any other chronic sleep 
complaints. Subjects were also excluded if they had a BMI above 33 kglm2• The exclusion 
criteria were set by the sponsor for the studies of which healthy subjects were selected from. 
3.2.2 PSG overnight recording and sleep staging 
All recordings were carried out in the sleep laboratories at the Surrey-CRC as stated in the 
general methods and materials (section 2.3) using the Compumedics Siesta System® 
(Compumedics Ltd., Australia). Time in bed was 8 hours (2300-0700) and both groups had a 
habituation night before the PSG study night in order to get used to the environment. The 
healthy control population group had previously been screened for sleep apnoea and periodic 
limb movements of sleep and could therefore be considered not only healthy but also without 
known sleep disorders. The PSG night for both groups was staged by the same sleep stager 
and according to the R&K criteria as stated in general methods and materials (section 2.4). 
3.2.3 Karolinska sleepiness Scale 
Karolinska Sleepiness Scale (KSS) was used to assess daytime sleepiness in both population 
groups. A brief description of KSS can be found under general methods and materials section 
2.5.2. 
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3.2.5 Statistical methods 
The subjects in the 2 datasets (diabetic group and healthy group) were matched pair wise and 
each one of these paired values were analysed as a dependent variable in a linear mixed 
model using SAS® PROC MIXED 9.1. The dataset identifier was a single categorical 
independent variable and dataset identifier as a repeated measure with unstructured variance-
covariance matrix. The modelling was carried out as a build-up operation with potential 
additional independent variable being the covariate body mass index (BMI). A model entry 
and rejection p-value threshold of 0.05 was used in this build-up model. 
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3.3 Results 
3.3.1 Demographics 
The control group was age (± 2 years) and gender matched with the diabetic group. Mean age 
for the diabetic population was 64.6, ± 9.1 years and mean age for healthy volunteer 
population was 64.7, ± 9.1 years. Mean body mass index (BMI) for the diabetic group was 
32.0 ± SD 5.8 kglm2 and 26.4 ± 2.6 kglm2 for the control group. 
3.3.2 Polysomnography (PSG) 
PSG variables analysed included; sleep efficiency (SE, %), total sleep time (TST, min), wake 
after sleep onset (W ASO, min), latency to persistent sleep (LP~, mia), and duration (min) and 
percentage of time awake throughout the night. Total duration (min) and percentage of stage 
1,2,3,4, rapid eye movement (REM) sleep and slow wave sleep (SWS) were also analysed. 
See appendix 6 for more detailed definition of sleep variables. 
In regards to the statistical analysis, all PSG analysis had BMI added as an independent co-
variant. However, BMI did not significantly change any of the sleep variables and the 
significant differences seen between the diabetic group and the healthy control group in the 
results below still persisted. The differences seen in sleep could therefore not be explained by 
the difference in BMI between the groups. 
3.3.2.1 Wake time and latency to sleep 
The results showed that diabetic patients had significantly more W ASO compared to healthy 
volunteers (mean, 81 min and 57 min, respectively, P<O.05) and longer duration of stage 0 
(wake) compared with the healthy control group (mean of 98 min and 67 min, respectively, 
P<O.Ol) (figure 3.1 and 3.2). 
92 
100 
* 
-c 80 
E 
-+J Q) 
III 
C 60 0 
a. 
Q) 
Q) 
Vi 
... 40 Q) 
~ 
c:( 
Q) 
~ 
to 20 3: 
o 
Healthy controls Diabetic patients 
Subjects 
Figure 3.1: Bar graph of wake after sleep onset (W A 0). Diabetic subjects (light blue) had significantly 
more WASO compare with healthy subjects (dark blue).n=38 for both Bars show mean ± SEM * = P<O.05 . 
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Figure 3.2: Bar graph of duration of tage 0 (Wake). Diabetic subjects (light blue bar) had a significantly 
longer duration of wake compared with healthy subjects (dark blue bar). n -= 38 for each group. Bar show 
mean ± SEM, ** - P<O.O I. 
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When looking at latency to persistent sleep (see definition in appendix 6), the diabetic group 
had a significantly longer latency to persistent sleep compared with the healthy group, (mean 
of22.5 min for diabetic patients and mean 14 min for healthy volunteers, P<O.05, figure 3.3). 
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Figure 3.3: Bar graph of latency to persistent sleep. Diabetic subjects (light blue bar) had significantly longer 
latency to persistent sleep compared with healthy volunteers (dark blue bar). n = 40 for each group. Bars show 
mean ± SEM, ... = P<0.05. 
3.3.2.2 Total Sleep Time and Sleep Efficiency 
PSG variables TST and SE, which gives an indication of quality and sleep continuity, were 
also significantly different between the two groups (figure 3.4 and 3.3 respectively). TST was 
less in the diabetic group compared with the healthy volunteer group (mean 383 min 
compared with mean 412 min, P<O.Ol), and diabetic patients had significantly worse SE 
(P<O.Ol) compared with the healthy volunteers (mean 79% compared with mean 86%). 
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Figure 3.4: Bar graph of total sleep time (TST). Diabetic subjects (light blue bar) have significantly less TST 
compared with healthy subjects (dark blue bar). n = 38 for each group Bars show mean ± standard error of mean 
(SEM), ** = p<O.O I. 
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Figure 3.5: Bar graph of leep efficiency ( E). Diabetic subjects (light blue bar) have significantly worse SE 
compared with healthy subjects (dark blue bar). n = 38 for each group Bars show mean ± EM, ** = P<O.Ol. 
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3.3.2.3 Sleep architecture NREM and REM 
Total sleep time can be divided into REM sleep and NREM sleep. Diabetic patients had 
significantly less REM sleep compared with healthy volunteers (mean of 79 min compared 
with 95 min, P<O.Ol), figure 3.6. However, there was no significant difference in duration of 
NREM, figure 3.7. 
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Figure 3.6: Bar graph of dura tion of REM sleep. Diabetic subjects (light blue bar) had a significantly shorter 
duration of REM sleep compare with healthy subjects (dark blue bar). n = 38 for each group Bars show mean ± 
SEM, ** = P<O.Ol. 
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Figure 3.7: Bar graph of duration of NREM sleep. Diabetic subjects (light blue bar) had less NREM 
compared with healthy subjects (dark blue bar) but this was not statistically significant (P = 0.07). n = 38 for 
each group. Bars show mean ± SEM. 
NREM sleep can be further divided into stage 1, 2, 3 and 4, and 3 and 4 can be combined to 
represent SWS. Inspection of the individual NREM stages showed that whilst there was no 
significant difference in stages 1, 2 and 3 between diabetic patients and healthy volunteers 
(figure 3.8-3.10) there was a significant reduction in stage 4 sleep in diabetic patients 
compared with the healthy volunteers (25 min for diabetics and 40 min for healthy 
volunteers, P<O.Ol, figure 3.l1). 
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Figure 3.8: Bar graph of duration of stage 1 sleep. There was no significant difference in stage 1 sleep 
between diabetic subjects (light blue bar) and healthy subjects (dark blue bar) n = 38 for each group Bars show 
mean ± SEM. 
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Figure 3.9: Bar graph of duration of stage 2 sleep. There was no significant difference in stage 2 sleep 
between diabetic subjects (light blue bar) and healthy subjects (dark blue bar) n = 38 for each group Bars show 
mean ± SEM. 
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Figure 3.10: Bar graph of duration of stage 3 sleep. There was no significant difference in stage 3 sleep 
between diabetic subjects (light blue bar) and healthy subjects (dark blue bar) n = 38 for each group Bars show 
mean ± SEM. 
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Figure 3.1 1: Bar graph of duration of stage 4 sleep, Diabetic subjects (light blue bar) had a significantly 
shorter duration of stage 4 sleep compared with healthy subjects (dark blue bar). n = 38 for each group 
Bars show mean ± SEM, ** = P<O.O I. 
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When looking at duration of SWS (stage 3 and 4 together) there was no significant difference 
between the two groups. However, the latency to SWS was significantly increased in the 
diabetic patient group (mean 60 min compared with 31 min for the healthy group, P<O.Ol , 
figure 3.12). 
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Figure 3. 12: Bar graph ofSWS latency. Diabetic group (light blue bar) had a significantly longer latency to 
WS compared with the healthy group (dark blue bar). n = 38 for both . Bars show mean ± SEM, p** = P<O.Ol . 
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With regards to %REM and %NREM sleep as a proportion of TST there was no significant 
difference between the two groups. The diabetic patient group had 79% NREM while healthy 
volunteers had 77% NREM sleep, figure 3.13. For REM sleep the diabetic patient group had 
21 % and healthy volunteers had 23%, (figure 3.14). 
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Figure 3.13: NREM leep a a % of TST. There was no significant difference in %NREM ofTST between 
diabetic group (l ight bl ue bar) and healthy group (dark blue bar). n = 38 for both Bars show mean ± EM. 
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Figure 3.14: REM sleep a % of T T. There was no significant difference in %REM sleep of T T between 
diabetic group (light blue bar) and healthy group (dark blue bar). ). n = 38 for both Bars show mean ± EM. 
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3.2.3.3.1 Analysis per third a/the night 
When analysing sleep one can also investigate sleep architecture in thirds of the night. Only 
REM sleep and SWS was analysed in this way. Results showed that REM duration was not 
significantly different between the two groups when each third of night was compared (figure 
3.l5). For SWS there was a significant reduction in amount of SWS for the first third of the 
night in the diabetic group compared with healthy volunteer group (mean of 29 min 
compared with 39 min, P<0.05) and this was mainly made up by the difference in stage 4 
sleep (figure 3.16). There was no difference in SWS in the second and third 3rd of the night 
and as mentioned earlier, no significant difference in the night in whole. 
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Figure 3.15: Duration of REM sleep in 3rd of the night. A. There was no statistical significant difference in 
amount of REM sleep between diabetic subjects (light blue bar) and healthy subjects (dark blue bar) in the first 
3rd of the night. B. There was no statistical significant difference in amount of REM sleep between diabetic 
subjects (light blue bar) and healthy subjects (dark blue bar) in the second 3rd of the night. C. There was no 
statistical significant difference in amount of REM sleep between diabetic subjects (light blue bar) and healthy 
subjects (dark blue bar) in the third 3rd of the night. 
REM I = Duration of REM sleep in first 3rd of night, REM2= Duration of REM sleep in second 3rd of night, 
REM3= Duration of REM in third 3rd of night. n = 38 for each group Bars show mean ± SEM. 
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Figure 3.16: Duration of Slow wave sleep ( WS) in 3rd of the night. A. Diabetic subjects (light blue bar) had 
significantly less duration of SWS compared with healthy subjects (dark blue bar) in the tirst 3rd of the night. 
B. There was no significant difference in SWS duration between the two groups in the second 3rd of the night. 
C. There was no significant difference in SWS duration between the two groups in the third 3rd ofthe night. 
SWS1 = Duration ofSWS in (jrst 3rd of night, SWS2= Duration ofSWS in second 3rd of night, SWS3= Duration 
ofSWS in third 3rd of night. n = 38 for each group Bars show mean ± SEM, * = P<O.05. 
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3.3.2.4 Gender differences 
There was no significant gender differences in the amount of TST or in SE. Healthy women 
had similar SE and TST as healthy men, while there was only a slight difference seen 
between diabetic women and diabetic men with diabetic women having more TST and higher 
SE than diabetic men, however this was still not significant (figure 3.17 for SE). 
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Figure 3.17: Bar graph of sleep efficiency (SE) for gender. Gender did not affect the % of SE and there was 
therefore no significant difference between men and women. Healthy females (dark orange bar) and healthy 
males (dark purple bar) had similar amount ofSE, while diabetic females (light orange bar) had a slightly higher 
% SE compared with diabetic males (light purple bar) but this difference was still not statistically significantly. 
n = 23 males and 17 females for both groups. Bars show mean ± SEM. 
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Figure 3.19: Bar graph of REM sleep duration for gender. Gender did not affect the amount of REM sleep 
and there was therefore no significant difference between men and women. Healthy females (dark orange bar) 
and healthy males (dark purple bar) had similar amount of wake time, while diabetic females (light orange bar) 
had slightly less REM sleep compared with diabetic males (light purple bar) but this was still not significantly 
different. n = 23 males and 17 females for both groups. Bars show mean ± SEM. 
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Figure 3.20: Bar graph of duration of SWS for gender. Gender did have a significant effect on SWS with 
women across both groups having significantly more SWS compared with the men. Healthy females (dark 
orange bar) and diabetic females (light orange bar) compared with healthy males (dark purple bar) and diabetic 
males (light purple bar) n = 23 male and 17 females in both groups Bars show mean ± SEM, p** = P<O.O I. 
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Figure 3.21: Bar graph of duration of stage 4 sleep for gender. Gender did have a significant effect on stage 
4 sleep with women across both groups having more stage 4 sleep compared with the men. Healthy females 
(dark orange bar) and diabetic females (light orange bar) compared with healthy males (dark purple bar) and 
diabetic males (light purple bar) n = 23 male and 17 females in both groups Bars show mean ± SEM, 
P** = P<O.O 1. 
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3.3.2.5 Age differences 
Age may also affect sleep and analysis showed that both SE and TST were significantly 
reduced with increasing age (P<O.Ol) in both diabetic patients and healthy volunteers. The 
effect of age on SE can be seen figure 3.22 below. 
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Figure 3.22: Scatter plot of sleep efficiency (SE) over age. SE decreases significantly with age (P<O.Ol) in 
both diabetic subjects (light blue) and healthy subjects (dark blue). 
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Further analysis of both population groups showed that age had a significant impact on 
W ASO and duration of wake (figure 3.23 for the latter), both increasing with increasing age 
(P<O.Ol for both). 
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Figure 3.23: Scatter plot of duration of tage 0 (wake) with age. Duration of wake significantly increased 
with age in both diabetic subjects (light blue) and healthy subjects (dark blue). P<O.O 1 
109 
When looking at the effect of age on sleep architecture it was shown that stage 1 sleep 
increased with increasing age, while stage 2 sleep decreased (p<0.05 for both), (figure 3.24 
and 3.25, respectively). There was no significant age effect on stages 3, 4, while the effect of 
age on REM sleep approached significance, P = 0.052. 
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Figure 3.24: Scatter plot of duration of stage 1 sleep with age. Duration of stage I sleep significantly 
increased with age in both diabetic subjects (light blue) and healthy subjects (dark blue). P<O.05 
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Figure 3.25: Scatter plot of duration of stage 2 sleep with age. Duration of stage 2 sleep significantly 
decreased with age in both diabetic subjects ( light blue) and healthy subjects (dark blue). P<O.05 
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3.3.3 Subjective day time sleepiness 
There was a significant difference in subjective day time sleepiness between the two groups 
(see figure 3.26) which was measured using Karolinska Sleepiness Scale (KSS). Diabetic 
patients were significantly more sleepy compared with healthy volunteers (mean 5.0 and 2.9, 
respectively, P<0.001). Range 1-7 for healthy subjects and 2-9 for diabetic patients (see 
percentage of distribution in figure 3.27). 
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Figure 3.26: Bar graph of Karolinska Sleepiness Scale. Diabetic subjects (light blue bar) were significantly 
more sleepy compared with healthy subjects (dark blue bar). KSS = Karolinska Sleepiness Scale. Bars show 
mean ± SEM, *** = P<O.OOI 
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Figure 3.27: Bar graph of distribution of KSS scores. Diabetic subjects (light blue bars), Healthy subjects 
(dark blue bars) KSS = Karolinska Sleepiness Scale. 
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3.4 Discussion 
Poor sleep is commonly reported in diabetic patients and the prevalence of insomnia, restless 
leg syndrome, periodic limb movement and sleep disordered breathing have been previously 
reported as being high in this patient group (Foley et aI., 2004) and they can all affect sleep 
and cause sleep disturbances (Resnick et aI., 2003; Vigg 2003). Furthermore, obesity is 
commonly seen in diabetic patients, especially in patients with type 2 DM and it has been 
reported that obese individuals, even in the absence of sleep disordered breathing, have 
reduced quality of sleep with low amounts of slow wave sleep (Tasali et aI., 2007). 
Another factor that may affect sleep in this patient group is common diabetic complications 
such as painful diabetic peripheral neuropathy (DPN). Pain can have a negative effect on 
sleep and pain is often reported to worsen at night (Benbow et at, 1998; Galer et al., 2000; 
Gore et aI., 2005). Night time pain can interfere with time falling asleep, increase awakenings 
during the night and therefore result in difficulties in maintaining sleep (Moldofsky, 2001). 
In addition, sleep disturbances may also be associated with impaired glucose metabolism. 
One study by Trento et al. (2008) using actigraphy as an objective measure of sleep showed 
that HbAlc correlated inversely with sleep efficiency and positively with moving time during 
sleep suggesting that impaired glucose control led to an increase in wake during sleep and 
consequently poorer sleep efficiency. The study also compared actigraphic sleep from type 2 
diabetic patients on oral agents only (M = 32, F = 17, mean age = 61.0 years, mean BMI = 
27.1 kg/m2) with a matched planned healthy control group (M = 11, F=l1, mean age = 58 
years, mean BMI = 25.5 kg/m2I mean age, BMI, gender). The results showed that the diabetic 
patient group had lower sleep efficiency and higher fragmentation index and moving time 
compared with the healthy volunteer group. These results suggest that diabetic patients have 
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disturbed sleep even in the absence of exogenous insulin treatment and complications such as 
neuropathy or obesity. All patients with symptoms of neuropathy were excluded and no 
patients on exogenous insulin treatment were included in the study. The diabetic patients had 
a mean BMI of 27 kglm2 which is considered overweight but not obese as definition of 
obesity is BMI > 30. The BMI in diabetic groups was also matched with that of the healthy 
group (Trento et ai., 2008). 
The aim of the analysis presented here was to characterise sleep, using polysomnography, in 
diabetic patients with painful DPN and to investigate if there were any differences in sleep 
quality and sleep architecture in this patient group compared with a historical healthy 
population. The two groups were matched for age and gender and all the analyses were 
adjusted for BMI in order to distinguish whether potential differences could be explained by 
covariates such as BM!. 
The results showed that there were several differences in sleep between the two groups. 
Diabetic patients had significantly worse SE, less IST, more WASO and a longer duration of 
wake during the whole night compared with healthy subjects and this indicated poorer sleep 
quality and worse sleep continuity. In addition, diabetic patients had a significantly longer 
LPS compared with the healthy control group. Poor sleep quality and sleep continuity may 
result in increased daytime sleepiness and indeed analysis of the KSS showed that diabetic 
patients were significantly sleepier during the day compared with healthy subjects and this 
may have an impact on patients' overall well being. 
The analysis also showed distinct differences in sleep architecture between diabetic patients 
and healthy volunteers. Diabetic patients overall had a significantly shorter duration of REM 
sleep compared with healthy subjects. This difference was observed in all thirds of the night 
although was only statistically significant when looking at the night as a whole. Diabetic 
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patients also had less SWS compared with healthy subjects, but this was only statistically 
significant in the first 3rd of the night. When dividing SWS into stage 3 and 4 one could see 
that diabetic subjects had less stage 4 sleep compared with healthy subjects. This difference 
was statistically significant and was observed across the whole night. The difference seen 
between the healthy volunteers and diabetic patients might partly be explained by the fact that 
the diabetic group had a mean BMI of 32 whilst the healthy volunteer group had a mean BMI 
of 26. Previous reports have suggested that obese individuals may have a lower amount of 
SWS (Tasali et al., 2007). However, adjustment for BMI did not affect the significant 
differences in TST, SE and SWS across the two groups nor did it affect stage 4 sleep or any 
other sleep stages. The loss of SWS seen in the diabetic group seems to be replaced with 
increased duration of the lighter stage 1 sleep and increased amount of stage 2 sleep 
compared with the healthy group. This increase in stage 1 sleep, at the expense of deeper 
stage 4 sleep leads to the finding of no overall significant change in NREM sleep across the 
two groups. 
Despite changes in TST, duration of REM sleep and stage 4 sleep it appeared that the 
proportion of NREM and REM sleep as a percentage of TST was still preserved. Both the 
diabetic patients and healthy volunteers had a similar percentage of REM (21 and 23 % 
respectively) and NREM sleep (79 and 77% respectively). This suggested that although 
absolute amounts of sleep stages may differ, the overall sleep architecture is preserved. 
Finally, the effect of age and gender on sleep in both diabetic patients and healthy volunteers 
was examined. Age related changes in sleep have previously been reported in healthy 
subjects (Boselli et aI., 1998; Hume et aI., 1998; Neubauer et aI., 1999). Total sleep time 
decreases with age, partly due to increased wake periods within sleep, therefore more 
fragmented sleep. Older adults also have a tendency to have more arousals than younger 
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adults (Boselli et aI., 1998; Hume et aI., 1998; Neubauer, 1999). This change in sleep in 
healthy subjects could also be seen in this study as there was a worsening of TST and SE and 
increase in wake and W ASO with increasing age, but the changes with age were consistent 
across both the healthy group as well as the diabetic group. Furthermore, the amount of SWS 
has been previously reported to decrease with age, while the amount of REM is thought to be 
only slightly reduced (Carrier et al., 2001; Ehlers and Kupfer, 1997; Neubauer, 1999). The 
results of the present study showed that there was no evidence of a statistically significant 
reduction in SWS with age, but that the age effect on REM sleep approached significance 
with REM sleep decreasing with increasing age. This reduction in REM sleep could be seen 
in both the healthy volunteers and the diabetic patients. 
It is unclear why there was no evidence of a loss of SWS with increasing age in this present 
study however it may possibly be due to the narrow age range of patients and volunteers 
investigated. As diabetic patients were required to have a history of painful diabetic 
peripheral neuropathy a complication which normally appears many years after diabetic 
diagnosis, the majority of patients and aged matched healthy volunteers were in the narrow 
age range of 55 -75 years. 
With regards to gender differences and sleep, SWS has also previously been reported to differ 
between males and females, with females having longer duration SWS compared with age-
matched males (Ehlers and Kupfer, 1997). Indeed, the results from the current showed that 
gender did indeed have a significant effect on SWS with females having longer duration SWS 
compared with men. The gender effect was strongest with regard to stage 4 sleep with 
females having almost twice as much stage 4 sleep as their male counterpart. This gender 
difference could be seen across both the diabetic patient group and healthy volunteer group, 
however it was most prominent in the diabetic group with diabetic males having far less SWS 
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and stage 4 sleep compared to not only diabetic and healthy females but also compared with 
healthy males. This would suggest that the diabetic condition has a more detrimental effect 
on SWS in men compared with females as diabetic females and healthy females had similar 
amount of SWS when compared and it was only between the males that a difference was 
seen. There was no significant effect of gender on any other sleep stages or on any variables 
of sleep quality and continuity. 
In conclusion, both the healthy volunteer group and the diabetic patient group displayed 
expected changes with respect to age and gender. However, age and gender could not explain 
the difference in sleep seen between the two groups as the analysis was based on age and 
gender matched groups. Overall, diabetic patients with painful DPN appear to have worse 
sleep quality, less total sleep time, a lower amount of REM sleep and reduced stage 4 sleep. 
The loss of REM and SWS may be of importance as REM sleep is thought to be involved in 
memory consolidation whilst SWS is thought to be the restorative part of sleep (Kamel and 
Gammack, 2006; Najib, 2006; Tasali et al., 2007; V gontzas and Kales, 1999). Whilst one can 
establish such differences, it is still difficult to determine the cause. It appears from the 
analysis that changes in BMI cannot explain the differences seen as BMI was used as a 
covariate in the analysis and did not change the differences seen in the results. However, the 
poor sleep in this diabetic population may result from a combination of factors such as 
possible sleep disorders like sleep apnoea, periodic limb movements, glucose control and/or 
neuropathic pain itself. These factors will be investigated further in chapter five. 
Poor sleep can have a profound effect on everyday functioning and quality of life with sleep 
loss and poor sleep quality known to be associated with cognitive decline and changes in 
mood (Benbow et aI., 1998; Davies et aI., 2006; Galer et aI., 2000). All of these negative 
effects of poor sleep can add further to the burden of living with DM and it is therefore 
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important to take sleep problems into consideration when looking at different treatment 
options for DM patients with painful DPN. This will be investigated and discussed further in 
chapter 4. 
There are limited PSG data published looking at sleep in diabetic patients with painful DPN 
compared with healthy subjects. This exploratory analysis shows that there are objective 
differences in sleep between these two groups. In order to more fully elucidate the impact of 
diabetes and pain on sleep future studies should include a patient group with diabetes but 
without painful DPN as well as a planned healthy control group matched for age and gender. 
This would enable the effect of neuropathic pain, glucose control and other factors associated 
with the diabetic condition to be explored and modelled in order to establish the main causes 
of sleep disturbance in both diabetic patients and diabetic patients with further complications. 
117 
CHAPTER 4 - RESULTS 
118 
CHAPTER 4 RESULTS 
4. The effects of pregabalin, duloxetine and amitriptyline on sleep 
architecture, sleep quality and pain in type 1 and type 2 diabetic patients 
with painful DPN. 
4.1 Introduction 
Chronic painful diabetic peripheral neuropathy (DPN) is often very difficult to treat, with 
treatment regimes often inadequate at controlling pain and limited by side-effects and drug 
tolerance (Barbano et a1. , 2004; Quattrini and Tesfaye 2003 ; Vinik and Mehrabyan, 2004). 
The aim when treating chronic painful DPN is to reduce pain and improve a patient' s quality 
of life (QOL). 
Various treatments, both pharmacological and non-pharmacological are available. One non-
pharmacological treatment that has been reported to reverse symptoms of DPN is the 
Anodyne Therapy System. A study by Leonard et al showed that treatment with this near-
infrared medical device improved sensation in feet, improved balance and also reduced pain 
in subjects with DPN (Leonard et a1. , 2004). Pharmacological treatments however are more 
common and include lidocaine patches, opioid analgesics, tricyclic antidepres ants and 
antiepileptic such as gabapentin, and more recently pregabalin. 
Of the phannacological agents most commonly used to treat chronic pain in DPN we have 
focused on three treatments: amitriptyline (AMI), duloxetine (DUL) and pregabalin (pGB) 
and have inve tigated the effects of the treatments on pain, sleep architecture and sleep 
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quality in type 1 and 2 DM patients with painful DPN. More detailed information on 
mechanism of action, efficacy and safety of each of these drugs is given below. 
4.1.1 Amitriptyline 
Tricyclic antidepressants (TCA) are known to have an analgesic effect on neuropathic pain 
and have been considered as the first-line therapy in painful DPN (Joss, 1999, McQuay et aI., 
1996). Amitriptyline is known to be the most effective TCA in the treatment of neuropathic 
pain and its good efficacy has been shown in several clinical trials, however, it is not licensed 
for neuropathic pain (Dallocchio et al., 2000; Max et al., 1988; Max et al., 1987; Morello et 
al., 1999). Side effects are known to be many and the drug is therefore not well tolerated and 
these are limiting factors for the usage of AMI (Dallocchio et al., 2000; Morello et al., 1999). 
4.1.1.1 Pharmacology and mechanism of action 
Amitriptyline inhibits the re-uptake of noradrenaline and serotonin initially potentiating the 
effect of these neurotransmitters but longer term inducing changes in post- and pre-synaptic 
receptors which is thought to underlie the principal mechanism of action of the drug. 
Amitriptyline is not highly selective and acts on a number of receptors including muscarinic 
acetylcholine receptors, HI histamine receptors and aI-adrenergic receptors. Amitriptyline 
effects on both the muscarinic acetylcholine and histaminergic receptors have the potential to 
impact sleep. Muscarinic receptors are thought to be involved in the regulation of REM sleep 
with muscarinic antagonists lengthening REM latency and reducing REM activity and 
density, and histamine HI receptors are involved in wake regulation with antagonism of these 
receptors linked to promotion of sleep (Haas and Panula, 2003). However, the full 
mechanism of action of amitriptyline in humans is not known (Bryson and Wilde, 1996; 
Gupta et aI. 1999; Haas and Panula, 2003). 
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4.1.1.2 Pharmacokinetics 
Amitriptyline is rapidly absorbed with peak plasma concentration usually occurring between 
4 and 8 hours after administration and an elimination half-life of between 10-28 hours, 
average 15 hours. It is metabolized in the liver and the active metabolite nortriptyline has a 
half-life of 16 to 80 hours. It is excreted in the urine and small amounts are excreted in the 
bile (Bowden et aI., 1985; V'Prichard et aI., 1978). 
4.1.1.3 Dose range and efficacy in Painful DPN 
Amitriptyline is administered orally in 25 mg tablets containing amitriptyline hydrochloride. 
It is normally administered 75mg/day in either divided doses or as a single dose at night time. 
The dose can then be increased up to 150mg/day if required. 
Amitriptyline has been shown to be effective in the treatment of painful DPN even at very 
low doses (McQuay et al., 1992). The mechanism of action of the analgesic effect of 
amitriptyline is not fully understood but it is suggested that it activates the opioid endogenous 
system through an elevation in noradrenaline levels possibly caused through the antagonism 
of (12 -adrenoceptors. In addition, AMI has been shown to block both Na + channels and Ca2+ 
channels. The inhibition of serotonin re-uptake and also blockade of muscarinic receptors 
may also play a role. These mechanisms combined are thought to contribute to the analgesic 
effects seen with amitriptyline (Ashina et al., 2004; Mico et al. 2006). 
4.1.1.4 Adverse events 
Adverse events from AMI are common and this is as mentioned earlier a limiting factor in 
treatment regimes. Several studies have shown that night time dosing with AMI leads to 
'residual effects' the morning after, with increased drowsiness, increased subjective rating of 
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sedation and difficulty waking as well as worsened subjective alertness and increased 
daytime somnolence when compared with placebo (Hindmarch et aI., 2000; Rosenzweig et 
aI., 1998; Versiani et al., 1999). Other common side effects include weight gain, nausea, 
dizziness, headache, increase sweating, irritability, dry mouth and constipation. Some of 
these side effects are thought to result from the antimuscarinic, antihistaminic and a-
adrenergic activites of AMI, and are present even at low dosages (Bryson and Wilde, 1996; 
Dallocchio et aI., 2000; Gupta et al. 1999). 
4.1.1.5 Effect on sleep and quality of life 
Amitriptyline has been shown to have an effect on sleep with several studies demonstrating 
that it causes REM suppression (Kerkhofs et al., 1990; Mertz et al., 1998; Staner et al., 1995). 
A study by Mertz et al (1998) showed that 50 mg amitriptyline per night not only reduced 
REM sleep, but also resulted in poorer sleep efficiency and an increased number of arousals 
when compared with placebo. A study by Casper et al (1994) however, contradicted the latter 
and suggested that sleep efficiency and total sleep time were actually increased with 
amitriptyline (100-150 mg). This contradiction in findings between the two studies may be 
due to the difference in dose administered. 
As mentioned earlier, residual effects and cognitive impairment are common with 
amitriptyline treatment. Subjects may experience next day sedation, trouble waking up from 
sleep, worsening in alertness and in behaviour upon waking compared with placebo. This can 
impair patients' cognitive function and also have a negative effect on patients' QOL 
(Hindmarch et al., 2000; Rosenzweig et at., 1998). 
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4.1.2 Duloxetine 
Duloxetine was initially developed as an antidepressant drug, however pain and depression 
often co-exist and clinical trials also showed an improvement in pain (Detke et aI., 2002; 
Goldstein et al., 2005; Goldstein, 2007). Duloxetine was the first drug to get regulatory 
approval (in 2004) for the treatment of painful DPN in the US by Food and Drug 
Administration (Raskin et aI., 2005; Smith, 2006). It was licensed in the UK for the treatment 
of major depressive episodes in early 2005 and was later in 2005 licensed for the treatment of 
painful DPN (UK Medicine information, NHS). 
4.1.2.1 Pharmacology and mechanism of action 
Duloxetine is a selective serotonin and noradrenaline re-uptake inhibitor and differs from the 
tricyclic antidepressant amitriptyline by being more selective in its action with no other 
significant channel or receptor activities (Goldstein et aI., 2005; Katoh et al., 1995; Smith, 
2006). It is a balanced serontonin and noradrenaline re-uptake inhibitor which means its 
affinity for both serotonin and noradrenaline reuptake inhibition is relatively equal 
(Goldstein, 2007). However, duloxetine's exact mechanism of action in humans is still 
unknown (Goldstein et al., 2005; Raskin et al., 2005). 
4.1.2.2 Pharmacokinetics 
Duloxetine is rapidly absorbed after oral administration and have a peak plasma 
concentration of around 6 hours post dose. The elimination half-life of duloxetine is about 12 
hours with a range of 8 to 17 hours. Duloxetine is eliminated through hepatic metabolism 
involving cytochrome P450 enzymes, CYP2D6 and CYP 1 A2. Most of the metabolites are 
found in the urine and around 20% is excreted in the faeces (Data from medication guide, 
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duloxetine hydrochloride, delayed-release capsules, Eli Lilly & Co, 2004; Westanmo et aI., 
2005). 
4.1.2.3 Dose range and efficacy in painful DPN 
Duloxetine is administered orally and is given as capsules containing 20, 30 or 60 mg of 
duloxetine. In the treatment of diabetic neuropathic pain, it is recommended that duloxetine is 
given at a dose of 60 mg/day, once a day, however, a lower starting dose may be considered 
for some patients. 
Several studies have evaluated the efficacy of duloxetine for the management of neuropathic 
pain from DPN and duloxetine has been reported to be safe and effective in the treatment of 
neuropathic pain in diabetes patients. In a study by Raskin et al (2005) it was reported that 
both duloxetine 60mg once a day and 60 mg (twice a day) was safe, well tolerated and 
effective as a treatment of diabetic peripheral neuropathic pain. These results were supported 
in another study by Goldstein et al (2005). The results of this 12 week double-blind. placebo 
controlled study showed that the treatments of duloxetine 6Omg/day or 120mg/day 
significantly improved pain severity scores compared with placebo, while 20mg/day dose 
was not significantly more effective than placebo. It was also considered safe and well 
tolerated with less than 20% discontinuation due to adverse events (Goldstein et al., 2005). 
Clinical trial data suggested that there was no significant improvement in analgesic action 
with the higher, 120 mg/day, dose and therefore 60mg/day is the current recommended dose. 
The mechanism of action of the analgesic effect of duloxetine is not fully understood but it is 
thought that the increase of neurotransmitter noradrenaline due to the re-uptake inhibition is 
involved in the drug's effectiveness against neuropathic pain. 
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4.1.2.4 Adverse events 
The most common adverse events seen in duloxetine-treated DPN patients are nausea, 
somnolence, dizziness, dry mouth, decreased appetite, constipation and hyperhidrosis 
(excessive sweating), asthenia (feeling of weakness) (American Society of Health-System 
Pharmacists 2009; Data from medication guide, duloxetine hydrochloride, delayed-release 
capsules, Eli Lilly & Co, 2004; Westanmo et aI., 2005) 
4.1.2.5 Effect on sleep and quality of life 
A study by Chalon et al (2005) showed that duloxetine had a similar effect on sleep as other 
antidepressant drugs including REM suppression and increased REM latency. It was also 
found that sleep continuity was significantly reduced with duloxetine 60 mg twice a 
daycompared with placebo, although there was some evidence that 80mg once a day acted to 
improve sleep continuity (Chalon et al., 2005). Furthermore, data from medication guide (Eli 
Lilly &Co) showed an increase in prevalence of insomnia in patients with painful DPN when 
treated with duloxetine 20 mg once a day and 60mg once and twice a day compared with 
placebo, with studies showing that the incidence of insomnia was greater with the highest 
doses of duloxetine 60mg twice a day (Data from medication guide, duloxetine 
hydrochloride, delayed-release capsules, Eli Lilly & Co, 2004). 
4.1.3 Pregabalin 
Pregabalin is a relatively new compound, derived from gabapentin. It was initially launched 
as a adjunctive therapy for treatment of partial seizures in adults with epilepsy. It is now 
licensed for the treatment of peripheral neuropathic pain in adults (Sills, 2006). 
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4.1.3.1 Pharmacology and mechanism of action 
Pregabalin is an analog of the neurotransmitter gamma-aminobutyric acid (GABA) but does 
not appear to interact with the GABA receptors or alter GABA uptake. It hasanxiolytic, 
anticonvulsant and analgesic effects and is thought to have a greater analgesic activity than its 
sister compound gabapentin. Pregabalin's full mechanism of action is still unclear but it's 
thought that when it binds to the (12-0 subunit of voltage-gated calcium channels in the central 
nervous system it causes a reduction in calcium influx which decreases the release of 
excitatory neurotransmitters such as glutamate. It is this modulation of neurotransmitter 
release that is thought to contribute to pregabalin's analgesic effect (Ben-Menachem, 2004; 
Frampton and Foster, 2005; Frampton and Scott, 2004; Richter et aI., 2005; Rosenstock et al., 
2004; Tassone et al., 2007). 
4.1.3.2 Pharmacokinetics 
The pharmacokinetics of pregabalin has been studied in healthy volunteers as well as in 
patients with chronic pain. Pregabalin is rapidly absorbed after oral administration with the 
time taken to peak plasma concentration being around 1.5 hours. Hepatic metabolism 
involving cytochrome P450 enzymes is minimal and 98% of pregabalin is eliminated as 
unchanged drug. Pregabalin (on single dose of 300mg in healthy volunteers) has an 
elimination half-life of between 4.6-6.8 hours following a single dose and was appears to be 
independent of the dosage. Furthermore, elimination of pregabalin occurs primarily by renal 
excretion (Frampton and Foster, 2005; Frampton and Scott, 2004). 
4.1.3.3 Dose range and efflcacy in Painful DPN 
Pregabalin is administered orally in a hard capsule each containing either 25, 50, 75, 100, 
150, 200 or 300mg of pregabalin. Pregabalin is usually taken two or three times a day and the 
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recommended dosage in neuropathic pain is 150-600mg/day. Normally treatment is started at 
75mg twice a day with doubling of the dose if necessary at weekly intervals (150mg and 
300mg twice a day, respectively) (Frampton and Foster, 2005; Frampton and Scott, 2004). 
The efficacy of pregabalin in neuropathic pain has been evaluated in several studies. A study 
by Rosenstock et al (2004) showed that pregabalin 300 mg/day was safe, well tolerated and 
effective in reducing pain associated with painful DPN. This study had a 1 week baseline 
phase, followed by a 8 weeks fixed-dose treatment phase. 146 diabetic patients with painful 
DPN were randomized and received either pregabalin 300mg/day or placebo for the whole 
duration of the 8 weeks treatment period. Pain was significantly reduced compared with 
placebo and pregabalin was well tolerated and safe as most adverse events were mild to 
moderate and did not result in withdrawal. Another study by T5lle et al (2008) showed that 
pregabalin doses ranging from 150-600mg/day were all well tolerated with generally mild to 
moderate adverse events reported. The study was a 12 week trial with 395 diabetic patients 
with painful DPN randomized to placebo, 150, 300 or 600 mg/day pregabalin. In regards to 
pain reduction, pregabalin 600mg/day significantly improved pain scores compared with 
placebo, while 150 and 300mg/day did not change from placebo. This was supported by 
another study by Richter et al (2005) were 246 patients with painful DPN were randomized to 
placebo or pregabalin (150 or 600mg/day) for 6 weeks. The results showed that pregabalin 
60Omg/day significantly reduced pain compared with placebo controls, while pregabalin 
15Omg/day did not differ from placebo. Furthermore, in a study by Freynhagen et al (2005), it 
was found that both a flexible schedule of 150,300,450 and 600 mg pregabalin per day, with 
a weekly dose escalation and a fixed schedule of 300mg/day for a week followed by 
600mg/day for 11 weeks, significant relieved pain compared with placebo controls. 
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4.1.3.4 Adverse events 
Adverse events reported during clinical trials with pregabalin are usually mild. Most common 
adverse events reported are dizziness and somnolence. Other adverse events include, dry 
mouth, increased appetite and weight gain, peripheral oedema, memory impairment, 
confusion, vertigo, disturbance in attention, blurred vision, vomiting, and fatigue (Frampton 
and Foster, 2005; Frampton and Scott, 2004; Richter et al., 2005; Rosenstock et al., 2004). 
4.1.3.5 Effect on sleep and quality of life 
Several studies have suggested that pregabalin has a positive effect on sleep by improving 
pain-related sleep disturbance (Freynhagen et aI., 2005; Lesser et al., 2004). Better night time 
sleep may result in improved mood and there is evidence that patients may also feel less 
fatigued during the day and that this together with pain relief can improve patients' quality of 
life (QOL) (Rosenstock et al., 2004). Lesser et al (2004) found that pregabalin 300 and 600 
mglday had a beneficial effect on sleep in patients with diabetic DPN and a randomized, 
double-blind, placebo controlled study by Rosenstock et al (2004) showed that pregabalin 
300mglday improved mood, sleep disturbance and QOL. A study by Freynhagen et al (2005) 
reported that both a fixed dose regime of 300 mglday, increasing to 600 mglday after one 
week and flexible dose regime of 150-600 mglday significantly improved pain-related sleep 
interference. Similar results were seen in studies done by Tolle et al (2008) and Richter et al 
(2005) were pregabalin 600mg/day reduced pain-related sleep interference. Furthermore, 
Hindmarch et al (2005) found that pregabalin also had an effect on sleep in healthy 
volunteers with 450mglday improving sleep efficiency, increasing the proportion of slow 
wave sleep (SWS) and reducing sleep onset latency compared with placebo. 
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4.1.4 Pain and sleep 
All above medications are commonly used in the treatment of neuropathic pain with good 
documentation of efficacy and safety as mentioned earlier. However, the full mechanisms by 
which the treatments affect sleep are not fully understood. The effects on sleep may be 
through a direct pharmacological action or via indirect routes such as pain relief. It is known 
for example, that sleep disturbance is very common in patients with pain and between 50-
70% of people seeking help for chronic pain have reported sleep impairment (Gore et al., 
2005). In a study by Galer and associates it was shown that painful DPN had a high impact 
on sleep and more than half of the patients experienced worsening of the pain at night time 
(Galer et al., 2000). This was also supported in a study by Benbow et ale where the diabetic 
study group had problems with their sleep as their neuropathic pain got worse at night 
(Benbow et aI., 1998). 
4.1.5 Study Aim 
The results of the analysis in chapter 3 suggest that DM patients with painful DPN have 
differences in their sleep architecture when compared with healthy aged and gender matched 
controls. Patients with painful DPN appear to have reduced sleep quality and a higher level 
of daytime sleepiness compared with healthy subjects of the same age and gender. This may 
be due to neuropathic pain and other common complications seen in diabetes. Pregabalin, 
duloxetine and amitriptyline are all used in treatment of neuropathic pain and one would 
therefore like to investigate the effect of these three drugs on pain, sleep architecture and 
sleep quality in type 1 and 2 DM patients with painful DPN. There are currently no published 
reports comparing pregabalin, duloxetine and amitriptyline in the same clinical trial. 
Furthermore, most studies with regards to pregabalin's effect on sleep in patients with painful 
DPN have only reported subjective data (Richter et al., 2005; Rosenstock et al., 2005; TOlle 
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et aI., 2008). In fact, a literature search showed that objective polysomnography assessment 
of the effect of pregabalin on sleep in patients with painful DPN is limited and published data 
only found in healthy subjects or in patients with epilepsy (de Haas et aI., 2007; Hindmarch et 
aI., 2005) as well as one ongoing study with patients with fibromyalgia (clinicaltrials.gov). 
The aim of the current study was to assess the effects of all three treatments on sleep and pain 
in patients with painful DPN and to determine, if possible, whether improvement of sleep was 
related to reduced pain or directly as a result of the treatment regime. As both pain and poor 
, 
quality of sleep can have a negative effect on a patient's health and quality of life it is 
important to establish the treatment effect on both of these variables. The ideal treatment 
would be one that reduced pain and improved sleep without evidence of daytime sedative 
effects. 
4.2 Methods 
4.2.1 Subjects 
A total of 83 type 1 and 2 DM patients were randomised (26 females and 57 males) onto the 
trial. Subjects had to be over 18 years old and have been diagnosed with DM for at least a 
year with neuropathic pain of diabetic origin and a score above 12 on the Leeds Assessment 
of Neuropathic Symptoms and Signs (LANSS). For more detailed description inclusion and 
exclusion criteria see general methods and materials section 2.1. 
4.2.2 PSG overnight recording and Sleep staging 
PSG overnight recordings in order to assess the effects of each drug on sleep architecture 
were carried out on visit 1 = night 7 (baseline with placebo), visit 2 = night 21 (chronic low 
dose), and visit 3 = night 35 (chronic high dose). 'Low dose' was defined as pregabalin 
ISOmg (twice a day), duloxetine 60mg (every morning), or amitriptyline 2Smg (twice a day) 
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and 'high dose' was defined as pregabalin 300 mg (twice a day), duloxetine 60mg (twice a 
day), or amitriptyline 25mg (every morning); 50mg (every evening). See section 2.2 of 
general methods and materials for more detailed description of the study, and an overview of 
the study schedule can be seen in appendix 1. All PSG recordings were carried out in sleep 
labs at the Surrey Clinical Research Centre as stated in general methods section 2.3 using the 
Compumedics Siesta System® (Compumedics Ltd., Australia). Time in bed was 8 hours 
(2300-0700). All subjects had a habituation night before each study night in order to get use 
to the environment (equal to night 6, 20 and 34). The PSG nights were staged by a single 
sleep stager according to the Rechtschaffen and Kales criteria as stated in general methods 
and materials section 2.4. 
4.2.3 Karolinska sleepiness Scale 
The Karolinska Sleepiness Scale (KSS) was used to assess levels of daytime sleepiness and 
was carried out at 0800h, 1000h, 1300h and 1600h on day 8 for placebo (visit 1), day 22 for 
low dose (visit 2) and day 36 for high dose (visit 3). A brief description of the KSS can be 
found under general methods section 2.5.3. 
4.2.4 Leeds Sleep Evaluation Questionnaire 
The Leeds Sleep Evaluation Questionnaire (LSEQ) was carried out at 0800h on day 8 for 
placebo (visit I), day 22 for low dose (visit 2) and day 36 for high dose (visit 3), and was 
used to assess subjective ratings of sleep quality and early morning behaviour (Hindmarch 
and Gudgeon, 1980; Parrot and Hindmarch, 1980; Zisapel and Laudon, 2003). A description 
of the LSEQ can be found in general materials and methods section 2.5.1. 
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4.2.5 Brief Pain Inventory 
The brief pain inventory (BPI) was used to assess patient's pain and was filled in on a daily 
basis throughout the study. A description of BPI can be found in general materials and 
method section 2.5.4. Patients was divided into mild, moderate and severe pain group defined 
as BPI worse pain score of 0-3 for mild, 4-6 for moderate and 7 -10 for severe. 
4.2.6 Visual Analogue Scale 
The Visual Analogue Scale (V AS) was used for rating subjective pain and was carried out at 
0800h, 1000h, 1300h and 1600h on day 8 for placebo (visit 1), day 22 for low dose (visit 2) 
and day 36 for high dose (visit 3).The VAS is a common tool to assess the analgesic 
properties of various drugs (Langley and Sheppeard, 1985). A description of V AS can be 
found in general materials and methods section 2.5.5. 
4.2.7 Statistical methods 
Data set was analysed in a linear mixed model using SAS® PROC MIXED 9.1. Observations 
under treatment were analysed in a linear mixed model using SAS® PROC MIXED 9.1. The 
observations were the dependent variable and fixed effect was treatment with visits being a 
repeated measure. Subjects were added as a random effect. Additional independent covariates 
included body mass index (BMI) and age. Statistical significance level was set to 5% (0.05). 
The sample size of the study groups were decided based on power calculations for the BPI 
pain variables. Decision on concentration of study drugs were as mentioned earlier based on 
previously documented effective analgesic dosages. 
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4.3 Results 
4.3.1 Demographics and Screening results 
A total of 83 patients (57 males and 26 females) were randomised onto the trial and 65 
subjects completed all 3 treatment visits. 27 patients were randomised to pregabalin, 28 to 
duloxetine and 28 to amitriptyline (see table 4.1 for all demographics). 11 patients had type 1 
DM and 72 patients had type 2 DM. 48 patients were receiving insulin treatment and 35 
patients were not receiving insulin treatment. 
Pregabalin Duloxetine Amitriptyline All 
N =27 N = 28 N = 28 N = 83 
Gender Males 19 19 19 57 
Females 8 9 9 26 
Age (years) Mean (SD) 66.3 (7.5) 65 .0 (9.6) 64.2 (9.6) 65.1 (8.9) 
Min 55 40 38 38 
Max 82 80 79 82 
8MI (kglm2) Mean (SD) 32.1 (5.2) 32.0 (5.5) 31.9 (5.6) 32.0 (5.4) 
Min 18.3 23.7 20.3 18.3 
Max 40.0 39.7 41.9 41.9 
Race Caucasian 27 28 28 83 
Table 4.1: Demographic characteristics of study population. 
4.3.2 Subjective Pain measures 
4.3.2.1 Visual analogue scale 
Subjective pain was significantly reduced over time in all three treatment groups with 
subjects having less pain at visit 2 (low dose of treatment) compared with placebo at visit 1 
(pregabalin P< 0.05 , duloxetine and amitriptyline P< 0.01). Furthermore, subjects in the 
duloxetine group had significantly reduced pain at visit 3 compared with the placebo visit (P< 
0.001), table 4.3. There were large differences between treatment groups at baseline so in 
133 
order to correct for this baseline was added as a co-variant. However, there was still no 
significant difference in treatment effect between the three treatments (figure 4.1). 
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Figure 4.1: Treatment effect on visual analogue scale (VAS) pain score. VAS showed that pain was reduced 
in all three treatment groups; a high V AS score indicates worse pain. There was no significant difference in 
treatment effect between the drugs, pregabalin (. ), duloxetine (. ), amitriptyline ( ) Symbols shows mean 
score ± standard en'or of mean (SEM). 
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4.3.2.2 Brief pain inventory 
Pain severity and pain interference on sleep was significantly reduced in all treatment groups, 
(table 4.3). Subjects self-rated pain severity score decreased at visit 2 compared with placebo 
visit 1 (pregabalin and amitriptyline P< 0.05, duloxetine P< 0.01). Pain interference on sleep 
was significantly reduced at visit 2 and 3 compared with placebo (Pregabalin; P<O.Ol and 
0.05 for visit 2 and 3, respectively; amitriptyline; P<O.Ol for both visits and duloxetine; 
P<0.05 for visit 2 and P<O.Ol for visit 3). 
There was a difference between the treatment groups as baseline and baseline was therefore 
added as a co-variant. However, there was still no significant difference of treatment effect on 
pain when comparing the three treatments (figure 4.2). 
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Figure 4.2 Treatment effect on pain: A. BPI - Pain Severity Score. BPI pain severity was significantly 
reduced from visit I to visit 2 in all three treatment groups (a high BPI pain score indicates worse pain). There 
was no significant difference in treatment effect between the drugs. B. BPI - Pain Interference on Sleep. BPI 
pain interference on sleep was significantly reduced from visit I to visit 2 and 3 in all three treatment groups (a 
higher pain interference score indicates a higher level of pain interfering with sleep). There was no significant 
difference in treatment effect between the drugs. pregabalin(. ), duloxetine C- ), amitriptyline ( ). Symbols 
show mean score ± standard error of mean CSEM) 
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Table 4.5: Treatment by visit effect. 
Lower dose Higher dose 
Treatment by 
visit 
Effect p-value Treatment p-value Treatment p-value 
PGBv DUL 0.001 PGBv DUL 0.001 
TST(mln) 0.001 PGBvAMI NS PGBvAMI NS 
DULvAMI 0.001 DULvAMI 0.01 
PGBv DUL 0.001 PGBv DUL 0.001 
SE(%) 0.001 PGBvAMI NS PGBvAMI NS 
DULvAMI 0.001 DULvAMI 0.01 
PGBv DUL 0.05 PGBv DUL 0.001 
SOL (min) 0,01 PGBvAMI NS PGBvAMI 0.01 
DULvAMI NS DULvAMI NS 
PGBv DUL NS PGBv DUL 0.001 
LPS (min) 0.01 PGBvAMI NS PGBvAMI NS 
DULvAMI NS DULvAMI 0.05 
PGBv DUL 0.01 PGBv DUL 0.01 
WASO(mln) 0.01 PGBvAMI NS PGBvAMI NS 
DULvAMI 0.001 DULvAMI 0.05 
Duration of PGBv DUL 0.001 PGBv DUL 0.001 
Wake (min) 0,001 PGBvAMI NS PGBvAMI NS DULvAMI 0.001 DULvAMI 0.01 
Duration of PGBv DUL NS PGBv DUL NS 
stage 4 sleep 0.05 PGBvAMI NS PGBvAMI NS 
(min) DULvAMI 0.05 OULvAMI NS 
Duration of 
PGBv DUL NS PGBv DUL 0.05 
0.0526· PGBvAMI NS PGBvAMI NS NREM(min) DULvAMI 0.05 DULvAMI NS 
Duration of PGBv DUL 0.001 PGBv DUL 0.001 0.01 PGBvAMI NS PGBvAMI NS REM (min) DULvAMI 0.05 DULvAMI 0.01 
Number of PGBv DUL 0.0001 PGBv DUL 0.0001 0.0001 PGBvAMI NS PGBvAMI 0.01 REM periods DULvAMI 0,001 DULvAMI NS 
REM Latency 
PGBv DUL 0.05 PGBv DUL 0.001 
0.01 PGBvAMI 0.05 PGBvAMI 0.05 (min) DULvAMI NS DULvAMI NS 
SWSLatency PGBv DUL 0.01 PGBv DUL 0.01 0.01 PGBvAMI 0.05 PGBvAMI 0.05 (min) 
DULvAMI NS DULvAMI NS 
·When gender is a covariant =significant treatment by visit effect, p< 0.05, NS = Not significant 
PGB = pregabalin, DUL = duloxetine, AMI = amitriptyline, TST = total sleep time, SE = sleep efficiency, 
SOL = sleep onset latency, LPS = latency to persistent sleep, REM = rapid eye movement sleep, 
NREM = non rapid eye movement sleep, SWS = slow wave sleep, NA W = number of nocturnal awakenings 
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4.3.3 Polysomnograpby (PSG) 
PSG variables analysed included; latency to sleep onset (SOL, min), latency to persistent 
sleep (LPS, min), wake after sleep onset (W ASO, min), number of awakenings (NA W), and 
duration of time awake (stage 0, min) throughout the night. Total duration (min) and 
percentage of stage 1, 2, 3, 4, rapid eye movement (REM) sleep, non rapid eye movement 
(NREM) sleep and slow wave sleep (SWS) (stages 3 and 4 combined) were also analysed 
together with variables such as sleep efficiency (SE) and total sleep time (TST). See appendix 
6 for more detailed definition of sleep variables. 
4.3.3.1 Sleep continuity and quality of sleep 
SE, TST, WASO, duration of wake and NA Wall reflect sleep continuity and quality of sleep. 
Comparison of the three treatments showed that there was a significant treatment by visit 
effect on SE, TST, wake and WASO (P<O.OOI for SE, TST and duration of wake, P<O.OI for 
WASO, table 4.5). Duloxetine significantly reduced TST, SE and increased the duration of 
wake when compared with pregabalin and amitriptyline (low dose; duloxetine v pregabalin, 
P< 0.001 and duloxetine v amitriptyline P< 0.001, high dose; duloxetine v pregabalin, 
P< 0.001 and duloxetine v amitriptyline P< 0.01), (figure 4.3 for TST and SE). Duloxetine 
significantly increased W ASO compared with pregabalin and amitriptyline (duloxetine v 
pregabalin P<O.Ol for both low and high dose, duloxetine v amitriptyline P<O.OOI and 
P<0.05 for low and high dose respectively), (figure 4.3C). There was no significant treatment 
by visit effect on NA W when comparing the three drugs, (figure 4.3D). 
Post hoc analysis showed that low and high dose duloxetine had a medium to strong 
treatment effect with a significant reduction in SE and TST compared with placebo (SE LS 
mean for placebo 79.4 %, reduced to 70.4% with low dose and to 74.2% with high dose, 
P<O.OOOI and P<0.05, respectively, TST LS mean was 381.4 min reduced to 338.1 min for 
140 
low dose and to 356.6 min for high dose, P<O.OOOI and P< 0.05, respectively), while WASO 
was significantly increased with low dose (LS mean 85.6 min for placebo, 120.2 min low 
dose and 100.5 min high dose, P<O.OI for low dose). In contrast, pregabalin significantly 
increased SE and TST and reduced W ASO at visit 3 (high dose) compared with placebo at 
visit 1 (LS mean for SE was 77.3% at placebo increased to 85.4 % with high dose and TST 
was 371.6 min for placebo and increased to 410.3 min with high dose and WASO was 90.9 
min for placebo and 57.2 min for high dose, P<O.OI for all. Amitritptyline had no significant 
treatment effect on TST or SE but did significantly reduce W ASO compared with placebo 
(LS mean 91.0 min for placebo and 66.6 min for high dose, P<0.05, table 4.4). 
NA W was the only one of above variables that did not change significantly with any of the 
three treatments, (figure 4.3D). 
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Figure 4.3: Treatment effect on leep continuity and sleep quality. There was an overall significant treatment 
by visit effect on SE and TST (P<O.OO I for both) and W ASO (P<O.O I), but no significant effect on NA W. 
Comparison between treatments; duloxetine v pregabalin = * and duloxetine v amitriptyline = t. Level of 
significance t /* = P<O.05, tt /** = P<O.O I and ttt /*** = p<O.OO 1. Plots shows mean, ± standard error of mean 
(SEM). Amitriptyline ( ), pregabalin (. ), duloxetine (_ ) A. leep efficiency (SE) and B. Total leep time 
(T T). There wa a significant difference between duloxetine compared with pregabalin and amitriptyline, with 
dulo etine significantly reducing E and TST, while pregabalin increased E and TST. Amitriptyline showed 
no changed compared with placebo. C. Wake after sleep onset. There was a significant difference between 
duloxetine compared with pregabalin and amitriptyline, with duloxetine significantly increasing WA 0, while 
pregabalin and amitriptyline significantly decreased WASO compared with placebo. D. Number of nocturnal 
awakening (NA W). There was no significant difference in NA W between the three treatments or compared 
with placebo. 
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4.3.3.2 Latency to sleep 
Both SOL and LPS are standard PSG variables used to assess how long it takes to fall asleep 
and both variables were significantly affected by the three treatments (treatment by visit 
effect = P<O.OI for both), table 4.5. Pregabalin significantly decreased SOL and reduced LPS 
compared with duloxetine and amitriptyline (SOL; pregabalin v duloxetine P<0.05 for low 
dose and P<O.OOI for high dose and pregabalin v amitriptyline P<O.OI for high dose, LPS; 
pregabalin v duloxetine P<O.OOI, figure 4.4A and B). 
When looking at the effect of dose, pregabalin significantly reduced LPS at the higher dose 
(LS mean 29.0 min for placebo compared with 14.1 min for high dose, P<0.05) and 
decreased SOL, even if the latter was not statistically significant when compared with 
placebo (LS mean 22.3 min for placebo to 18.8 min with high dose). In contrast, duloxetine 
high dose significantly increased LPS and SOL compared with placebo (LPS; LS mean 
16.1 min for placebo compared with 33.6 min for high dose, P<O.OI, SOL; LS mean 17.5 min 
with placebo to 30.9 min with high dose, P<O.OOI). Amitriptyline treatment did not change 
LPS or SOL significantly when compared with placebo, (table 4.4). 
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Figure 4.4: Treatment effect on sleep onset latency SOL and LPS. There was an overall significant treatment 
by visit effect on SOL and LPS (P<O.O I for both). Comparison between treatments; duloxetine v pregabalin = *, 
amitriptyline v pregabalin = x and duloxetine v amitriptyline = t. Level of significance t /* = P<O.05 , xx = 
P<O.Ol and *** = P<O.OO 1. Plot shows mean, ± standard error of mean (SEM). Amitriptyline ( ), 
pregabalin C+), duloxetine C. ). A. Sleep Onset Latency. There was a significant difference between 
pregabalin when compared with amitriptyline and duloxetine. PregabaIin decreased OL and duloxetine 
increased SOL compared with placebo, while amitriptyline did not change significantly compared with placebo. 
B. Latency to Per istent leep. There was a significant difference between the treatments with duloxetine 
significantly increasing LPS compared with pregabalin and amitriptyline. Pregabalin decreased LPS and 
duloxetine increased LPS compared with placebo, while amitriptyline did not change significantly from placebo. 
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4.3.3.3 Sleep architecture NREM and REM 
When looking at patients' sleep architecture there was no significant treatment by visit effect 
on stage 1, 2 and 3 sleep and there was therefore no significant differences between 
amitriptyline, duloxetine or pregabalin treatments with regards to the amount of stage 1, 2 
and 3 sleep (figure 4.S). There was a significant treatment by visit effect (P<O.05) for stage 4 
sleep with a difference between duloxetine and amitriptyline at visit 2, (P<O.05, figure 4.5). 
Post hoc analysis showed that there was a significant visit effect, likely to be due to dosage. 
Duration of stage 1 increased across all treatment groups, and all treatments showed a 
moderate to strong treatment effect (table 4.4). Pregabalin: LS mean 67.2 min with placebo at 
visit 1 to 82.3 min low dose and 85.S min high dose (P<O.OS and P = 0.OSI3, respectively). 
Duloxetine: LS mean 65.8 min placebo to 85.4 min low dose and 93.7 min high dose, 
(P<O.Ol for both), and amitriptyline: LS mean 59.3 min placebo to 82.5 min low dose and 
79.5 min high dose, (P<O.Ol for both). In addition, patients in the pregabalin and 
amitriptyline treatment groups had a significant increase in duration of stage 2 sleep on visit 2 
and 3 compared with placebo at visit I, with high dose pregabalin and low and high dose 
amitriptyline increasing stage 2 sleep, while there was no significant difference in the 
duration of stage 2 sleep with duloxetine treatment compared with placebo (table 4.4). 
Pregabalin: LS mean 170.3 min for placebo to 212.2 min for high dose, P<O.OI and 
amitriptyline: LS mean 178.7 min for placebo compared with 197.1 min for low dose and 
215.4 min for high dose, (P<0.05 and P<O.OI, respectively). There was no significant change 
in duration of stage 3 sleep in any of the treatment groups compared with placebo, and 
duration of stage 4 sleep only showed significant difference in duloxetine group with 
decrease in stage 4 sleep at visit 2 compared with placebo at visit 1(p<0.01). 
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Figure 4.5: Treatment effect on sleep architecture. There was no significant treatment by visit effect on stage 
1, 2 and 3 sleep, while there was a significant treatment by visit effect on stage 4 sleep (P<O.05). Comparison 
between treatments; duloxetine v amitriptyline = t. Level of significance t = P<O.05. Plots shows mean, ± 
standard error of mean (SEM). Amitriptyline ( ), pregabalin (. ), duloxetine (_ ) A. Stage I sleep duration. 
There was no difference between treatments. All treatments increased the duration of stage I sleep compared 
with placebo. B. Stage 2 sleep duration. There was no difference between treatments. Amitriptyline and 
pregabalin significantly increased the amount of stage 2 sleep compared with placebo, while duloxetine did not 
change significantly compared with placebo. C. Stage 3 sleep duration. There was no significant difference 
between treatments or when compared with placebo. D. Stage 4 sleep duration. There was a significant 
difference between treatments with duloxetine having less stage 4 sleep compared with amitriptyline at visit 2. 
Duloxetine low dose also significantly reduced stage 4 sleep compared with placebo, while stage 4 sleep during 
treatment with pregabalin and amitriptyline did not change significantly. 
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When stage 3 and 4 sleep was combined (Slow Wave Sleep, SWS) there was no significant 
difference in the duration of SWS between the three treatment groups (table 4.4 and figure 
4.6). A similar result was seen when looking at the thirds of night as there was no significant 
difference between the three treatments in SWS on the IS\ 2nd or 3rd third of the night. 
However, there was a significant difference between visits (P<O.05). On the 1 st third of the 
night high dose pregabalin significantly increased the amount of SWS compared with placebo 
(LS mean 27 min with placebo to 41 min with high dose, P<O.OI), while amitriptyline and 
duloxetine had no significant effect on the amount of SWS in the 1st third of the night 
compared with placebo (DUL; 28 min placebo and 29 min high dose; AMI; 29.5 min placebo 
and 31 min high dose). 
When looking at the latency to SWS there was a significant difference between the treatments 
(P<O.OI), with pregabalin significantly decreasing SWS latency compared with amitriptyline 
and duloxetine (table 4.5 and figure 4.6). Pregabalin decreased SWS latency compared with 
placebo (LS mean 63.2 min at placebo compared with 44.8 min for low dose and 38.8 min for 
high dose, P<O.OI for both), while duloxetine increased SWS latency (LS mean 55.8 min at 
placebo compared with 62.8 min for low dose and 88.6 min for high dose, P<O.05 for high 
dose). There was no significant change with amitriptyline when compared with placebo (table 
4.4). 
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Figure 4.6: Treatment effect on duration SWS and latency to SWS. There was no significant treatment by 
visit effect on duration ofSWS, while there was a significant treatment by visit effect on SWS latency (P<O.Ol). 
Comparison between treatments; pregabalin v duloxetine = * and pregabalin v amitriptyline = x Level of 
significance x = P<O.05, ** = P<O.O I, *** = P<O.OOI . Plots shows mean, ± standard error of mean (SEM). 
Amitriptyline ( ), pregabalin C. ), duloxetine C- ) A. SWS duration. There was no significant difference 
between the treatments or compared with placebo. B. SWS latency. There was a significant difference between 
treatments, with pregabalin decreasing latency to SWS and duloxetine increasing latency to SWS compared with 
placebo. There was no significant effect of amitriptyline on SWS latency when compared with placebo. 
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When looking at stage 1, 2, 3 and 4 sleep combined (NREM sleep), the overall treatment by 
visit effect was approaching significance (P=0.0526). Analysis showed a significant 
treatment by visit effect with the duloxetine group having significantly less NREM sleep 
compared with amitriptyline at visit 2 (low dose) and compared with pregabalin at visit 3, 
high dose (P<0.05 for both, table, 4.5, figure 4.7). There was evidence of a significant visit 
effect with NREM sleep increasing in all three treatments groups. Pregabalin increased 
NREM duration compared with placebo (LS mean 291.5 min compared with 319.0 min for 
low dose and 348.3 for high dose, P<O.OI and P<O,OOOI, respectively). Amitriptyline showed 
similar results (LS mean 291.6 min for placebo, increasing to 328.6 min for low dose and 
further increase to 343.6 min for high dose, P<O.OOOI for both). Duloxetine was the only 
treatment that did not significantly increase NREM duration at the lower dose, however there 
was a significant increase at the high dose (LS mean 298 min for placebo compared with 
326.7 min for high dose, P<0.05, table 4.4). 
For REM sleep duration there was a significant treatment by visit effect when comparing the 
three treatments with each other (P<O.OI, table, 4.5). Low dose of duloxetine significantly 
decreased REM sleep duration compared with pregabalin and amitriptyline (P<O.OOI and 
0.05, respectively) and the same could be seen with high dose duloxetine (P<0.001 and 0.01, 
respectively, figme 4.7). 
There was also a significant visit effect (P<O.OOOl) with a significant reduction in REM sleep 
duration across all three treatment groups, (table 4.4). Pregabalin decreased REM sleep with a 
LS mean of 80.1 min for placebo compared with 61.6 min for low dose and 62 min for high 
dose (P<O.OI for both), duloxetine had an even stronger treatment effect and reduced REM 
sleep from a LS mean of 83.4 min for placebo to 34.8 min low dose and 29.9 min high dose 
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(P<O.OOOI for both) and amitriptyline had a LS mean of 77.0 min for placebo compared with 
49.7 min for low dose and 50.2 min for high dose (P<O.OOOI for both). 
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Figure 4.7: Treatment effect on duration of NREM/REM sleep. There was a significant treatment by visit 
effect on the duration of REM sleep (P<O.O I), while the duration of NREM sleep approached significance 
(P=O.0526); Comparison between treatments; pregabalin v duloxetine = * and duloxetine v amitriptyline = t. 
Level of significance t /* = P<O.05, *** = P<O.OOl. Plots shows mean, ± standard error of mean (SEM). 
Amitriptyline ( ), pregabalin C. ), duloxetine C- ) A. NREM sleep duration. All treatments significantly 
increased the duration of NREM sleep compared with placebo. There was also a difference between the 
treatments with duloxetine having significantly less NREM sleep compared with amitriptyline at low dose and 
pregabalin at high dose. B. REM sleep duration. All treatments significantly reduced the duration of REM 
sleep compared with placebo. There was still a significant difference between treatments with duloxetine 
significantly decreasing the duration of REM sleep compared with pregabalin and amitriptyline. 
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Furthermore, REM latency and the number of REM periods during the night were also 
significantly affected by treatment, (treatment by visit effect, P<O.Ol and P<O.OOOl, 
respectively) when comparing the three drugs (table 4.5). REM latency was significantly 
increased by low dose duloxetine compared with low dose pregabalin and amitriptyline 
(P<0.05 for both) and the same effect was observed at high dose (P<O.OOI and P<0.05, 
respectively, figure 4.8). Post hoc analysis showed that there was also a significant change 
with visit (table 4.4). Both duloxetine and amitriptyline significantly increased REM latency 
compared with placebo. Duloxetine (LS mean of 79.9 min at placebo compared with 166.8 
min with low dose and 226.7 min with high dose, P<O.OOO 1 for both) and amitriptyline (LS 
mean 65.2 min for placebo compared with 148.0 min at low dose and 148.8 min at high dose, 
P<O.OOOI for both). Pregabalin low and high dose had no significant effect on REM latency 
compared with placebo. 
For the number of REM periods duloxetine significantly reduced the number of REM periods 
when compared with pregabalin, both at the low dose and high dose (P<O.OOOI for both). In 
addition, low dose duloxetine reduced the number of REM periods compared with 
amitriptyline (P<O.OOI). There was also a significant reduction in the number of REM 
periods following high dose amitriptyline when compared with pregabalin (P<O.OI, figure 
4.8). With regards to changes with visits (Table 4.4), duloxetine and amitriptyline 
significantly reduced the number of REM periods compared with placebo. Duloxetine had a 
LS mean of3.8 REM periods for placebo compared with 1.5 at low dose and 1.8 at high dose 
(P<O.OOOl for both) and amitriptyline had LS mean 3.7 for placebo compared with 2.7 low 
dose and 2.3 high dose (P<O.OOl and P<O.OOOl, respectively). Pregabalin demonstrated a 
weaker treatment effect with a LS mean of 3.3 REM periods for placebo, 2.8 at low dose and 
3.1 at high dose) with only the low dose, visit 2 being significantly different compared with 
placebo (P<0.05). 
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Figure 4.8: Treatment effect on REM latency and number of REM periods. There was a significant 
treatment by visit effect on both REM latency and the number of REM periods P<O.O 1 and P<O.OOO I, 
respectively. Comparison between treatments; pregabalin v duloxetine = * pregabalin v amitriptyline = )( and 
duloxetine v amitriptyline = t . Level of significance )(/* = P<O.05, X)( = P<O.O I, ttt/*** = P<O.OO I. Plots show 
mean, ± standard error of mean (SEM). Amitriptyline ( ), pregabalin (. ), duloxetine (_ ) A. REM latency. 
There was a significant difference between treatments with pregabalin shortening REM latency compared with 
amitriptyline and duloxetine. The latter two significantly increased REM latency when compared with placebo, 
while pregabalin did not significantly change from placebo. B. Number of REM period. There was a 
significant difference between the treatments with duloxetine significantly reducing REM periods compared 
with amitriptyline and pregabalin. Duloxetine and amitriptyline decreased number of REM periods compared 
with placebo. 
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4.3.3.4 Sleep stages as a percentage of TST 
When looking at stage I, 2, 3 and 4 sleep as a percentage of TST there was no significant 
treatment by visit effect. There was no difference between the treatments and no difference 
when comparing the treatments with placebo. However, when looking at REM sleep there 
was there was a significant treatment by visit effect (P<0.05) with the high dose of duloxetine 
reducing % of REM sleep significantly more compared with pregabalin and amitriptyline 
(P< 0.001 and P<O.OI, respectively). Post hoc analysis showed that all three treatments 
reduced the % of REM sleep when compared with placebo and this reduction was significant 
both at the low and high doses (P<O.OOOI for all, figure 4.9). 
As a result of the significant change in % REM sleep, there was also an overall significant 
treatment by visit effect (P<0.05) for % NREM sleep, with high dose of duloxetine increasing 
% of NREM sleep of TST significantly more when compared with pregabalin and 
amitriptyline (P< 0.001 and P<O.OI, respectively). All treatments showed an increase in the 
% NREM sleep compared with placebo and this was significant in both low and high doses 
(P<O.OOOI for all, figure 4.10). 
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Figure 4.10: Treatment effect on % NREM sleep of TST. There was a significant treatment by visit effect on 
%NREM sleep of TST when comparing the three treatments (P<O.05). Comparison between treatments: 
duloxetine v amitriptyline - t Level of significance: tt = P<O.O I, ttt = P<O.OO I. All three treatment increased 
% NREM sleep compared with placebo (*** = P<O.OO I for al\). Bars show mean, ± standard error of mean 
(SEM). 
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4.3.4 Correlation between pain and sleep 
Pearson correlations were done to assess possible relationship between pain and sleep. Pain 
variables included pain severity score, pain interference score and pain interference on sleep 
score all from the BPI. Sleep variables included NA W, SE, TST, WASO, and LPS. There 
were no significant correlations between pain and any of above sleep variables at baseline 
(visit 1) and there were no significant correlations when looking at the change from placebo 
at baseline to visit 3. This dissociation between pain and sleep was still present when looking 
at correlations within each drug treatment. 
Patients were also divided into groups of mild, moderate and severe pain but again results 
showed no significant correlations between pain and sleep in the moderate or severe pain 
patient groups when compared at baseline. The only group that showed significant 
correlations was the mild pain patient group at baseline. Increased pain severity score and 
pain interference score correlated with an increase in LPS (P<O.05 for both). Correlation with 
pain severity score and SE and TST approached significance with an increase in the pain 
severity score correlating with a decrease in SE and TST (P<O.065 for both). BPI pain 
interference on sleep showed a significant correlation with TST and W ASO. Increased pain 
interference on sleep correlated with a decrease in TST and an increase in W ASO (P<O.05 for 
both, Table 4.6). 
There were no significant correlations when comparing change from baseline to visit 3 in any 
of the pain groups (mild; N= 18, moderate; N=22 and severe; N=l1) suggesting that any 
improvement in pain did not lead to significant improvements in sleep quality or continuity. 
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4.3.5 Subjective sleep measures and daytime sleepiness 
4.3.5.1 Karolinska sleepiness scale 
There was no evidence of a significant treatment by visit effect with no significant difference 
in treatments when all three drugs were compared with each other, table 4.5 and figure 4.11. 
There was also no significant difference in daytime sleepiness in the pregabalin and 
duloxetine treatment groups when compared with placebo. However, subjects in the 
amitriptyline treatment group showed a significant increase in daytime sleepiness compared 
with placebo with a KS LS mean o[ 4.1 for visit 1 (placebo) compared with 4.6 for visit 2 
(low dose) and 4.3 [or visit 3 (high dose), (P<O.05 for both, table 4.3) 
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Figure 4. 11 : Treatment effect on Karolin ka leepiness ca le (K ). There was no significant treatment by 
visit effect. Plot shows mean ± standard error of mean (SEM) amitriptyl ine ( ), pregabalin (. ). duloxetine (- ) 
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4.3.5.2 Leeds sleep evaluation questionnaire 
There was no significant treatment by visit effect on any of the LSEQ variables (Getting to 
Sleep, GTS; Quality of Sleep, QOS; Awakening From Sleep, AFS; Behaviour Following 
Awakening, BFW) when comparing the three drugs with each other, (table 4.5 and figure 
4.12). 
With respect to each visit, subjects in the pregabalin treatment group found it significantly 
easier to get to sleep and had significantly better subjective quality of sleep at visit 3 
compared with placebo at visit 1 (P<O.OI for both, table 4.3). There was no significant 
difference in the ease of getting to sleep, nor subjective quality of sleep when looking at the 
duloxetine or amitriptyline treatment groups compared with placebo. There was no 
significant difference in awakening from sleep and behaviour following sleep with any of the 
treatment groups when compared with placebo, (table 4.3). 
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Figure 4.12: Treatment effect on Leeds Sleep Evaluation Questionnaire (LSEQ). There was no significant 
treatment by visit effect on any of the LSEQ questions when comparing the three drugs. Plots shows mean, ± 
standard error of mean (SEM). Amitriptyline ( ), pregabalin (. ) , duloxetine (. ). The black line indicates no 
change in the subjective feeling of ease of getting to sleep compared to normal (before treatment began). 
A. L EQ-Getting to leep. There was no significant difference between the treatments. Pregabalin significantly 
improved getting to sleep compared with placebo while amitriptyline and duloxetine did not change 
significantly compared with placebo. B. LSEQ-Quality of sleep. There was no significant difference between 
the treatments. Pregabalin significantly improved quality of sleep compared with placebo while amitriptyline 
and duloxetine did not change significantly compared with placebo. C. LSEQ-awakening following sleep. 
There was no significant difference when comparing the three treatments or when compared with placebo. 
D. L EQ-behaviour following sleep. There was no significant difference when comparing the three treatments 
or when compared with placebo. 
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4.3.6 Safety data 
Safety data showed that 83 patients were randomized. 75 completed visit 1. 69 completed 
visit2 and 65 patients completed all 3 visits. (table 4.2). 4.82 % (n=4) were excluded due to 
protocol deviation and 1.20% (n=l) were excluded due to non-compliance and 3.61% (n=3), 
withdrew consent. 12% (n=10) withdrew from the study due to adverse events. Adverse 
events included; panic attack (n=I), hepatitis (n=I), salmonella enteritis (n=I), weakness 
(n=I), diarrhoea (n=I), chest pain (n=I), balance disorder (n=I), flulike symptoms (n=I), 
infection in left foot (n=I), and ruptured abdominal aortic aneurysm (n=I). None of the above 
adverse events were classified, by the Principal Investigator, as likely to be due to any of the 
three treatments. Other reported adverse events were mild to moderate and did not result in 
withdrawal from the study. Protocol deviations and non-compliance resulting in withdrawal 
were for example feeling of claustrophobia when in the sleep laboratory, ingestion of 
analgesic medication not permitted by the protocol and non compliance in regards to study 
procedures. 
160 
4.4 Discussion 
Pregabalin, duloxetine and amitriptyline are prescribed in the treatment of neuropathic pain in 
patients with painful DPN, and they all have good documentation of efficacy and safety 
(Frampton and Foster, 2004; Goldstein et al., 2005; McQuay et aI., 1992; Raskin et aI., 2005; 
Rosenstock et aI., 2004). The results in this study supported this as all doses were safe and 
well tolerated with generally mild to moderate adverse events. Only 12 % (n=10) of patients 
withdrew from the study and no withdrawals were classified as being likely to be due to 
treatment. Furthermore, all three medications significantly reduced pain compared with 
placebo. Although subjective pain was reduced in all treatment groups during the study one 
has to be careful when saying that this pain reduction was a therapeutic effect of the given 
medical intervention as this study did not have a placebo arm in order to confirm this. The 
main reason for not including a placebo arm was that it was not considered ethically correct 
to have a placebo arm for the whole duration of the study (total of 5 weeks) since the safety 
and efficacy of all three treatments had previously been reported (Goldstein et al., 2005; 
McQuay et aI., 1992; Raskin et al., 2005; Richter et al, 2005; Rosenstock et at., 2004). 
Therefore, the pain reduction seen in the current study may be either a drug effect or an effect 
of time or a combination of both, however it is more likely that it is due directly to the 
treatment. There was no significant difference between any of the treatment groups with 
respect to pain relief and therefore the conclusion was that no drug was superior with regards 
to pain reduction in this patient group. 
Pain is thought to impair sleep (Benbow et aI., 1998; GaIer et aI., 2005) and it has been 
suggested that patients with painful DPN have worse sleep compared with a heaIthy 
population (see chapter 3). It is already known that pregabaIin, duloxetine and amitriptyline 
are effective at reducing pain (Goldstein et aI., 2005; McQuay et aI., 1992, Raskin et aI., 
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2005; Richter et aI., 2005 and Rosenstock et al., 2004), but this is the first time all three drugs 
have been compared with each other in the same clinical trial and the first time it has been 
shown that there is no significant difference in pain relief when the three drugs are compared 
together. 
It is not fully known how these medications affect sleep, and no studies have compared the 
three drugs and their effect on sleep in painful DPN patients. The results from this study 
showed that sleep in patients with painful DPN was significantly affected by all three 
medications and analysis showed that there was a significant difference between the 
treatment groups. TST and SE, both good indicators of quality of sleep, were significantly 
reduced by duloxetine while pregabalin significantly increased TST (min) and SE (%) when 
compared with placebo. SE was for example increased from a mean of 77 % (± SEM 2.46) to 
a mean of 85% (± SEM 2.l3) in patients on the pregabalin treatment regime. A SE of 85% is 
similar to that seen in a healthy population of the same age and gender (see results chapter 3). 
W ASO was also significantly affected with high dose of pregabalin reducing W ASO while 
low dose duloxetine increased WASO. The reduction in sleep continuity with increased 
WASO and reduced SE has been seen previously with duloxetine in healthy subject (Chalon 
et al., 2005). In the present study it appeared that the negative effect on sleep was 
particularly prominent at low dose duloxetine. W ASO was only significantly increased at the 
low dose and there was also a greater reduction in TST and SE with low dose duloxetine 
compared with high dose (although the high dose still significantly reduced TST and SE 
compared with placebo). 
SOL and LPS were also greatly affected by the drug treatments with duloxetine increasing 
both SOL and LPS, meaning that it took longer for patients to fall asleep when on duloxetine 
treatment compared with placebo. In fact duloxetine at the high dose (12Omglday) had a 
162 
strong negative treatment effect, resulting in a SOL and LPS almost twice as long on high 
dose as compared with placebo. These results indicate similarities with previously published 
data. Data published by Eli Lilly and Co (2004) showed an increased prevalence of insomnia 
(characterized as difficulties initiating and/or maintaining sleep and commonly associated 
with impairments of functioning while awake) in patients with painful DPN and the 
prevalence was highest with the dose of 120mglday. In contrast, pregabalin reduced SOL and 
LPS with the latter significantly shorter compared with placebo. Unlike pregabalin and 
duloxetine, amitriptyline had little effect on objective sleep. Amitriptyline had no significant 
effect on, TST, SE, LPS, SOL or duration of wake when compared with placebo and only 
W ASO was significantly reduced at the high dose of amitriptyline. 
Although objective measures of sleep quality (TST and SE) and ease of getting to sleep (SOL 
and LPS) were improved by pregabalin and worsened on duloxetine, subjectively there was 
no significant difference between the three treatments. It was however possible to see 
improvements in subjective sleep variables in the pregabalin treatment group, with the 
pregabalin group by visit 3 showing improved subjective quality of sleep and ease to get to 
sleep when compared with placebo. 
The positive effect on sleep seen with pregabalin was only present at the high dose of 
600mglday with the lower dose of 300 mglday showing little difference compared with 
placebo. The effects of pregabalin on sleep have been previously reported although the 
majority of studies have investigated subjective and not objective sleep variables. Studies 
done by T611e et al (2008) and Richter et al (2005) showed that 600mglday pregabalin 
significantly lowered sleep interference score compared with placebo, while a study by 
Rosenstock et al (2004) showed significant reduction in sleep interference score with 
300mglday pregabalin when compared with placebo. There are limited data published with 
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regards to objective PSG variables. One PSG study by Hindmarch et al (2005) found that 
pregabalin 450/mg day improved SE and reduced SOL compared with placebo when assessed 
in healthy volunteers. Another PSG study in patients with epilepsy showed that pregabalin 
300mglday significantly improved SE and reduced number of awakenings compared with 
baseline, and W ASO approached significant difference (de Haas et al., 2007). The result of 
the present study shows a similar improvement in sleep in patients with painful DPN (on 
pregabalin equivalent to 600mglday). Any improvement in sleep in the patients with DPN 
may have been thought to be due to pain relief, however as a similar level of improvement 
has also been seen in healthy volunteers, this suggests that pregabalin improves sleep through 
another distinct mechanism other than that of reducing neuropathic pain. 
It was hypothesised that an improvement in sleep quality or continuity might enhance the 
analgesic efficacy ofpregabalin when compared to other treatments (e.g. duloxetine) that did 
not improve but instead disrupted sleep. This however was not shown as there was no 
significant difference in the three treatments on analgesic efficacy. 
On closer examination of the sleep data one could also see a significant change in sleep 
architecture with the three treatments. There was a strong and significant treatment by visit 
effect with regards to REM sleep. REM sleep was significantly suppressed by the low and 
high doses of all three treatments when compared with placebo. With amitriptyline this was 
expected as classic antidepressants (tricyclic antidepressants, TCAs) are known for their 
REM suppression (Mertz et al., 1998; Staner et al., 1995). The REM suppression seen with 
duloxetine however, was significantly greater compared with that of pregabalin and 
amitriptyline. Closer inspection suggested that the first REM period was lost following 
duloxetine treatment as the REM latency increased from 79 min to almost 227 min and the 
number of REM periods was reduced from approximately 4 to 2. These results are in 
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agreement with previous published data where duloxetine has been shown to cause REM 
suppression and increased REM latency in healthy subjects (Chalon et aI., 2005). Another 
PSG study in patients with major depression showed that there was a significant increase in 
REM latency from 58.5 min at baseline to 193.6 min with duloxetine (60mglday) and REM 
sleep duration was also significantly reduced (Kluge et al., 2007). The REM suppression seen 
with SSNRIs such as duloxetine is similar to that seen with other antidepressants such as 
TCAs and SSRIs. Studies for the past 30 years have showed a suppression of REM sleep and 
also a marked increase in REM latency with these types of drugs (Gillin et al.1978; Kerkhofs 
et al., 1990; Mertz et aI., 1998; Staner et aI., 1995). This data would suggest that the first 
REM period in sleep is fragile and is easily disrupted accounting for the increase in REM 
latency seen in patients treated with SSNRIs, SSRIs and TCAs. The long term effect of REM 
suppression is not fully known, some suggest that REM sleep has an important role in 
memory consolidation but evidence for this is found to be weak (Siegel, 2001). 
There was no significant difference in any of the other stages of sleep when comparing the 
three treatments. All three drugs increased the amount of stage 1 compared with placebo and 
stage 2 sleep was increased with pregabalin and amitriptyline. Stage 3 and 4 and SWS (stage 
3 and 4 combined) remained unchanged. However, there was a slight reduction in stage 4 
sleep and SWS with all three medications even if this was not statistically significant. This 
reduction was unexpected, especially with pregabalin which is known to enhance stage 4 
sleep and SWS (Hindmarch et al., 2005). The reduction may be due to the high dosages used 
in this study as one need higher dosage of, for example pregabalin, in order to achieve good 
analgesic efficacy and this may therefore have a negative impact on SWS. However, when 
looking at SWS as thirds of the night it was shown that high dose pregabalin significantly 
increased / consolidated the amount of SWS in the 1 st third of the night to 41 min of SWS 
compared with 27 min for placebo, while SWS in the 1 st third of night on amitriptyline and 
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duloxetine remained unchanged. Pregabalin also reduced the latency to SWS compared with 
amitriptyline and duloxetine. The reduction in SWS latency on pregabalin from 63 min to 39 
min brought the DPN patients in line with an age and gender matched healthy volunteer 
historical control group who had a mean SWS latency of 30 min (see chapter 3). This 
reduction, together with the increase of S WS in the 1 st third of the night suggested that even if 
the amount of SWS overall was not significantly increased with any of the treatments, it was 
shifted to the earlier part of the night in the patient group on pregabalin. 
When looking at the percentage of NREM and REM of TST there was also a significant 
difference both between the treatments as well as compared with placebo. During the placebo 
treatment all groups could be considered to have a normal percentage of REMINREM sleep 
with around 20-22% spent in REM sleep and 78-80% spent in NREM (Kryger et al., 2005). 
However, during active treatment the REM suppression seen with all of the treatments altered 
the REM! NREM percentage and the percentage of REM was significantly reduced to 8.4% 
for duloxetine to 12.7% with amitriptyline and 15% with pregabalin and NREM percentage 
increased. 
With regards to day time sleepiness, as assessed by KSS, there was no significant difference 
between the three treatments and there was no difference between pregabalin and duloxetine 
compared with placebo, while amitriptyline slightly increased daytime sleepiness compared 
with the placebo visit. In addition, there was no significant difference on awakening 
following sleep and behaviour following sleep (LSEQ) between the three treatments or when 
compared with placebo. Finally there was no significant difference between any of the 
treatments or compared with placebo on next day performance. This was assessed using a 
psychometric test battery including memory tasks and reaction tasks (internal 
communication, Miss Laura Gribble, University of Surrey). It was of interest that there was 
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no evidence of significant objective daytime performance impairment with amitriptyline and 
only slightly increased daytime sleepiness as daytime sedation, excessive sleepiness and 
impairment the next day has been reported in previous studies with amitriptyline and 
therefore might have been expected (Hindmarch et ai., 2000; Rosenzweig et aI., 1998). 
In conclusion, the results suggest that all three treatments are effective in reducing 
neuropathic pain of diabetic origin and it has for the first time been shown that none of the 
drugs have a superior analgesic effect. Duloxetine disrupted sleep and showed a strong 
negative treatment effect on sleep with reduced SE and TST, increased wake time and an 
increase in the time taken to fall asleep which may be due to an alerting effect of the drug. 
Selective serotonin re-uptake inhibitors have for example showed increase in wakefulness 
and a general alerting effect (Hicks et aI., 2002; Wilson et aI., 2000). Despite the negative 
effect on sleep with duloxetine there was no evidence of excessive daytime sleepiness or a 
subjective perception of worse sleep. However this may also be due to the alerting effect of 
the drug giving cognitive enhancement and a general feeling of improved wake performance. 
Whether any direct alerting effect could be maintained longer term is unknown, and the 
disruption of sleep continuity and sleep quality may have a detrimental effect long term, but 
future studies are needed to establish whether this is the case. In contrast, pregabalin 
improved sleep in patients with painful DPN and had a positive treatment effect on both 
subjective and objective sleep and no significant daytime sleepiness or sedative effects the 
next day. Amitriptyline did not have any effect on subjective or objective sleep, no significant 
sedation effect or impairment the next day, but showed some evidence of excessive daytime 
sleepiness. 
The lack of correlations between pain and sleep suggest that although pregabalin improved 
sleep quality this improvement in sleep did not lead to subsequent improvements in pain 
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relief or perception of pain interference on sleep. The reason for this is unclear, however pain 
improvements may have become more apparent with a longer treatment regime and it may 
not have been possible to see such effects over a short period. Another possible reason why 
there did not seem to be a significant interplay between improvement in quality of sleep and 
further improvement of pain may be because there was a distribution of patients classified as 
suffering from mild, moderate and severe pain (as defined by BPI worst pain question) with 
the majority of patients in the mild-moderate grouping (40 patients) and only 11 patients in 
the severe pain group. This was also particularly apparent in the pregabalin treatment group 
with the pregabalin group having the lowest mean pain severity score at the baseline, placebo 
visit. Future research may be to include patients reporting only moderate or severe pain 
rather than mild as one may expect a greater treatment effect and a possible difference in 
analgesic efficacy between the different treatments. 
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CHAPTER 5 - RESULTS 
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CHAPTER 5 RESULTS 
5. Clinical sleep characteristics of type 1 and 2 diabetic patients with 
painful DPN and possible treatment effects. 
5.1 Introduction 
One of the previous chapters (see chapter 3) showed that diabetic patients with painful DPN 
indeed had worse sleep when compared with a healthy historically created control group 
which was matched for age and gender. The diabetic patient group took longer to fall asleep, 
had worse sleep quality (defined by reduced sleep efficiency and total sleep time, and more 
time awake), and they also felt sleepier during the day compared with the healthy volunteer 
group. 
The reduced sleep quality seen may have been due, at least in part, to the observation that 
diabetic patients with painful DPN often find that their pain has a negative effect on their 
sleep and it is well documented that one of the most common reported complaints of chronic 
pain is sleep disturbance (Benbow et aI. , 1998; Galer et aI., 2000; Gore et ai. , 2005 ; 
Moldofsky, 2001) however, the results in chapter 4 showed little correlation between pain 
and objective sleep. Other factors such as periodic limb movement (PLMS), sleep disordered 
breathing and nocturnal hyperglycaemia/hypoglycaemia may also be contributing to the 
worsening in sleep quality and the increase in wake time seen in this patient group as all of 
these features are commonly associated with diabetes (Chansens, 2007; Foley et al., 2004; 
Resnick et aI. , 2003' Vigg 2003). 
PLMS are often associated with arousals which can lead to difficulties in staying asleep, 
resulting in sleep fragmentation and excessive daytime sleepiness (Ancoli-Israel and Ayalon, 
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2009). Sleep apnoeas are often associated with oxygen desaturation which can lead to 
nocturnal hypoxemia and also cause arousals and awakenings (Alsaeedi and Aishammari, 
2005; Neubauer, 1999; Pallayova et aI., 2006; Paulson, 2000). Furthermore, it is thought that 
sleep apnoea, severe oxygen desaturations and sleep fragmentation are risk factors for altered 
glucose metabolism and are associated with nocturnal hyperglycaemia (Pallayova et aI., 
2006; Punjabi and Polotsky, 2005), with several studies showing a link between obstructive 
sleep apnoea, sleep loss and insulin resistance (Pallayova et al. 2006; Punjabi et al., 2002 
Punjabi et aI., 2004, Spiegel et al., 2005). 
Nocturnal glucose levels alone may also contribute to worse sleep. Hypoglycaemic episodes 
are for example thought to reduce slow wave sleep and increase in awakenings, although the 
effect on sleep is not fully known (Bendtson et aI., 1992). 
5.1.1 Study Aim 
Several studies have looked in isolation at factors that may affect the sleep of diabetic 
patients with painful DPN (Alsaeedi and Alshammari, 2005; Paulson, 2000;Resnick et al., 
2003; Rijsman et al., 2004; West et al., 2006). In this study one aim was to explore the 
relationship between pain, clinical sleep characteristics and nocturnal glucose and also to 
ascertain what the key factors in this population group were. One hypothesis to be tested was 
that an increase in the apnoealhypopnoea index (AHI) was correlated with increased oxygen 
desaturations and hypoxemia leading to nocturnal hyperglycaemia. As hyperglycaemia is also 
thought to be a risk factor for worsening of peripheral neuropathy, correlations between 
nocturnal glucose levels and pain severity were also to be explored in this patient group. 
Another aim of the study was to establish whether PLMS and/or obstructive sleep apnoea 
correlated with the poor sleep seen. 
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Finally, the effects of duloxetine, amitriptyline and pregabalin, on clinical sleep parameters 
and glucose levels were assessed in order to gain a full profile of the treatments. 
5.2 Methods 
5.2.1 Subjects 
A total of 83 type 1 and 2 DM patients were included in the analysis. Subjects had to be over 
18 years old and have been diagnosed with DM for at least a year and have neuropathic pain 
of diabetic origin with a score above 12 on the Leeds Assessment of Neuropathic Symptoms 
and Signs (LANSS). For more detailed description of recruitment and inclusion and 
exclusion criteria see general methods and materials section 2.1 
5.2.2 PSG overnight recording 
PSG overnight recordings were carried out on visit 1 = night 7 (baseline with placebo), visit 2 
= night 21 (chronic low dose), and visit 3 = night 35 (chronic high dose). The low dose visit 
corresponded to pregabalin 150mg (twice a day), duloxetine 60mg (every morning), or 
amitriptyline 25mg (twice a day) and high dose corresponded to pregabalin 300 mg (twice a 
day), duloxetine 60mg (twice a day), or amitriptyline 25mg (every morning); 50 mg (every 
evening). See section 2.2 of general methods and materials for more detailed description of 
the study, and an overview of the study schedule can be seen in appendix 1. All PSG 
recordings were carried out in sleep labs at the Surrey Clinical Research Centre as stated in 
general method section 2.3 using the Compumedics Siesta System® (Compumedics Ltd., 
Australia). Time in bed was 8 hours (2300-0700). The PSG nights were staged according to 
the Rechtschaffen and Kales criteria as stated in general methods and materials section 2.4. 
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5.2.3 Clinical Sleep Assessment 
Clinical sleep variables analysed included arousals, PLMS and sleep apnoeas/hypopnoeas. 
Arousals were measured using the EEG recording with an arousal defined as awakening of 
least 3 sees in duration and less than 15 sees (see section 2.4.2.1 Micro Arousals for more 
information). PLMS and sleep apnoeas were assessed from a full body PSG assessment, 
including leg EMG, respiratory belt, oximeter and thermistor. Arousals, PLMS and the 
apnoealhypopnoea index (AHI) were all scored according to the criteria of The AASM 
Manual for the Scoring of Sleep and Associated Events, 2007. For statistical analysis, the 
arousal index was used and defined as number of arousals per hour of sleep, the PLMS index 
was defined as the number of PLMS per hour of sleep and the AHI index was defined as 
number of apnoeas and hypopnoea per hour of sleep. For more detailed description of how 
apnoeas/hypopnoeas and PLMS were scored and defined, see general method and material 
chapter 2 section 2.4.2.2 Sleep Apnoea and Hypopnoea and section 2.4.2.3 Periodic Limb 
Movement of Sleep (PLMS). 
5.2.4 Continuous Glucose Monitoring 
The interstitial glucose levels were monitored overnight using the CGMSiI> System Gold™ 
Continuous Glucose Monitoring (Medtronic MiniMed, Inc., CA U.S.A). This system was 
designed to provide continuous measurements of interstitial glucose levels over the range 2.2-
22.0 m.molll. See general method and material chapter 2 in section 2.6 Continuous Glucose 
Monitoring for more detailed description of the CGMS. 
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5.2.5 Statistical methods 
Pearson correlations were used to analyse possible relationship between different variables of 
the baseline data at visit 1. Low correlation was defined 0.2 to 0.4, moderate 0.4 to 0.7 and 
strong 0.7 to 0.9. Statistical significance level was set to 5% (P<0.05). 
Observations under treatment were analysed in a linear mixed model using SAS® PROC 
MIXED 9.1. The observations were the dependent variable and fixed effect was treatment 
with visits being a repeated measure. Additional independent covariates included body mass 
index (BMI) and age. Statistical significance level was set to 5% (P<0.05). 
5.3 Results 
5.3.1 Demographics and Screening results 
A total of 83 patients (57 males and 26 females) were randomised onto the trial, 27 patients 
were randomised to pregabalin, 28 to duloxetine and 28 to amitriptyline and 65 subjects 
completed all visits (Table 4.2 Patient disposition in chapter 4 result section for more detailed 
description). Mean age of all patients was 65.1 ± 8.9 years and mean BMI was 32 ± 5.4 kg/m2 
(Table 4.1 Demographic characteristics of study population in chapter 4 result section for 
more detailed description). 72 patients had type 2 OM. 48 patients were receiving insulin 
treatment and 35 patients were not receiving insulin treatment. Mean HbAlc at screening was 
7.93 ± 1.47% and at the end of the study 7.83 ± 1.29 %. 
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5.3.2 Baseline characteristics 
5.3.2.1 Clinical Sleep Variables 
5.3.2.1.1 Periodic Limb Movements in Sleep 
The results showed that the diabetic patients (n = 70) had a mean PLMS index (PLMlhour of 
sleep) of 17 ± 20.7 with an index ranging from 0-85. 59% of patients had a PLMS index of 
greater than 5 and 39 % had a PLMS index greater than 15. PLMS are known to increase 
with increasing age, however during this study there was no significant correlation between 
age and PLMS index (r = 0.11, figure 5.1). 
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Figure 5.1: Correlation between PLMS index and age. There was no correlation between increase in PLMS 
Index and increasing age (r = 0.11). n = 70 diabetic patients. 
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5.3.2. J. 2 Sleep Apnoeas 
The results showed that 36 % of the diabetic patients in this study population had mild sleep 
apnoea, defined as AHI > 5. Only 3% of the patients had moderate sleep apnoea defined as 
AHI 15-30 and no patient had severe sleep apnoea defined as AHI > 30. The mean AHI in 
this study group was 4.3 ± 5.2 with a range from 0-27. Sleep apnoea is commonly associated 
with 8MI, with a higher AHI with increasing 8MI. There was a significant correlation 
between these two variables in this study popUlation, (r = 0.30, P<0.05, figure 5.2). 
30 
25 
20 
-:::z: 15 C 
10 
5 
0 
0 10 
• 
• 
• 
.... .. 
•••• 
•• 
20 30 40 
BMI (kl/mZ) 
so 
Figure 5.2: Correlation between AUI and BMI. There was a correlation between AHI and BMI in this study 
group (r = 0.30, P<O.OS). n = 66 diabetic patients. 
Nocturnal oxygen (02) levels (% of 02 saturated haemoglobin = SP02), and number of 02 
desaturations (~desats) during the night were also measured. Mean nocturnal SP~ in this 
diabetic study group was 92 ± 3 % (range from 79-98%) and the mean number of 02 
desaturations was 3.3 ± 3.8 per hour of sleep (range from 0-19). 
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There was no significant correlation between mean SP02 and AHI, (r = 0.045, figure 5.3). 
However, there was a very strong correlation between AHI and number of 02 desaturations 
during the night (r = 0.91), and this correlation was significant (P<O.OOOl, figure 5.4). 
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Figure 5.3: Correlation between AUI and mean nocturnal SP01• There was no correlation between the AHI 
and SP02 in this study group (r = 0.045 and r = 0.002). n = 66 diabetic patients SP02 = % of oxygen saturated 
haemoglobin. 
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Figure 5.4: Correlation between AlB and number or 0 1 desaturatloDI (Ozdesats). There was a s1rong 
correlation between an increase in the number of apnoeas and hypopnoea and an increase in the number of 02 
desaturations (r = 0.91, P<O.OOOI). n = 66 diabetic patients. 
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5.3.2.1.3 Arousals 
The number of nocturnal arousals was also analysed. Arousals were divided into spontaneous 
arousals, arousals associated with PLMS, and arousals associated with apnoea and 
hypopnoea. For spontaneous arousals patients had a mean of 4.0 ± 2.9 arousals/hour (range 
0.8-15), while for arousals associated with PLMS and arousals associated with 
apnoealhypopnoea patients had a mean of 1.6 ± 2.0 (range 0-12) and 0.7 ± 1.5 (range 0-8.2) 
arousals/per hour of sleep, respectively. 
5.3.2.2 Glycosylated haemoglobin and glucose levels 
5.3.2.2.1 Glycosylated haemoglobin (HbAld 
HbAlc measurements were used to assess long term glycaemic control. The International 
Diabetes Federation recommends HbAlc values below 6.5% for diabetic patients, while the 
American Diabetes Association recommends a value below 7%. The mean HbAlc for this 
study group was 7.93 ± 1.47 % and the result showed that only 13% of all diabetic patients in 
this study had HbAlc values below the recommended 6.5% (figure 5.5). 
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Figure 5.5: Scatter plot of HbAlc for diabetic patients. The mean HbA 1 c for the diabetic patients was 
7.93%. The black line represents the 6.5 % HbAlc which is recommended by the International Diabetes 
Federation. Only 13% of the patients had a HbAlc value on or below the recommended 6.5%. n = 83 diabetic 
patients. 
5.3.2.2.2 Glucose levels 
Patients' glucose levels were analysed by using a CGMS. The mean glucose levels for the 
entire placebo visit (~ 48 hours) was 9.4 ± 2.3 mmollL, range 6-16 mmollL (n = 66). The 
mean nocturnal glucose for night 2 visit 1 (baseline) was 7.8 ± 2.1 mmollL, range 3-15 
mmollL (n=71). 
Nocturnal hypoglycaemic events (defined as glucose levels < 3.3 mmol/L) was rare in this 
patient group, analysis showed that only 4 % of patients (n=3) had a hypoglycaemic event 
during the night. Nocturnal hyperglycaemia was far more common with 79% of patients 
(n=56) having hyperglycaemic events during the night (defined as glucose levels> 7.8 
mmollL), and a quarter of these patients spent the entire night with glucose levels 
>7.8mmollL. If looking at hyperglycaemic events> 11.0 mmol/L the result showed that 31 % 
179 
(n=22) of patients had nocturnal hyperglycaemic events> 11.0 mmol/L and 4% (n=3) had 
events> 15 mmollL. Figure 5.6 demonstrates the differences in nocturnal glucose between 
patients. (A) A patient who is classified as having nocturnal hyperglycaemia with a mean 
glucose of >7.8mmoI/L for the entire night. (B) A patient with a stable glucose curve and no 
hyperglycaemic/hypoglycaemic events during the night. (C) A patient with hypoglycaemic 
events and nocturnal glucose levels <3.3 mmol/L. 
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Figure 5.6: Nocturnal glucose curve. Graph shows representative traces of nocturnal glucose levels for 3 
different patients on night 7, visit I. Patient A had nocturnal hyperglycaemia with a mean glucose of 
>7.8mmollL for the whole night, patient B showed a stable glucose curve with no 
hyperglycaemic/hypoglycacmic events during the night, while C shows an example of patient with 
hypoglycaemic events and glucose levels <3.3 mmollL. 
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5.3.2.3 Correlations between AHI, oxygen saturations, sleep, glucose and pain at baseline 
Results in section 5.3.2.1.2 Sleep Apnoeas, showed a significant correlation between AHI 
and the number of oxygen desaturations (P<O.OOOl). Further correlations showed that both 
AHI and number of oxygen desaturations correlated with number of awakenings (NA W) 
(r = 0.35, P<0.05 and r = 0.37, P<O.Ol , respectively, figure 5.7). The increase in apnoeas, 
number of oxygen desaturations and NA W did not correlate with nocturnal glucose levels 
(mean nocturnal glucose or glucose >7.8mmollL). And there was no correlation between 
nocturnal glucose levels and pain severity or pain interference. 
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Figure 5.7: Correlation between AHI, number of 02 desaturations and number of awakening (n =58). A. 
Correlation between AHI and number of awakenings. Increase in AHI correlated with increase in number of 
awakenings (r = 0.35 and P<O.05) n = 57. B. Correlation between number of O2 desaturations and number 
of awakenings. Increase in number of O2 desaturations correlated with increase in number of awakenings (r = 
0.37 and P<O.Ol). 
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When looking at AHI prevalence at different sleep stages the result showed that AHI was 
most commonly associated with stage 1 sleep with increased stage 1 sleep duration associated 
with an increase in the AHI (P<O.OI, figure 5.8). In contrast, an increase in both stage 3 and 4 
sleep resulted in a decrease in the AHI and this was statistically significant for stage 4 sleep 
(P<O.05) and approached significance for stage 3 sleep (P=O.0507). There was no correlation 
between stage 2 or REM sleep duration and AHI (figure 5.8). 
Similar results could be seen with NA W, where an increase in NA W was associated with an 
increase in stage 1 sleep (P<O.OOOI) whereas when stage 3 and 4 sleep increased this was 
associated with a decrease in NA W (P<O.OOI and P<O.05, respectively). There was no 
correlation between NA W and REM sleep. 
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Figure 5.8: Correlation between AHI and duration of leep tages. (n =57) A. Correlation between AHI 
and duration of stage I leep. Increase in AHI correlated significantly with increase in stage I sleep (r = 0.36 
and P<O.O I). B Correlation between AH[ and duration of 2 leep. There was no significant correlation 
between AHI and duration of tage 2 sleep (r = 0.17). C. Correlation of AHI and duration of stage 4 sleep. 
Increase in Aill correlated significantly with an increase in stage 4 sleep (r = 0.28 and P<0.05). D. Correlation 
between AHI and duration of REM leep. There was no significant correlation between amount of REM sleep 
and AlII (r = 0.14). 
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5.3.3 Treatment effects on clinical variables 
The following section describes the effect of the three treatments (pregabalin, amitriptyline 
and duloxetine) on clinical variables. For clinical sleep variables (PLM8, AHI and arousals) 
only the visit 1 (placebo baseline) and visit 3 (chronic high dose) were included in the 
analysis. The reason for inclusion of visit 3 data alone was that in the time available it was 
not possible to perform complete analysis of visit 2 (chronic low dose) data and that if a drug 
effect was seen then it would be expected to be most apparent in the highest dose. Future 
work could be to score and analyse the low dose records in order to see if a dose response 
exists. For HbAlc levels assessment was made at medical screening before the clinical start of 
the study and then again at the follow up visit after treatment had been terminated. The 
analysis of glucose levels however included data from all three visits: visit 1 (placebo 
baseline), visit 2 (chronic low dose) and visit 3 (chronic high dose). 
5.3.3.1 Clinical Sleep 
5.3.3.1.1 Periodic Limb Movements in Sleep 
There was a significant treatment by visit effect (P<O.OOl) on PLMS Index with a 
significantly lower PLM8 Index with high dose pregabalin treatment compared with 
duloxetine and amitriptyline (P<O.OOI for both, table 5.1 and figure 5.9). 
Post hoc analysis showed that pregabalin significantly decreased PLM8 compared with 
placebo (L8 mean 19.7 for placebo to 12 with high dose Cohen's d= 0.68 and P<O.OI), while 
duloxetine and amitriptyline significantly increased PLM8 compared with placebo. 
Duloxetine had a L8 mean of 16.2 for placebo compared to 24.4 with high dose (Cohen's d = 
0.66 and P<0.05) and amitriptyline had a L8 mean of 16.2 for placebo compared with 19.9 
with high dose (Cohen's d= 0.74 and P<O.OI, figure 5.9). 
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Figure 5.9: Treatment effect on PLMS index. There was a significant treatment by visit effect (P<O.OO I). 
Pregabalin significantly lowered the PLMS index compared with pregabalin and duloxetine. Comparison 
between treatments = t. Pregabalin significantly decreased PLMS index while duloxetine and amitriptyline 
significantly increased PLMS index compared with placebo at baseline. Comparison with placebo = *. Level of 
significance: ttt = P<O.OO I, ** = P<O.O I, * = P<O.05). Bars show mean, ± standard error of mean (SEM) 
PGB = pregabalin, DUL = duloxetine, AMI = amitriptyline. 
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Table 5.1: Treatment by visit effect. 
Lower dose Higberdose 
Treatment by visit 
Effect p-value Treatment p-value Treatment p-value 
PLMSIndex PGBv DUL 0.001 
(PLM/hours of sleep) 0.001 NA NA PGBv AMl 0.001 DULv AMI NS 
AHI PGB v DUL 0.0001 (Apnoea-
Hypopnoea/hour of 0.0001 NA NA PGBv AMT 0.001 
sleep) DULv AMI NS 
PGBv DUL NS 
Spontaneous arousals NS NA NA PGBv AMI NS 
DULv AMl 'NS 
PGBv DUL 0.05 
Respiratory arousals 0.055 NA NA PGBvAMI 0.05 
DULvAMI NS 
Arousals associated PGB vDUL NS 
with PLMS NS NA NA PGBvAMI NS DULvAMI NS 
Mean number of PGBvDUL 0.0001 
nocturnal 02 0.0001 NA NA PGBv AMI 0.001 
desaturations DULvAMI NS 
Mean nocturnal 02 PGBv DUL NS 
saturation NS NA NA PGBy AMI NS 
(%) DULyAMI NS 
Mean nocturnal PGB v DUL 0.05 PGBvDUL 0.001 
glucose levels 0.01 PGBv AMI NS PGBy AMI 0.05 
(mmol/L) DULv AMI NS DULvAMI NS 
Mean glucose levels POB vDUL NS POB vDUL NS 
for whole visit NS PGBvAMI NS PGBvAMI NS 
(mmoIJL) DULv AMI NS DULy AMl NS 
Mean % of nocturnal NS PGBvDUL NS POByDUL NS glucose levels <3.3 POBvAMT NS PGBv AMI NS 
mmolJL DULv AMI NS DULvAMI NS 
Mean % of nocturnal POBvDUL NS PGBy DUL NS 
glucose levels> 7.8 NS POBy AMI NS PGByAMI NS 
mmol/L DULv AMI NS DULvAMI NS 
NS = Not significant 
PGB = pregabalin, DUL = duloxetine, AMI = amitriptyline, 
PLMS = periodic limb movement in sleep, AHI = apnoea-hypopnoea Index 
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5.3.3.1.2 Sleep Apnoeas 
There was a significant treatment by visit effect on AHI (P<O.OOOl) with a significant 
increase in apnoeas and hypopnoeas in the pregabalin treatment group compared with 
duloxetine and amitriptyline (P<O.OOOI and P<O.OOl, respectively, table 5.1, figure 5.l0). 
Pregabalin significantly increased the AHI compared with placebo at visit 1 (LS mean 5.8 
apnoealhypopnoea per hour of sleep at placebo to 11.9 apnoealhypopnoea per hour of sleep 
with high dose at visit 3, Cohen's d= 1.26 and P<O.OOOl), while duloxetine and amitriptyline 
did not change significantly the AHI compared with placebo at baseline (figure 5.10). 
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Figure 5.10: Treatment effect on the apnoea-hypopnoea index (AHI). There was a significant treatment by 
visit effect (P<O.OOO I). Pregabalin significantly increasedAm compared with duloxetine and amitriptyline. 
Comparison between treatments = t. Pregabalin significantly increased AHI compared with placebo while 
duloxetine and amitriptyline had no significant effect on AHT compared with placebo at baseline. Comparison 
with placebo = *. Level of significance: ttt/*** = P<O.OOl. Bars show mean, ± standard error of mean (SEM). 
PGB = pregabalin, DUL = duloxetine, AMI = amitriptyline. 
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The number of O2 desaturations/hour of sleep also demonstrated a significant treatment by 
visit effect (P<O.OOOl), with the pregabalin treatment group having a significantly higher 
number of 02 desaturations I hour compared with both the duloxetine and amitriptyline 
treatment groups (P<O.OO 1 for both, table 5.1 and figure 5.11). Further analysis showed that 
high dose pregabalin increased number of O2 desaturations compared with placebo (LS mean 
3.9 at placebo to 10.2 with high dose, Cohen's d = 1.31 and P<O.OOOl) while amitriptyline 
and duloxetine had no significant effect on O2 desaturations compared with placebo at 
baseline, (figure 5.11). 
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Figure 5.11: Treatment effect on number O2 desa ts/bour of sleep. There was a significant treatment by visit 
effect (P<O.OOO I). Pregabalin signi ficant ly increasednumber of O2 desaturations compared with duloxetine and 
amitriptyline. Comparison between treatments = t. Pregabalin significantly increase number O2 desaturations 
compared with placebo, while with du loxetine and amitriptyline there was no significant change compared with 
placebo at baseline. Comparison with placebo = *. Level of significance: ttt/*** = P<O.OOL Bars show mean, 
± standard error of mean (SEM). PGB = pregabalin, DUL = duloxetine, AMI = amitriptyline. 
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There was no significant treatment by visit effect on mean nocturnal 0 2 saturation with all 
treatment groups having similar mean O2 saturation when compared with each other as well 
as compared with placebo (pregabalin; 92.4 % for placebo and 93.3% for high dose, 
duloxetine; 93.2% for placebo and 93.9% for high dose, amitriptyline; 93 .7% for both 
placebo and high dose, figure 5.12). 
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Figure 5.12: Trea tm ent effect on mea n O2 saturation. There was no significant treatment by visit effect. Bars 
show mean, ± standard error of mean ( EM) PGB = pregabalin, DUL = duloxetine, AMY = amitriptyline. 
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5.3.3.1.3 Arousals 
There was no significant treatment by visit effect on the number of spontaneous arousals, no 
significant difference between the treatments or when compared with placebo (table 5.1 and 
figure 5.13). 
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Figure 5.13: Treatment effect on number of spontaneous arousals. There was no significant treatment by 
visit effect and no significant difference when compared with placebo. Bars show mean, ± standard error of 
mean (SEM). POB = pregabalin, DUL = duloxetine, AMI = amitriptyline 
Although there was a significant treatment effect on number of PLMS, there was no such 
treatment effect on the arousals associated with the PLMS. Pregabalin significantly decreased 
PLM while duloxetine and amitriptyline both increased number of PLMS, however, the 
arousals associated with PLMS remained unchanged and similar between treatment and to 
that seen at the placebo baseline (table 5.1 and figure 5.14). 
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Figure 5.14: Treatment effect on number of arousals associated with PLMS. There was no significant 
treatment by visit effect and no significant difference compared with placebo. Bars show mean, ± standard error 
of mean (SEM). PGB = pregabalin, DUL = duloxetine, AMI = amitriptyline. 
For respiratory arousals the treatment by visit effect approached significance, P=0.055 with 
respiratory arousals mirroring the changes in the AHI. There was a significant increase in the 
number of respiratory arousals in the pregabalin group compared with amitriptyline and 
duloxetine (P<0.05, for both). Post hoc analysis showed that pregabalin significantly 
increased the number of respiratory arousals compared with the placebo at baseline (LS mean 
1.4 with placebo to 3.4 with high dose, Cohen's d = 0.70 and P<O.Ol), while duloxetine and 
amitriptyline had no significant effect on respiratory arousals (table 5.1 and figure 5.15). 
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Figure 5.15: Treatment effect on number of respiratory arousals. The treatment by visit effect approached 
significance, P=O.055. Pregabalin significantly increased thenumber of respiratory arousals compared with 
duloxetine and amitriptyline. Comparison between treatments = t. Pregabalin significantly increased the number 
of respiratory arousals compared with placebo, while there was no significant change with duloxetine and 
amitriptyline compared with placebo at baseline. Comparison with placebo = *. Level of significance: t = 
P<O.05 , ** = P<O.Ol. Bars show mean, ± standard error of mean (SEM). PGB = pregabalin, DUL = duloxetine, 
AMI = amitriptyline. 
5.3.3.2 Glycosyfated haemoglobin and glucose levels 
5.3.3.2.1 Glycosylaled haemoglobin (HbAld 
There was no significant difference in HbA le measurements post treatment compared with 
before treatment had started (7.93 ± 1.47% before treatment and 7.83 ± 1.29% post treatment) 
and no significant difference between the treatments (Table 5.2). Even though a slight 
improvement was observed the glycosylated haemoglobin levels were still above the 
International Diabetes Federation recommended HbAle value of below 6.5%. 
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Pregabalin Duloxetine Amitriptyline All 
N=27 N=28 N=28 N=83 
HbA1c (%) Mean (SD) 7.67 (l.55) 7.91 (1.49) 8.21 (1.35) 7.93 (1.47) 
Pre treatment Min 5.80 5.70 6.50 5.70 
Max 12.00 11.00 11.20 12.00 
HbA 1c (%) Mean (SD) 7.51 (1.31) 7.76 (1.27) 8.17 (1.27) 7.83 (1.29) 
Post treatment Min 6.00 5.80 6.60 5.80 
Max 10.80 10.30 11.30 11.30 
Table 5.2: HbAlc levels pre treatment and post treatment. There was no significant difference between 
HbA 1 c levels at pre treatment compared with post treatment and there was no significant difference between the 
treatments. 
5.3.3.2.2 Glucose levels 
Glucose levels were measured and analysed for all 3 visits. There was a significant treatment 
effect on mean nocturnal glucose levels (P<O.Ol) with the pregabalin treatment group having 
significantly higher nocturnal glucose levels compared with the duloxetine and amitriptyline 
treatment groups (low dose; pregabalin v duloxetine P<0.05, high dose; pregabalin v 
duloxetine P<O.OOl, pregabalin v amitriptyline P<0.05, table 5.1 and figure 5.16). 
Post hoc analysis showed that pregabalin significantly increased glucose levels at visit 3 
compared with placebo with LS mean of 7.1 mmollL for placebo and 8.7 mmollL for high 
dose (Cohen's d = 0.68 and P<O.Ol). In contrast, duloxetine significantly decreased nocturnal 
glucose levels compared with placebo with LS mean 8.1 mmollL for placebo to 6.8 mmollL 
low dose and 7.0 mrnollL high dose (Cohen's d = 0.78 and P<O.Ol for low dose and Cohen's 
d = 0.60 and P<0.05 for high dose) while amitriptyline had no significant effect on nocturnal 
glucose levels, (figure 5.16). 
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Figure 5.16: Treatment effect on nocturnal glucose levels. The overall treatment by visit effect was 
significant (P<O.O I). Comparison between treatments; pregabalin v duloxetine = * and pregabalin v 
amitriptyline = x. Both low and high dose duloxetine decreased glucose levels and high dose pregabalin 
increased glucose levels when compared with placebo, while amitriptyline did not change glucose levels 
significantly compared with placebo at baseline. Level of significance */ x = P<O.05, *** = P<O.OO I. Plot shows 
mean, ± standard error of mean (SEM). Amitriptyline ( ), pregabalin (. ) , duloxetine (. ). 
When looking at hypoglycaemia (defmed as glucose levels < 3.3 mmollL) during the night 
results showed that there was no significant difference between any of the three treatments or 
compared with placebo for percentage of nocturnal glucose < 3.3 mmollL (table 5.1). A 
similar result was seen when looking at hyperglycaemia (defined as glucose levels >7.8 
mmol/L). Again there was no significant difference between any of the three treatments or 
change when compared with placebo (table 5.1). 
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When looking at glucose levels for the whole visit (- 48 hours) there was no significant 
treatment by visit effect. There was no significant difference in overall mean glucose levels 
either between the three treatments or when compared with the placebo baseline (table 5.1 
and figure 5.17). 
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Figure 5.17: Treatment effect on glucose levels (whole visit), The overall treatment by visit effect was not 
significant and there was no significant difference between the three treatments compared with placebo. 
Duloxetine (_ ) pregabalin (. ), amitriptyline ( ). Plot shows mean, ± standard error of mean (SEM). 
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5.4 Discussion 
This study was the first one to investigate the inter-relationship of several factors that may 
affect sleep in diabetic patients with painful DPN and to analyse if pregabalin, duloxetine and 
amitriptyline could affect these factors and therefore possibly improve pain and sleep in this 
patient group. The aim was to explore the relationship between pain, clinical sleep 
characteristics such as PLMS and sleep apnoea, nocturnal oxygen de saturations and nocturnal 
glucose to ascertain what were the key factors in this population group. 
In previous chapters (chapter 3 and 4) it was shown that diabetic patients with painful DPN 
had worse sleep compared with healthy subjects of the same age and gender, however results 
indicated that there was little correlation between pain and worsening in sleep quality and 
sleep continuity. Therefore, other factors mentioned above were thought to be contributing to 
the disruption in sleep. 
The results in this chapter showed that the diabetic patients had a mean PLMS index 
(PLMlhour of sleep) of 17, SO 20.7 with an index ranging from 0-85 PLMlhour of sleep. 
59% of patients had a PLMS index of greater than 5 and 39 % had a PLMS index greater than 
15. Between 30 - 45% of the older adult population have been estimated to have PLMS 
(Ancoli-Israel and Ayalon, 2009; Kaplan and Fischer, 2005). PLMS may cause arousals 
which can lead to difficulties in staying asleep, and result in sleep fragmentation (Ancoli-
Israel and Ayalon, 2009). However, only 1.6 of the 17 PLMlhour were associated with 
nocturnal arousals and there was no correlation between an increase in PLMS and any of the 
sleep variables TST, SE, WASO, LPS, and NA W, suggesting that the high incidence of 
PLMS in this patient group did not have a negative effect on sleep. 
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The prevalence of sleep apnoea in this diabetic patient group was perhaps not as high as 
expected. The results showed that 36 % of the diabetic patients had mild sleep apnoea, 
defined as AHI > 5 and 3% of the patients had moderate sleep apnoea defined as AHI 15-30 
with no patients being classified as having severe sleep apnoea defined as AHI > 30. There 
was a significant correlation between BMI and sleep apnoea, with a higher BMI correlating 
with an increase in the AHI. This was expected as it is known that obesity is a common risk 
factor in the development of obstructive sleep apnoea (Resnick et aI., 2003). Clinical 
diagnosis of sleep apnoea is normally made at an AHI ~ 10-15 and is more common in older 
adults. The results from the Sleep Healthy Heart Study showed that prevalence increased with 
aged and 20% of those aged 60 years or older had an AHI ~ 15 (Ancoli-Isreal and Ayalon, 
2006). Sleep apnoea can be associated with oxygen desaturation which can lead to nocturnal 
hypoxemia and this can also cause arousals and awakenings (Alsaeedi and Alshammari, 
2005; Neubauer, 1999; Pallayova et al., 2006; Paulson, 2000). The results of the current 
study showed a strong correlation between AHI and number of awakenings and oxygen 
desaturations. Increase in AHI correlated significantly with an increase in oxygen 
de saturations ~ 4% and with an increase in number of awakenings. Mean nocturnal oxygen 
level was 92% (range 79-98%), but did not correlate with AHI. 
The prevalence of apnoeas and hypopnoeas also correlated with distinct sleep stages. An 
increase in AHI and number of awakenings correlated significantly with an increased 
duration of lighter, stage 1, sleep. This might suggest that apnoeas and hypopnoeas cause 
awakenings and lightening of sleep resulting in patients having difficulty entering and 
maintaining stage 2 sleep In contrast, patients with a longer duration of stage 3 and 4 sleep 
(SWS) show a reduced AHI and reduced number of awakenings. In particular, there was a 
significant correlation between the increase in stage 4 sleep and the decrease in number of 
awakenings and AHI, while this correlation approached significance with regards to stage 3 
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sleep. There was no evidence of a correlation between stage 2 and REM sleep and the AHI or 
number of awakenings. A reduced number of awakenings with increases in slow wave sleep 
but not with REM sleep have previously been shown in healthy subjects (Dijk et al., 2006). 
This indicates that an increase in slow wave sleep reflects less fragmented sleep with fewer 
numbers of awakenings during the night. 
Furthermore, it is thought that sleep apnoea and severe oxygen desaturations are associated 
with altered glucose metabolism resulting in nocturnal hyperglycaemia and several studies 
have shown a link between obstructive sleep apnoea, sleep loss and insulin resistance 
(Pallayova et al. 2006; Punjabi et al., 2002 Punjabi et at, 2004, Spiegel et al., 2005). 
Nocturnal glucose levels may also contribute to worse sleep (Bendtson et al., 1992). One 
hypothesis was that an increase in AHI would correlate with an increase in oxygen 
desaturations resulting in an increase in the duration of lighter stage 1 sleep and nocturnal 
awakenings and this could indeed be seen in the analysis. Furthermore, sleep fragmentation 
and hypoxemia are reported to alter glucose metabolism (Punjabi and Polotsky, 2005) and 
therefore it was expected that with an increase in the AHI there would be increased nocturnal 
glucose levels (hyperglycaemia) and a worsening of the neuropathic pain. The results 
however, showed that there was no correlation between hypoxemia (number of desaturations 
and mean nocturnal oxygen levels), and glucose levels (mean nocturnal glucose levels and % 
above 7.8mmollL). Furthermore, there was no correlation between NAW or WASO and 
nocturnal glucose levels suggesting that sleep fragmentation did not result in hyperglycaemia. 
The reversed effect has also been reported with nocturnal hypoglycaemia and/or 
hyperglycaemia affecting sleep in a negative way (Bendtson et aI., 1992). There was however 
no correlation between hyperglycaemic or hypoglycaemic events and sleep quality or sleep 
continuity in this patient group. The lack of correlation between nocturnal hypoglycaemic 
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events (defined as glucose levels < 3.3 mmollL) and sleep may be due to that these events 
were rare in this patient group and analysis showed that only 4 % of patients had a 
hypoglycaemic event during the night during the residential visits. Nocturnal hyperglycaemia 
was far more common with 79% of patients having hyperglycaemic events during the night 
(defined as glucose levels> 7.8 mmollL), and a quarter of these patients spent the entire night 
with glucose levels >7.8mmollL, but there was still no correlation between hyperglycaemia 
and sleep. 
However, even if there was no evidence that nocturnal glucose levels had a negative effect on 
sleep one should always aim to lower glucose levels. The results showed that the patient 
population group had a high degree of nocturnal hyperglycaemia, with a mean HbA)c of 7.93 
± 1.47% and only 13% of patients having a value equal to or below the recommended 6.5%, 
indicating poor glycaemic control in this patient group (International Diabetes Federation). 
HbA)c is a measure of long term glucose control and a high value is known to be a risk factor 
in developing microvascular complications such as peripheral neuropathy. Hyperglycaemia is 
also associated with a worsening of peripheral neuropathy and an increased risk of 
cardiovascular complications (Gore et al., 2005; Haffner and Cassells, 2003; Idris et al., 
2006; Laakso, 1999; Tesfaye and Kempler, 2005; Vinik and Flemmer, 2002). A worsening in 
peripheral neuropathy could lead to increase in neuropatic pain, but there was no correlation 
between hyperglycaemia and pain severity or pain interference in this patient group. 
The incidence and severity of obstructive sleep apnoea was also affected by treatment with a 
significant increase in apnoeas and hypopnoeas in the pregabalin treatment group compared 
with duloxetine and amitriptyline and compared with placebo. This finding support previous 
data which have indicated that pregabalin increases snoring index compared with placebo 
(Saletu-Zyblarz et al. 2006). Furthermore, it was expected that both duloxetine and 
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amitriptyline might have a beneficial effect on the prevalence of apnoeas and hypopnoeas as 
it has previously been reported that TeAs and SSRIs might enhance ventilation and provide 
some benefit in the treatment of OSA (Hanzel et al., 1991) although the exact mechanism for 
this is unclear. The result of this study showed however no significant difference between 
amitriptyline and duloxetine when compared with placebo. 
Finally the study investigated the effects of pregabalin, duloxetine and amitriptyline on 
glucose levels and HbA1c to see if any of the treatments would have a protective / beneficial 
effect on the metabolic condition itself. There are very little data published in regards to the 
three treatments possible effect on glucose levels. An analysis done by Hardy et al. (2007) 
collecting data from three different clinical trials with duloxetine showed that duloxetine 
treatment (60mg/day or 120mglday) increased fasting plasma glucose levels in both short and 
long-term studies. However, this increase was modest (0.5 and 0.67 mmol/L, respectively). 
The results of the present study showed no significant difference in long term glucose as 
measured by HbA}c with none of the treatments causing a significant difference post 
treatment compared with before treatment had started (7.93 ± 1.47% before treatment and 
7.83 ± 1.29% post treatment). Even though a slight improvement was observed, the 
glycosylated haemoglobin levels were still above the International Diabetes Federation 
recommended HbA}c value of below 6.5%. T. However, HbA}c is a measure of long term 
glucose control of the past 2-3 months (6zmen and Boyvada, 2003) so longer treatment may 
be needed to see possible full effect if any. 
There was evidence that nocturnal glucose levels were affected by treatment with results 
suggesting that the pregabalin treatment group had significantly higher nocturnal glucose 
levels compared with the duloxetine and amitriptyline treatment groups and a significant 
increase in nocturnal glucose levels at the high dose pregabalin visit compared with placebo. 
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In contrast, duloxetine significantly decreased nocturnal glucose levels compared with 
placebo with while amitriptyline had no significant effect on nocturnal glucose levels. 
Although the results showed a statistically significant difference between treatments these 
results must be read with caution as the overall increase in nocturnal blood glucose with 
pregabalin was only 1.6 mmollL and the decrease in nocturnal glucose with duloxetine was 
only 1.3 mmollL (with mean glucose levels ranging from 6.8mmollL to 8.7 mmollL across 
treatment groups and visits). It is unlikely that these changes would represent a clinically 
significant change. In addition, there was no significant difference between the treatments or 
in comparison with placebo with regards to nocturnal hyperglycaemic or hypoglycaemic 
events. 
In conclusion, the results of this study suggest that diabetic patients with painful DPN have a 
higher prevalence of PLMS compared with general population but the PLMS index overall 
was considered mild (Ancoli-Israel and Ayalon, 2009; Kaplan and Fischer, 2005) and was 
not associated with many arousals and did not disturb sleep in these patients. In contrast 
although OSA in these patients was considered to be predominantly mild, sleep apnoeas and 
hypopnoeas appeared to disturb sleep with an increased number of awakenings, an increase in 
stage 1 sleep and a reduction in the deeper, SWS (stage 3 and 4). There was some evidence 
that pregabalin increased the AHI significantly. However, whether pregabalin led to the 
development or worsening of apnoeas or whether the patients in this treatment group had a 
higher prevalence of apnoeas and were more unstable needs to be investigated further. 
However the study highlights the importance of comprehensive assessment of drug effects as 
the results presented here would suggest that pregabalin should be prescribed with caution in 
patients with a history of sleep apnoea. 
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Finally, it can be established that patients with painful DPN in this study have overall a poor 
glucose control with high HbA)c and an increased prevalence of hyperglycaemia. The 
treatments appeared to have no effect on HbA)c or hyperglycaemic/hypoglycaemic episodes 
within a 2-4 week period of treatment. Although poor glucose control did not appear to affect 
sleep directly it may contribute to a worsening of peripheral neuropathy and increase the risk 
of other complications such as cardiovascular disease. 
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CHAPTER 6 - GENERAL DISCUSSION 
203 
CHAPTER 6 GENERAL DISCUSSION 
6.1 General Discussion 
Diabetes is a very complex metabolic disorder affecting millions of people of all ages all over 
the world. The prevalence is estimated to be over 220 million with 150 million having type 2 
diabetes. Type 2 diabetes is increasing in epidemic proportions with the prevalence predicted 
to double by 2025 (International Diabetes Federation; King et aI. , 1998). A large amount of 
research is currently being undertaken in this field to try to prevent and treat the disease but 
more research is needed. 
Living with diabetes is often difficult with a risk of a number of debilitating complications 
and as a result reduced quality of life. One common complication is painful DPN. The 
mechanisms of painful DPN are poorly understood and drug treatment often has a poor 
response rate and poor patient tolerance long term. The aim of our study was to try to identify 
which of the most commonly used drug treatments might be the most effective in the 
treatment of painful DPN; reducing pain, improving sleep and daytime functioning and as a 
result hopefully improving quality of life. 
The compounds investigated in this study were duloxetine, pregabalin and amitriptyline and 
this was the first study to compare the three drugs in the same clinical trial. Eighty-three type 
1 and 2 diabetic patients with painful DPN were recruited and randomized onto the trial. 
Forty of these patients were randomly selected to be used in a sub analysis comparing sleep 
in this patient group with that of a healthy population. A historically healthy control group 
was created from the large Surrey Sleep Research Centre (SSRC) database. 
Polysomnography was used to assess sleep in both diabetes group and healthy control group. 
It could be established that diabetic patients with painful DPN had poor sleep in comparison 
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with the healthy volunteers (table 6.1). Several studies have previously shown that diabetic 
patients have poor sleep using subjective sleep questionnaires but few studies have assessed 
sleep objectively using polysomnography and, as far as the author is aware, no previous study 
has compared objective sleep in this patient group with that of healthy controls. 
The main analysis of the study included all 83 randomized patients of which 65 completed 
the whole study (all three visits). The study consisted of a single blind placebo run in of one 
week, a 2 week double-blind dosing period of a lower dosage of study medication and a 2 
week double-blind dosing period of a higher dose of study medication. During the dosing 
periods patients were admitted to the Surrey CRC for a comprehensive (48 hr) assessment at 
baseline placebo (day 6-8), chronic low dose (day 20-22) and chronic high dose (day 34-36). 
Baseline analysis at visit 1 suggested that the poor sleep in the diabetic study group was not 
associated with pain or nocturnal glucose levels with hyperglycaemic/hypoglycaemic events 
during the night. Prevalence of periodic limb movement was high in this patient group but the 
number of events was considered mild and not associated with any arousals or awakenings. 
Sleep apnoea did however correlate with number of awakenings and there was a correlation 
between an increase in lighter. stage 1 sleep, and an increase in the apnoea index. 
Analysis of the low and high dose of treatments at visits 2 and 3 respectively, showed some 
very interesting results (table 6.2). For the first time one could compare the analgesic efficacy 
of these three drugs directly with each other and the results showed that all three treatments 
improved subjective pain and reduced pain interference on sleep in patients with painful 
DPN. As sleep is now one of the most common complaints in patients with diabetes one 
would hope that by reducing pain the treatments would also improve the subjective quality of 
sleep as well as objectively measured sleep parameters. The data showed that pregabalin 
indeed improved both subjective and objective sleep. Pregabalin improved sleep when 
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compared with placebo but also significantly improved sleep compared with duloxetine and 
to some extent with amitriptyline. In contrast, duloxetine significantly worsened sleep with 
patients spending more time awake, taking a longer time to fall asleep, and consequently 
having reduced SE and TST. Amitriptyline appeared to have little effect on sleep when 
compared with placebo (table 6.2). 
Although pregabalin improved sleep and duloxetine disrupted sleep there was no evidence 
that any of the treatments affected (improved or impaired) levels of daytime sleepiness when 
compared with placebo. In addition, a parallel analysis of the same study looking at the next 
day performance was carried out by Miss Laura Gribble (University of Surrey). A 
psychometric test battery was used to assess cognitive function and this demonstrated that 
there was no significant effect of treatment on cognitive tasks such as memory and attention 
but that there was some evidence that pregabalin impaired divided attention (tracking 
deviation) and that duloxetine exhibited an alerting effect with improved critical flicker 
fusion performance and reduced reaction time (personal communication with Miss Laura 
Gribble, University of Surrey). Whether this alerting affect of the duloxetine could be 
sustained longer term is unknown as the poor sleep seen with duloxetine might eventually 
result in a higher level of daytime sleepiness and reduced alertness. 
Deciding on the ideal treatment drug for painful DPN remains difficult, especially when there 
is no clear differentiation on pain outcome. However, duloxetine has a strong negative 
treatment effect on sleep and this may affect the patients long term, and one should take this 
into consideration when prescribing duloxetine, especially if patients have previously 
complained about sleep problems. Pregabalin on the other hand has a strong positive effect 
on sleep and the true benefits of this in regards to reduced pain and improved quality of life 
may not be seen in such a short duration as with this trial. However, the data from this study 
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suggest that pregabalin should be prescribed with caution in patients with a history of sleep 
apnoea as the prevalence of sleep apnoea was increased in the pregabalin treatment group. 
This study highlights the importance of comprehensive assessment of drug effects looking at 
all aspects with regards to possible benefits and also potential side effects. This study makes a 
substantial scientific contribution which will help diabetic consultants and GPs to make 
informed treatment choices for their patients. 
6.1.1 Future Work 
Future research would be to more fully understand the effect of diabetes on sleep. Studies 
should compare sleep in diabetic patients with painful DPN with diabetic patients without 
painful DPN and a real time healthy volunteer group, all matched for age, gender and BMI. 
The study should aim to control for clinical features such as PLMS and apnoeas/hypopnoes 
by possibly excluding people with a high prevalence of PLMS and AHI. This would allow 
the impact of diabetes and neuropathic pain on sleep to be more fully elucidated. The study 
should also consider using habitual bedtimes rather than a strict study regime of sleep at 
2300-0700 in order to get a good picture of sleep efficiency and latency to sleep across all 
groups and patients. Reason for this is that the patients on the current study were mainly older 
adults with a mean age of 6S years and therefore a bedtime of 23 :00 was possibly a bit late 
and not necessarily aligned with their circadian phase as older adults tend to go to bed earlier. 
Habitual bedtimes were collected for the duration of the study and varied greatly between 
subjects, with some subjects having a mean habitual bedtime as early as 21 :00 and some 
subjects having a mean bedtime as late as 01:00. This could possibly have had an effect on 
for example sleep onset latency and REM sleep when subject had restricted bedtime of 23:00 
during study days. 
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Further studies are also required to more fully investigate the effect of pregabalin on sleep 
apnoea. A range of patients should be included from those with no evidence of sleep apnoea, 
mild, moderate and severe apnoea in order to assess whether pregabalin worsens existing 
sleep apnoea and/or if pregabalin induces sleep apnoea in non apnoea patients. 
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Table 6.1: Summary of results of the comparison between DM patients and healthy subjects 
DM patients Healthy subjects 
P-value 
N=40 N=40 
Mean (SE) 
TST (min) 383 (7.6) 412 (5.1) <0.01 
SE(%) 79 (1.6) 86(1.1) <0.01 
LPS (min) 23 (3.3) 14 (1.6) <0.05 
WASO(min) 81 (7.8) 57 (4.9) < 0.05 
DURO (min) 98 (7.6) 67 (5.1) <0.01 
DUR) (min) 59 (5.5) 56 (3.9) NS 
OUR2 (min) 189 (8.3) 197 (4.6) NS 
OURJ (min) 30 (2.1) 25 (1.4) NS 
DUR4 (min) 25 (4.4) 40 (3.9) <0.01 
OURS (min) 79 (4.9) 95 (4.2) <0.01 
KSS 4.9 (0.3) 2.6 (0.2) <0.001 
OM = Diabetes Mellitus, TST - total sleep time, SE = sleep efficiency, LPS = latency to persistent sleep, 
W ASO = wake after sleep onset, OUR = duration in minutes per sleep stage, KSS = karolinska sleepiness scale 
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APPENDIX 1: Overview of study schedule 
STUDY PROCEDURES Pre-study TREATMENT PERIOD Post-study 
Screening 1 2 3 Follow-up 
DI-D8 D9-D22 D23-D36 
Informed Consent X 
Leeds Assessment of X 
Neuropathic Symptoms 
and Signs (LANSS) 
Mini Mental State Exam X 
(MMSE) 
Short-Form 36 (SF-36) X x 
Physical examination X x 
Electrocardiogram (ECG) X x 
Laboratory tests X x 
Medical X x x x 
history/medications 
Alcohol Breathalyser X X X 
Polysomnographic (PSG) x x x 
recording 
Continuous Glucose x x x 
Monitoring System 
(CGMS) 
Psychometric assessment X X X 
Wrist Actigraphy X x X x 
Overview of study scbedule. Alcohol breathalyser was used on 06, 020 and 034 before transported to the Surrey CRC. CGMS 
was carried out while the patients were in the Surrey CRC from 06-08 in treatment period 1, 020-022 in period 2 and 034-36 in 
period 3. PSG recording was carried out night 6, 7, 20,21 and 34, 35. Psychometric testing was carried out on 07 and 08 for 
treatment period 1,021 and 022 for period 2 and 035 and 036 for period 3. Wrist actigraphy was attached at screening and used 
for the whole study period. 
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APPENDIX 2: 
LEEDS SLEEP EVALUATION QUESTIONNAIRE 
Subj. Init.: 
Visit No: 
DDD SUbj.No: 
DDD Date: 
DDD 
DI ID 
· How would you compare getting to sleep last night with getting to sleep normally, 
i.e without study medication? 
Easier than usual 
Quicker than usual 
Felt more drowsy than _________________ _ 
usual 
Harder than usual 
Slower than usual 
Felt less drowsy than 
usual 
· How would you compare the quality of last night's sleep with your usual 
sleep? 
More restful than 
usual 
Fewer periods of 
wakefulness than 
usual 
Less restful than 
usual 
More periods of 
wakefulness than 
usual 
. How did your awakening today compare with your usual pattern of 
awakening? 
Easier than usual 
Took shorter than 
usual 
· How did you feel on waking? 
Alert 
Harder than usual 
Took longer than 
usual 
Tired 
• How was your sense of balance and co-ordination upon getting up? 
Less clumsy than 
usual 
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More clumsy than 
usual 
APPENDIX 3: 
Karolinska Sleepiness Scale 
Please indicate your level of sleepiness for the previous 5 minutes using the scale below. 
Very alert 1 
2 
Alert - normal level 3 
4 
Neither alert nor sleepy 5 
6 
Sleepy, but no effort to keep awake 7 
8 
Very sleepy, great effort to keep 9 
awake 
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APPENDIX 4: 
Brief Pain Inventory (Short Form) 
1. Throughout our lives, most of us have had paIn from tIme to tIme (such as mmor headJches, spraIns, and 
toothaches). Have you had pClln other than these everyday kinds of pOlIn today? 
DYes ONO 
2. On the diagram, shade m the areas where you teel pain. Put an X on the area that hurts the most. 
3. Please rJte your pam by marking the box beside the number that best desCribes your pilln at Its mill 
In the last 24 hours. 
Do 
No 
Pain 
06 07 08 09 010 
Pain As Boo As 
You Can Im30lne 
4. Please rate your pain by marking the box beside the number that best describes your pain at its 
I:m:J in the last 24 hours. 
Do 
No 
Pam 
04 05 06 08 09 010 
Pain As Boo As 
You can Imagine 
5. Please rJte your pam by marking the box besIde the number that best describes your pam on the ~ 
Do 
No 
Pain 
06 08 09 010 
Pain As Bad As 
You Can Imaolne 
6 Ple.r.:.e rate your pilln by marking the box besIde the number tl1at tells how mucll pain you have IiI:lilIiD 
Do 
No 
Pan 
II Page 1 of2 
06 
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08 09 010 
Pain As Bad As 
You Can Imagine 
II 
7. What treatments or medications are you receiving for your pain? 
I I I I I I I I I I I I I II I I I I I I I I I I I I I 
I I I I I I I I I I I I I II I I I I I I I I I I I I I 
8. In the last 24 hours, how much relief have pain treatments or medications provided? Please 
mark the box below the percentage that most shows how much mmyou have received. 
0% 
o 
No 
Relief 
10% 
o 
20% 
o 
30% 
o 
40% 
o 
50% 
o 
60% 
o 
70% 
o 
80% 
o 
90% 
o 
100% 
o Complete 
Relief 
9. Mn the box beside the number that describes how, dunng the past 24 hours, pam has Intertered 
with your: 
A . General Activity 
00 01 
DOes Not 
Interfere 
1:I M.t.i.M 
Do 01 
DOiis Not 
Interfere 
C . Walking ability 
00 01 
DOiis Not 
Interfere 
Os 
Os 
06 07 De 09 
06 07 De 09 
06 07 De 09 
D. Normal Work (includes both work outside the home and housework) 
00 01 
Does Not 
Interfere 
04 Os 06 
E . Relations w ith other people 
00 01 
DOes Not 
Interfere 
02 
G . Enjoyment of life 
00 01 
Doe~Not 
Int rfere 
II P3ge2of2 
05 06 
Os 06 
05 06 
CopyrIQht 1991 Charles S. CIeeIand, PhD 
PaIn Rasearcl\ GlOIIp 
AI rights reeerved 
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07 De 09 
De 09 
08 09 
De 09 
010 
COmpletely 
Interferes 
010 
COmpletely 
Interferes 
010 
completely 
Interferes 
010 
Co p tely 
Interferes 
010 
COmpletely 
Interferes 
010 
Competety 
Interferes 
010 
Co P tely 
Interferes 
II 
APPENDIX 5: LINE ANALOGUE RATING SCALE 
Remember, the marks you make are to show how you feel now compared to your usual feelings. 
More 
Competent 
Less 
Anxious 
Less 
Alert 
Less 
Drowsy 
Less 
Relaxed 
Less 
Clumsy 
More 
Sad 
More 
Tired 
Less 
Dizzy 
Less 
Energetic 
More 
Depressed 
More 
Slow-witted 
More 
Light-headed 
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Less Competent 
More Anxious 
More 
Alert 
More 
Drowsy 
More 
Relaxed 
More 
Clumsy 
Less 
Sad 
Less 
Tired 
More 
Dizzy 
More Energetic 
Less Depressed 
Less 
Slow-witted 
Less 
Light-headed 
APPENDIX 6: 
Polysomnographic assessments and definitions 
LlGHTOFF Lights off time Defined as the time (hh:mm:ss) when laboratory lights are switched off. Corresponds with the start ofthe analysis period 
LlGHTON Lights on time Defined as the time (hh:mm:ss) when laboratory lights are switched on. Corresponds with the end of the analysis period 
SOL2 Sleep onset Latency (min) Defined as the time in minutes occurring from lights off to the first epoch 
of stage 2, 3, 4 or REM 
LPS Latency to persistent sleep Defined as the time in minutes from lights off to the first consecutive 20 (min) epochs ofNREM or REM 
FINALAWK Final awakening Defined as the first epoch of wake which is not fonowed by any epoch of NREM or REM, or lights on whichever comes first 
TIB Time in bed (mins) Defined as the time in minutes from lights out to lights on 
Defined as the time in minutes scored as NREM or REM but excluding 
TST Total sleep time (min) epochs of MVT and Unscored within the period between lights off and 
lights on 
SPT Sleep Period Time (min) Defined as the total time in minutes scored as NREM, REM, WAKE or MYT occurring from SOL2 unti1lights on or the FINALA WK 
DURO Stage 0 duration (min) Defined as the time in minutes scored as WAKE from lights off to lights 
on 
DURI Stage I duration (min) Defined as the time in minutes scored as I from lights off to lights on 
PSPTI Percent of SPT for Stage I Defined as the percentage of epochs scored as I within the Sleep Period Time 
DUR2 Stage 2 duration (min) Defined as the time in minutes scored as 2 from lights off to lights on 
PSPT2 Percent of SPT for Stage 2 Defined as the percentage of epochs scored as 2 within the Sleep Period Time 
DUR3 Stage 3 duration (min) Defined as the time in minutes scored as 3 from lights off to lights on 
PSPT3 Percent of SPT for Stage 3 Defined as the percentage of epochs scored as 3 within the Sleep Period Time 
DUR4 Stage 4 duration (min) Defined as the time in minutes scored as 4 from lights off to lights on 
PSPT4 Percent of SPT for Stage 4 Defined as the percentage of epochs scored as 4 within the Sleep Period Time 
SWS Duration of Stage 3 + 4 Defined as the time in minutes scored as 3 or 4 from lights off to lights on 
sleep (min) 
PSPTSWS Percent of SPT for Stage 3 Defined as the percentage of epochs scored as 3 or 4 within the Sleep 
+4 sleep Period Time 
DURS Duration of REM sleep Defined as the time in minutes scored as REM from lights off to lights on (min) 
PSPTREM Percent of SPT for REM Defined as the percentage of epochs scored as REM within the Sleep 
sleep Period Time 
DURNREM Duration ofNREM sleep Defined as the time in minutes scored as NREM from lights off to lights 
on 
DURMVT Duration of MVT Defined as the time in minutes scored as MYT from lights off to lights on 
SEFF Sleep Efficiency Defined as the percentage of TST against (TST + total wake + total MYT) 
STAGEC Number of stage changes Defined as the number of stage transitions from SOL2 until lights on or FINALAWK 
TAWAKE Total Time Awake from Defined as the time in minutes scored as wake from SOL2 to lights on or SOL (min) FINALAWK 
Number of night -. 
NAW awakenings after LPS Defined as the number of blocks of consecutive epochs of wake from LPS 
until lights on until lights on 
NAWSP Number of awakenings Defined as the number of blocks of consecutive epochs of wake from LPS after LPS until final until FINALA WK 
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awakening 
WASO Wake after sleep onset Defined as the time in minutes of epochs scored as wake from SOL2 until (min) lights on 
Total duration of 
WASOSP awakenings after sleep Defined as the time in minutes of epochs scored as wake from SOL2 until 
onset until the final FINALAWK 
awakening 
WAS Wake after sleep Defined as the time in minutes from final awakening to lights on 
S2LAT Latency to stage 2 Defined as the time in minutes from lights out to the first epoch of 2 
SWSLAT Latency to SWS (min) Defined as the time in minutes from SOL2 to the first epoch of 3 or 4 
Duration of Stage 3 + 4 Defined as the time in minutes scored as 3 or 4 occurring within the 1 st SWSI sleep during Ist 3rd of 
night (min) 3rd of the period from lights off to lights on 
Duration of Stage 3 + 4 Defined as the time in minutes scored as 3 or 4 occurring within the 2nd SWS2 sleep during 2nd 3rd of 
night (min) 3rd of the period from lights off to lights on 
Duration of Stage 3 + 4 Defined as the time in minutes scored as 3 or 4 occurring within the 2nd SWS3 sleep during the final 3rd 
of night (min) 3rd of the period from lights off to lights on 
RLAT REM Sleep Latency Defined as the time in minutes from SOL2 to the first epoch of REM 
NCYCLE Number ofREMfnon- Defined as the number of REM cycles REM cycles 
NPERIODS Number of REM periods Defined as the number of REM periods 
DURCYC Duration of REMfnon- Defined as the average time in minutes, of all of the REM cycles in the REM cycles sleep period. 
REMRATIO REMfnon-REM ratio Defined as the total duration of REM divided by the total duration of NREM from SOL2 to the FINALA WK or lights on 
RLA T1 ,2,3,4, Latency to each REM Defined as the time in minutes from SOL2 to the first epoch of each REM 
5,6 cycle cycle 
Duration of REM sleep Defined as the time in minutes scored as REM occurring within the 1 st REM 1 during 1st 3rd of night 3rd of the period from lights off to lights on (min) 
Duration of REM sleep Defined as the time in minutes scored as REM occurring within the 2nd REM2 during 2nd 3rd of night 
(min) 3rd of the period from lights off to lights on 
Duration of REM sleep Defined as the time in minutes scored as REM occurring within the final REM3 during the final 3rd of 
night (min) 3rd of the period from lights off to lights on 
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